Annual report 2024

EXCELENCIA
SEVERO
OCHOA
04/2024 - 03/2030

Josep Carreras
LEUKAEMIA
Research Institute

Content


Institut de Recerca
CONTRA LA LEUCÈMIA
Josep Carreras

Annual report 2024

Josep Carreras
LEUKAEMIA
Research Institute

Foreword

Welcome to the Josep Carreras Institute's 2024 Annual Report. Throughout this report, we will look back at a pivotal year for our Institute, marking a milestone in our pursuit of excellence in research: our accreditation as a **Severo Ochoa Centre of Excellence**.

Since the creation of the Josep Carreras Leukaemia Research Institute, our community has worked tirelessly to find a cure for leukaemia and other haematological diseases, always maintaining a patient-centred approach and using the latest and most innovative technologies. The **Severo Ochoa accreditation**, granted by the State Research Agency, part of the Spanish Ministry of Science, Innovation and Universities, recognises the world-class research carried out at IJC in recent years. This accreditation places our Institute among the leading research centres in Spain based on factors such as excellence, scientific contributions, capacity to attract talent and economic and social impact.

Over the past year, our research groups have continued producing high-impact publications, further reinforcing our international leadership in the field of leukaemia and haematological research. We are also thrilled to have welcomed the team led by **Dr. Vincenzo Calvanese**, an expert in stem cell biology research, and have celebrated the launch of our new **Advanced Microscopy Core Facility,** a major enhancement to our technological capabilities and research infrastructure. Our people, expertise and capabilities are the key ingredients of the excellent research conducted at IJC.

One of our strategic priorities is to strengthen our international presence and broaden our scientific network globally. In this sense, we were proud to host a high-level **international symposium** that brought over 150 participants and an exceptional panel of world-renowned experts, who shared the latest updates on leukaemia and lymphoma research.

Our international leadership was also recognised through the award of two prestigious and highly competitive **ERC Synergy Grants**, which will enable Dr. Mariona Graupera and Dr. Anna Bigas to conduct their transformative research projects.

Attracting international talent remains one of our core goals. IJC has taken the leading role in several Marie Skłodowska-Curie Doctoral and Postdoctoral Networks, funded by the European Commission, such as COFUND **CarrerasLeaders**, which supports postdoctoral researchers in haematological cancers, and **IMMERGE**, our doctoral training programme in primary immunodeficiencies. We also recently launched **CarrerasPathfinders**, focused on training doctoral researchers in haematological cancers, and **NUCLEAR**, aimed at training the next generation of scientists in the emerging field of metabolic genome regulation.

Thanks to the unwavering commitment and dedication of our team, the Josep Carreras Institute remains at the forefront of research into leukaemia and other malignant blood diseases. Our ultimate goal is to make leukaemia a curable disease in every case – and **we will not stop until we achieve it**.

Thank you,

Dr. Evarist Feliu

President of the Josep Carreras Institute's Executive Committee.

About us

Who we are

The Josep Carreras Leukaemia Research Institute is a non-profit research institute based in Badalona (Barcelona), dedicated to biomedical research and personalized medicine in leukaemia and other malignant blood diseases. It was founded in 2010 by the Josep Carreras Foundation, together with the Catalan government, as the first European research centre focused exclusively on leukaemia and other malignant blood diseases.

As a comprehensive research centre, IJC works on the promotion, development, transfer and dissemination of research and scientific knowledge in the field of leukaemia and other haematological malignancies. Our main objective is the well-being of patients, by increasing their quality of life and lifespan.

The Josep Carreras Institute is a collaborative hub for basic and translational researchers who work together on the fundamental biological and clinical aspects of leukaemia at our state-of-the-art facilities, which provide an excellent work environment and serve as a magnet for outstanding researchers from all over the world.

The Josep Carreras Institute has its own identity and various facets:

> It is an Institute devoted to a single issue: research into malignant blood diseases.

> It is a multi-location Institute, like those that have been created by several hospitals and universities in the European Union (EU) and the United States of America (USA), something that represents a fundamental advantage to bring together very extensive series of patients to carry out and participate in large studies at international level.

> It is physically integrated into the health care, teaching and research facilities. Our laboratories on these clinical locations allow us to collaborate closely with clinicians from the five associated hospitals: Hospital Clínic, Hospital de Sant Pau, Hospital Germans Trias i Pujol, Hospital del Mar and Dr Josep Trueta Hospital.

Mission, vision and values

Mission

The mission of the Josep Carreras Leukaemia Research Institute is **to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer**, with a special emphasis on leukaemia and other malignant blood diseases, with the aim of finding a cure for these diseases.

Vision

The vision of the Josep Carreras Leukaemia Research Institute is to be a world-class reference and excellent research centre that contributes to the **improvement of results, and the cure of patients affected by leukaemia and other malignant hemopathies**, through innovation, sustainability, social responsibility, talent, and professional experience.

Values

> Scientific and Social Ethic
> Interdisciplinarity
> Equality and diversity
> Creativity
> Sustainability
> Perseverance and continuous improvement

Organizational Chart



Provisional Organizational Chart approved by the Board of Trustees on 29/11/2024



IJC Can Ruti | IJC Sant Pau | IJC Clínic | IJC Mar | IJC Josep Trueta

Scientific Founding Members

Professor Ciril Rozman

Prof. Ciril Rozman was born in Ljubljana (Slovenia) in 1929. He is one of the most relevant figures in the field of Spanish Internal Medicine with his own comprehensive vision of the meaning of this specialty. His research has focused on Haematology.

In the field of haematology, he is considered one of the world's leading experts on Chronic Lymphocytic Leukaemia (LLC) and is the first Spanish author to receive editorship of the prestigious *New England Journal of Medicine*. His involvement in therapeutic haematology has focussed on Bone Marrow Transplants and he carried out the first allograft transplant in Spain. He has also dedicated himself to the search for prognostic factors and morphological and biological analysis of malignant blood diseases, and more recently has led the establishment of the first Spanish haematopoietic donor bank of umbilical cord blood.

Amongst his honours and distinctions, he currently holds the Creu de Sant Jordi, the Narcís Monturiol and the José Trueta de la Generalitat de Catalunya medals; he holds the Premi Rei Jaume I; he is also scientific Ambassador for the Republic of Slovenia and Doctor Honoris Causa at the Universities of Granada and Salamanca.

Professor Evarist Feliu

Prof. Evarist Feliu is the President of the Executive Committee and Ombudsman of the Josep Carreras Leukaemia Research Institute.

He was Head of the Haematology Service at the Germans Trias i Pujol University Hospital - HGTiP (1991-1995), Medical Director of the HGTiP (1995-97) and Managing Director of the same centre (1997-2002). He has been Center Director of the Catalan Institute of Oncology (ICO) (2003-2009), Scientific Director of the ICO, Director of the University Relations Programme and Head of the Haematology-Laboratory Service of the ICO-Badalona until 2018. He is currently an honorary consultant of the ICO. He was tenured Professor of Medicine at UB and UAB (1985-1997 and 1997-2007, respectively) and, Professor of Medicine-Haematology at UAB from 2008 to 2018. From 2018 to 2021 he was Professor Emeritus of the UAB and from 2021 to the present day he is Honorary Professor of the same university.

He is Trustee and Scientific Director of the Josep Carreras Leukaemia Foundation, founding member of the Josep Carreras Leukaemia Research Institute, vice-president of the Josep Carreras Foundation, Numerary Academician of the Royal Academy of Medicine of Catalonia and Doctor "Honoris Causa" by the University of Asunción.

Prof. Feliu is a prestigious researcher in the field of procedures and integrated methods of haematological diagnosis, especially electron microscopy of blood and bone marrow cells and in the study of spleen pathology, with relevant contributions in these areas at national and international level.

Locations

The Josep Carreras Institute is a multi-location Institute, which is essential to bring together very extensive series of patients to carry out and participate in large studies at international level. IJC is physically integrated into health care, teaching and research facilities at the following scientific locations:



IJC Can Ruti

The Can Ruti location hosts IJC's headquarters and most of the groups focusing on the molecular mechanisms of cancer, with a particular interest on the genetics and epigenetics of cancer and leukaemia. It concentrates the largest representation of research groups and technological platforms (70% of staff), combining basic research labs with computational biologists and physicians from the ICO-Germans Trias i Pujol Hospital, to implement translational and clinical research.

IJC Sant Pau

IJC Sant Pau is located within the Hospital de la Santa Creu i Sant Pau and led by at the forefront of biological characterisation and therapeutic innovation of haematological malignancies, particularly leukaemia. Clinical research is the main focus at this location, but researchers also conduct translational and basic research.

IJC Clínic

IJC Clínic is located within the Hospital Clínic, one of the leading research hospitals in Spain. IJC has remodelled and upgraded some of the facilities, shared with the University, in the microscopy, proteomics and genomics areas. This site is mainly integrated by physicians focusing on stem cell biology. Some of the investigators have been actively involved in the development of the first academic CAR-T cell therapy approved in Spain.

IJC Mar

Located at the Barcelona Biomedical Research Park (PRBB), an inspiring environment for life sciences and biomedical research where researchers from the Josep Carreras Institute have access to a range of cutting-edge scientific and technical services. This site primarily conducts basic research with a focus on methods generating and maintaining hematopoietic stem cells, as well as the mechanism promoting cancer and leukaemia development.

IJC Josep Trueta

The Josep Carreras Institute's site in Girona is located at the facilities of ICO-Dr Josep Trueta Hospital, the Girona's public hospital reference. Clinical research is the main output of this location, devoted to clinical and translational trials in haematology, but also to descriptive and analytical epidemiology of cancer, with the aim of determining the incidence, prevalence and survival of haematological cancer patients.

IJC at a Glance

425.21

PROFESSIONALS (FTE)

4

DISEASE FOCUS PROGRAMMES

4

TRANSVERSAL KNOWLEDGE AND TECHNOLOGY-DRIVEN PROGRAMMES

40

RESEARCH GROUPS

9

CORE FACILITIES

218

INDEXED RESEARCH ARTICLES PER YEAR
(10,40 Median Impact Factor per article)

229

ONGOING PROJECTS

2

SPIN-OFFS
(17 Patent families)

Our team

CONTRACTED & SECONDED STAFF AND INTERNS BREAKDOWN (FTE)



MANAGEMENT VS. RESEARCH BREAKDOWN (FTE)



*Contracted staff includes seconded group leaders

Our team

LOCATIONS STAFF BREAKDOWN

CONTRACTED STAFF*

296,94

265,61 staff	22,84 staff	4 staff	2,29 staff	2,20 staff
89,45%	7,69%	1,35%	0,77%	0,74%
in IJC Can Ruti	in IJC Clínic	in IJC Sant Pau	in IJC Trueta	in IJC Mar

SECONDED STAFF

111,11

47,89 staff	34 staff	18 staff	8,22 staff	3 staff
43,10%	30,60%	16,20%	7,40%	2,70%
in IJC Can Ruti	in IJC Trueta	in IJC Clínic	in IJC Sant Pau	in IJC Mar

Research Programmes

Disease-Focus Programmes

Genesis of cancer

This programme covers the molecular aspects of cancers occurring beyond the bone marrow, blood or lymphoid tissues. This will include most relevant solid cancers such as breast, lung and liver cancer and study aspects that are relevant for all cancers but more accessible in solid cancers, such as inflammatory processes.
The programme also covers the study of cancer stroma and non-cancerous diseases sharing molecular causes and physiologic aspects with cancer.

> Cancer Epigenetics
led by Manel Esteller
> Cancer Genetics
led by Montse Sanchez-Cespedes
> Cancer Heterogeneity and Hierarchies
led by Verónica Rodilla
> Cancer Immunogenomics
led by Eduard Porta
> Cancer Metabolism
led by Lucas Pontel
> Chromatin Biology
led by Alejandro Vaquero
> Endothelial Pathobiology and Microenvironment
led by Mariona Graupera
> Epigenetics and Immune Disease
led by Esteban Ballestar
> Epigenetic Therapies
led by María Berdasco
> Immunohematology and Glycobiology
led by Fumiichiro Yamamoto
> Regulatory Genomics
led by Tanya Vavouri
> Regulatory RNA and Chromatin
led by Sònia Guil

Lymphoid malignancies

This programme covers all malignancies emerging from the lymphoid lineage and its tissues including acute lymphoblastic leukaemia, lymphoma and myeloma. For solid tissues, we will leverage the power of spatial transcriptomics to dissect the interactions of malignant cells with their microenvironment.

> 3D Chromatin Organization
led by Biola M. Javierre
> Acute Lymphoblastic Leukemia (ALL)
led by Josep Maria Ribera
> Cellular Immunotherapy and Gene Therapy
led by Javier Briones
> Cellular Systems Genomics
led by Elisabetta Mereu
> Lymphocyte Development and Disease
led by Maribel Parra
> Lymphoid Neoplasms
led by Tomàs Navarro
> Lymphoma Translational
led by Gaël Roué
> Mechanisms of cancer and ageing Lab (South)
led by Salvador Macip
> Multiple Myeloma
led by Albert Oriol
> Nuclear Architecture in Leukemia
led by Gregoire Stik
> Stem Cell Biology, Developmental Leukemia and Immunotherapy
led by Pablo Menéndez
> Stem Cells and Cancer
led by Anna Bigas
> T-Cell Lymphoma
led by Laura Mondragón

Myeloid Neoplasms

This programme covers acute myeloid leukaemia as well as other myeloid malignancies originating in the bone marrow such as myelodysplastic syndromes and myeloproliferative neoplasms.
We will study these diseases in the context of bone marrow as a complex tissue and consider clonal evolution as an early step.

> Chromatin, Metabolism and Cell Fate
led by Marcus Buschbeck
> Descriptive Epidemiology, Genetics and Cancer Prevention
led by Rafael Marcos Gragera
> Epigenetic Control of Hematopoiesis
led by José Luis Sardina
> Hematological Diagnosis
led by Josep Nomdedéu
> Hematological Diseases, Transplant and Cell Therapy
led by Jordi Sierra

> Leukemia and Immuno-Oncology
led by Laura Belver
> Myelodysplastic Syndromes
led by Francesc Solé
> Myeloid Neoplasms
led by Lurdes Zamora and Blanca Xicoy
> Myeloid Neoplasms (Hospital Clínic)
led by Jordi Esteve
> Oncogenesis and Antitumor Drugs
led by Ramon Mangues
> Transcriptional Dynamics in Leukemia
led by Sergi Cuartero

Transplantation and immunotherapy

This programme covers all aspects of hematopoietic stem cell transplantation including the immunological complications of allogenic transplants such as graft versus host disease. The programme further addresses all aspects of immunotherapy including cell-based therapies (NK, MSC, CAR-T) and immune check point inhibitors.

> Barcelona Endothelium Team (BET)
led by Enric Carreras
> Blood Stem Cell Identity
led by Vincenzo Calvanese
> Hematology Research
led by David Gallardo
> Stem Cell Transplantation and Cellular Immunotherapy
led by Álvaro Urbano-Ispizua



Transversal Knowledge and Technology-Driven Programmes

Multiscale-omics

The generation of high-content data sets provides a unique opportunity for discovery, but data interpretation and integration are challenging. Researchers will use massive parallel sequencing technologies including those with single cell and spatial resolution and generate proteomic data with latest mass spectrometric methods. Computational approaches will include methods involving artificial intelligence such as machine and deep learning.

Applied epigenetics

Research groups at IJC have long expertise in chromatin biology and epigenetics. The programme puts its particular focus on the question of how we can translate knowledge of epigenetic mechanisms into tools for the improvement of cancer management. This includes the use of DNA, histone modifications and chromatin 3D structure as biomarkers for diagnosis, prognosis, response to treatment and the exploration of the chromatin-regulatory space for the identification of novel drug targets.

Preclinical models

Research groups at IJC have a long expertise in preclinical disease modelling using primary cell cultures, established cell lines, genetically engineered animal models, and patient-derived xenografts, including orthotopic models. The development of patient-derived ex vivo organoid-like models remains a challenge for both lymphoid tissues and the bone marrow.

Population studies and clinical trials

This programme brings together researchers involved in clinical trials testing the safety of new treatments (CAR-T, monoclonal antibodies, Bites, kinase, epigenetic inhibitors and targeted therapies) to compare them against gold standard treatments and to increase the number of treatment options. The leading role of IJC investigators in medical cooperation groups is instrumental for the execution of multi-centre studies and includes the first investigator-initiated CAR-T trial.

Vertical disease - Focus groups



Research Groups /

Genesis of cancer

Cancer Epigenetics

led by Manel Esteller

Transversal Programme:
Multiscale-Omics

OVERVIEW

The group continues the wide-ranging work on epigenetics that Manel Esteller, the group leader, has carried out during his career until now. Current research is devoted to the establishment of the epigenome and epitranscriptome maps for normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.

OUR GOALS

Our group has had a long-standing interest in translating the use of epigenetic knowledge gained from research into biomarkers to predict clinical outcome and to assay new drugs to reverse the distorted epigenetic landscape.

For example, we have used epigenetic markers to predict response to anti-tumour therapies and following the initial observation that MGMT gene methylation predicted response to alkylating agents in glioma.

We have shown the relationship of methylation of MGMT with the response to alkylating agents in lymphoma; of WRN with the response to irinotecan; of BRCA1 with the response to PARP inhibitors and of DERL3 with the response to glycolysis inhibitors.

Methylation of SRBC and SLFN11 have also been identified as resistance markers for platinum derivatives in human tumours and the regulator of EGFR TBC1D16 has been identified as a sensitizer for therapies with BRAF and MEK inhibitors.

From a multiomics standpoint, we have contributed to the characterization of drug sensitivity in 1,000 cancer cell lines and unveiled the reasons for those patients described as “exceptional responders”.

OUR CHALLENGES

Continuing with this translational side of our work, we are also interested in the development and study of new epigenetic drugs that target DNA methylation and histone modification writers, readers and erasers and could have an anti-cancer effect.

Interestingly, the “repertoire” of epigenetic modifications of DNA is fairly limited, as we recently reviewed. In sharp contrast, more than one hundred post-transcriptional modifications occur in RNA.

Until very recently it was almost impossible to make a good map of the epigenetic modifications of the RNA molecule, which hampered many studies in this area and prevented advances in the study of the significance of each RNA modification. However, recent methodologies now allow the study of the so-called epitranscriptome. Knowledge in this area is limited and its study is the focus of intense research in the lab.

We have also a long-standing vocation for research in monogenic disorders affecting epigenetic genes, particularly in Rett syndrome. Over the years, we have identified the gene targets for MECP2, studied the genomics of Rett syndrome in detail and developed pre-clinical drug studies.

In a similar context, we are also curious about the epigenomic profiles of common diseases such as cardiovascular alterations and Alzheimer and other neurodegenerative diseases.

Finally, we have a strong interest in the establishment of new epigenomic platforms to elaborate comprehensive DNA methylome maps, our lab is the pioneer in the validation of the commonly used DNA methylation microarrays such as the 450K and the EPIC/850K, plus the mouse DNA methylation microarray.

KEYWORDS

Cancer epigenetics; DNA methylation; RNA epitranscriptomics; histone modification; epigenetic gene silencing.

GROUP MEMBERS

ESTELLER BADOSA, MANEL
Group Leader

DÁVALOS VEGA, MARIA VERÓNICA
Associate Researcher

FERRER AGUILAR, GERARDO
Associate Researcher

MUSULÉN PALET, EVA
Associate Researcher

SETIÉN BARANDA, ESTEBAN FERNANDO
Associate Researcher

ARENAS LAHUERTA, ENRIQUE JAVIER
Postdoctoral Researcher

BUENO COSTA, ALBERTO
Postdoctoral Researcher

CAMPILLO MARCOS, IGNACIO
Postdoctoral Researcher

CRESPO GARCIA, EVA
Postdoctoral Researcher

MARTINEZ-SABADELL ALIGUER, ALEX
Postdoctoral Researcher

NOGUERA CASTELLS, ALEIX
Postdoctoral Researcher

ORŠOLIĆ, INES
Postdoctoral Researcher

CASADO PELAEZ, MARTA
PhD Student

COSTABILE, DAVIDE
PhD Student

FRANQUESA SANCHEZ, ALEIX
PhD Student

GARCIA PRIETO, CARLOS ANTONIO
PhD Student

LEVY, TAMAR
PhD Student

MARTINEZ VERBO, LAURA
PhD Student

MARTINOVIC, LOVRO
PhD Student

QUERO DOTOR, CARLOS
PhD Student

SANCHEZ MIÑARRO, VICTOR
PhD Student

SANTOS PUJOL, ELOY
PhD Student

VESELINOVA KALAYDZHIEVA, YOANA
PhD Student

XIE, YUMO
PhD Student

ADMELLA, LOURDES NAIR
Research Assistant

BALCELLS CATALA, ARNAU
Research Assistant

BLANCH ARMADA, ARLET
Research Assistant

CVETKOVSKA, MIMI
Research Assistant

FERNANDEZ REBOLLO, IRENE
Research Assistant

GIMENEZ BARONA, TOMAS
Research Assistant

CAMACHO ROMERO, NOEMI
Senior Lab Technician

SOLER RIERA, MARTA
Senior Lab Technician

PELLICER TRAGANT, MIREIA
Research Specialist Technician

MARTIN TARIN, ELVIRA
Entrepreneur

Cancer Genetics

led by Montse Sanchez-Cespedes

Transversal Programme:
Multiscale-Omics

OVERVIEW

Lung cancer causes over 1.3 million deaths annually and remains the deadliest type of cancer worldwide. Although efforts in recent years to fully characterize human cancer on a genetic and molecular level have provided important insights to increase our understanding of the gene alteration profile underlying the development of Lung Cancer, the impact of this knowledge in the survival of patients remains modest. Our group is devoted to the genetic, epigenetic, and molecular study of the mechanisms that drive LC development. Ultimately, our purpose is to implement the clinical management of cancer patients and to design novel therapeutic strategies.

OUR GOALS

Our laboratory is currently engaged in several important projects::

1. Screening for factors that determine tumour immunoescape and the response to immunotherapy.
2. Genomic and genetic profiling of lung tumours to identify novel targets for therapeutics and determinants for the primary and acquired response to tyrosine kinase inhibitors (TKIs).
3. Genetic alterations at epigenetic factors: biological understanding and opportunity for novel therapeutics.

OUR CHALLENGES

Through our research, we hope to answer the following questions:

1. What are the genetic and molecular abnormalities that trigger the development of cancer, particularly Lung Cancer?
2. How can we use genetic/molecular information to identify novel targets to implement Lung Cancer therapeutics?
3. What is the molecular basis for the lack of response to immunotherapy?
4. How can we predict and prevent acquired resistance to targeted therapeutics?

KEYWORDS

Targeted therapeutics; immunotherapy; epigenetic regulation; SWI/SNF-complex; MYC/MAX-pathway

GROUP MEMBERS

SANCHEZ - CESPEDES, MONTSE
Group Leader

ROMERO FERRARO, OCTAVIO ALFREDO
Associate Researcher

SAIGÍ MORGUÍ, MARIA
Postdoctoral Researcher

CUCURULL SALAMERO, MARC
PhD Student

DÍAZ MUÑOZ, ANA CRISTINA
PhD Student

MORILLAS VIÑUALES, JUAN
PhD Student

NAVAJAS CHOCARRO, PABLO
PhD Student

BARTOLESSIS ARIAS, ISABEL
Senior Lab Technician

PROS SIMÓN, EVA
Senior Lab Technician

Cancer Heterogeneity and Hierarchies

led by Verónica Rodilla

Transversal Programme:
Preclinical models

OVERVIEW

Our laboratory studies the key signals governing stem cell and cell fate specification during malignant progression and the mechanisms by which different signalling pathways control cell plasticity in cancer. Specifically, we use in vivo lineage tracing, live imaging, cytometry, and expression profile analysis as experimental tools to achieve our goals. Our group combines murine transgenic models, patient-derived xenografts, and 3D organoids to unravel cellular hierarchies within tumours, to gain a better understanding of cancer heterogeneity and drug resistance.

OUR GOALS

Our group is passionate about cellular hierarchies and tumour heterogeneity. Our main lines of research and specific goals are:

1. To illustrate cellular hierarchies within tumours.
2. To discover cytotoxic agents for specific cellular subpopulations.
3. To target the tumour niche to prevent the spread of cancer.

OUR CHALLENGES

We hope to answer the following questions through our research:

1. How can cellular plasticity improve treatment for cancer patients?
2. Can we achieve truly personalized medicine by identifying single or combinatorial therapies to target different cellular populations at the same time?
3. Can we prevent metastasis and/or relapses by targeting the most frequently colonized tissues?

KEYWORDS

Cellular hierarchies, heterogeneity, cell plasticity, senescence, tumour microenvironment

GROUP MEMBERS

RODILLA BENITO, VERÓNICA
Group Leader

GUARDIA VALENZUELA, CRISTINA
Postdoctoral Researcher

BALIBREA RULL, JOAN
PhD Student

ORTEGA ÁLVAREZ, DANIEL
PhD Student

TÉBAR GARCÍA, DAVID
PhD Student

VINUESA PITARCH, ELENA
PhD Student

OLIVARES OSUNA, DAVID
Senior Lab Technician

Cancer Immunogenomics

led by Eduard Porta

Transversal Programme:
Multiscale-Omics

OVERVIEW

Our research lies at the interface of artificial intelligence, molecular biology, and medical oncology, and we bring together experts from all three fields. We use computational approaches to study the interaction between genetic variants in cancer genomes and multiple aspects of cancer, ranging from the immune response against tumours to the susceptibility of cancer cells to different treatments.

OUR GOALS

Our main goal is to understand how genetic variation influences the immune response against cancer cells and vice versa. Specifically, we are working on the following lines:

1. Understanding how inherited genetic variants change the immune response against cancer cells.
2. Understanding how inherited genetic variants interact with biological sex to influence cancer predisposition.
3. Integration of protein structure and genetic data to identify new cancer-associated mutations.
4. Creating a molecular and cellular map of the tumour microenvironment in bladder cancer.

OUR CHALLENGES

Through our research, we hope to answer the following questions:

1. Is it possible to use a person's genetic data to predict whether he/she will develop cancer?
2. Which genes play a role in the development of cancer?
3. How do genetic variants change the immune response against cancer cells?

KEYWORDS

Computational biology, cancer genomics, big data, GWAS, bladder cancer

GROUP MEMBERS

PORTA PARDO, EDUARD
Group Leader

KRANAS, HANNA
Postdoctoral Researcher

LOPEZ MALIZIA, ALVARO
Postdoctoral Researcher

CHATZIASLANI, MARIA FANOURIA
PhD Student

ESCOBOSA OLMO, MARC
PhD Student

IMBACH, KATHLEEN JANE
PhD Student

SIBAI, MUSTAFA
PhD Student

SHAHID, HIRA
PhD Student

GRASES MENDOZA, DANIELA
Senior Lab Technician

PÉREZ GARRIDO, MARIA ELENA
Senior Lab Technician

CERVILLA GARCÍA, SERGI
Medium Lab Technician

PEREIRA DA CRUZ, IVO ANDRE
Lab Assistant Technician

Cancer Metabolism

led by Lucas Pontel

Transversal Programme:
Applied epigenetics

OVERVIEW

Our laboratory is dedicated to understanding and exploiting the unique characteristics of cancer that could be targeted to halt the disease. We focus on the metabolic reprogramming of tumour cells, which has been recognized as a defining feature of cancer. Tumour cells often alter their metabolism to support their rapid growth and proliferation. However, these same metabolic reactions also produce harmful toxins, such as formaldehyde and reactive oxygen species, that can damage the cancer cells. Our research aims at identifying the mechanisms that cancer cells use to protect themselves from these toxins, and on exploiting these mechanisms to develop new cancer therapies.

OUR RESEARCH

1. Cellular defences against toxic metabolites in acute leukaemia.
2. Metabolic vulnerabilities in DNA repair deficient tumours.
3. Exploiting tumour-specific vulnerabilities for personalized treatment of refractory myeloid and lymphoblastic leukaemia.

This project focuses on uncovering druggable vulnerabilities in relapsed patients with AML and ALL, who have exhausted all current therapeutic options. We are developing a novel technology to identify druggable dependencies in patient-derived tumour biopsies, thus advising a personalized off-the-shelf drug for the treatment of these refractory cancers.

GROUP MEMBERS

PONTEL MILOCH, LUCAS BLAS
Group Leader

ALQUEZAR ARTIEDA, NATIVIDAD
Postdoctoral Researcher

MORELLATO, AGUSTÍN EZEQUIEL
PhD Student

VALVERDE SANTIAGO, MARTA
PhD Student

FABIJANIC, VALERIA
Support Technician

FERNANDEZ DEU, PAULA
Lab Assistant Technician

Chromatin Biology

led by Alex Vaquero

Transversal Programme:
Applied epigenetics

OVERVIEW

The chromatin biology lab's primary purpose is understanding the mechanisms of the stress response and their impact on cancer and ageing. Specifically, the group focuses its efforts on defining the contribution of sirtuins to this response in the maintenance of genome stability, epigenetics, and metabolic homeostasis.

To fulfil this main objective, the group's work encompasses a wide range of research areas, from basic aspects of sirtuin biology to their contribution in the development of human pathologies such as leukaemia and ageing.

OUR GOALS

We aim at the identification of novel mechanisms and factors involved in the onset and development of blood malignancies, and the creation of tools that could be helpful for its diagnosis and treatment. In this regard, the group's main objectives are:

1. Understand the enzymatic duality of sirtuins and their specific contribution to sirtuin function.
2. Characterize sirtuin-dependent mechanisms of genomic stability.
3. Define the role of sirtuins in B-cell differentiation and characterize their functional implication in cancer.
4. Understand the involvement of sirtuin function in the beneficial effects of nutrient restriction on ageing development.
5. Develop a new methodology to measure the activity of sirtuins *in vivo*.

OUR CHALLENGES

Through our research, we seek to answer the following questions:

1. What is the physiological mechanism associated with the genotoxic and metabolic stress response?
2. What is the contribution of the sirtuin family of enzymes to the maintenance of genome stability after stress?
3. What is the implication of these mechanisms in the onset and development of blood cancers and ageing?

KEYWORDS

Stress response; sirtuins; epigenetics; leukaemia; ageing.

GROUP MEMBERS

VAQUERO GARCÍA, ALEJANDRO
Group Leader

VÁZQUEZ PRAT, BERTA NIEVES
Associate Researcher

FERNÁNDEZ DURAN, IRENE
Postdoctoral Researcher

IANNI, ALESSANDRO
Postdoctoral Researcher

MARAZUELA DUQUE, ANA
Postdoctoral Researcher

CASTELLÓ GARCÍA, JOSE MANUEL
PhD Student

GÁMEZ GARCÍA - CERVIGÓN, ANDRES
PhD Student

GUITART SOLANES, ANNA
PhD Student

MOHAMMADALI, ELAHEH
PhD Student

PAÑOS MOLERO, LUIS EULALIO
PhD Student

ZHAO, JING
PhD Student

Endothelial Pathobiology and Microenvironment

led by Mariona Graupera

Transversal Programme:
Preclinical models

OVERVIEW

Our research is devoted to study the biology of the endothelium and its role in disease towards the development of therapeutic strategies to target this compartment. Specifically, we aim to discover the fundamental insights of vessel growth and function in developmental setting as well as to identify the pathological contexts in which the vasculature plays a critical role either intrinsically, as in vascular anomalies, or extrinsically as in cancer.

Over the past decade, we have taken advantage of the PI3K pathway as a paradigm to understand how intracellular roads regulate vessel morphogenesis, and how this knowledge can be translated into therapeutic opportunities for diseases with aberrant angiogenesis.

OUR GOALS

The Graupera lab is devoted to 5 main research lines:

1. Insights on developmental vessel growth and function.
2. Understanding oncoproteins-related developmental disorders.
3. To study tumour-stroma interaction.
4. Identify vascular therapies to treat metabolic disorders.
5. To study endothelial and hematopoietic cell interface.

KEYWORDS

Endothelium, vascular compartment, homeostasis, next generation sequencing, single cell, high-resolution imaging.

GROUP MEMBERS

GRAUPERA GARCIA - MILA, MARIONA
Group Leader

ANGULO URARTE, ANA
Postdoctoral Researcher

CASTILLO DIEZ, SANDRA
Postdoctoral Researcher

MORALES PAYTUVI, FREDERIC
Postdoctoral Researcher

SEGURADO GOUVEIA, LEONOR
Postdoctoral Researcher

VILALTA CASTANY, ODENA
Postdoctoral Researcher

ALBINYÀ PEDRÓS, ALBA
PhD Student

ALVES FIDALGO, MARTA FILIPA
PhD Student

CERDÀ SERRA, PAU
PhD Student

DENGRA CHILLON, JOSÉ ÁNGEL
PhD Student

INNEO, ANNAMARIA
PhD Student

MAES, LOUIS
PhD Student

MARTINEZ LARRINAGA, ANE
PhD Student

MUNAR GELABERT, MARGALIDA
PhD Student

NOLA MAROTTA, EMANUELE MARIA
PhD Student

PEROSANZ HIDALGO, XABIER
PhD Student

ROCA COLL, ARIADNA
PhD Student

SKIADAS, GEORGIOS
PhD Student

VAN SPLUNDER, HIELKE BENJAMIN
PhD Student

BONIN RALLO, LAISA
Research Assistant

GARRIDO CRUZ, MARIA
Research Assistant

CASTILLO AGEA, ELENA
Medium Lab Technician

MUIXI PONSA, LAIA
Project Manager

Epigenetics and Immune Disease

led by Esteban Ballestar

Transversal Programme:
Multiscale-omics

OVERVIEW

We aim at understanding the mechanisms underlying the deposition and removal of epigenetic modifications in immune cells, the influence of genetic and environmental determinants, and the acquisition of epigenetic alterations in immune-mediated disease including primary immunodeficiencies, autoimmune and autoinflammatory diseases. We also investigate the impact of the epigenetic regulation of immune cells in the microtumour environment.

OUR GOALS

Our main lines of research and specific goals are:

1. To understand the role of epigenetic control and its upstream determinants in relation with immune function.
2. To identify epigenetic alterations in immune-mediated diseases and investigate their clinical relevance.
3. To investigate the effects of immunomodulators and epigenetic compounds in shaping the epigenome and responses of immune cells.

OUR CHALLENGES

The study of epigenetic dysregulation can help understand the determinants of immune dysregulation and can have an impact in the treatment of these diseases. Therefore, with our research we want to answer:

1. How do immune cells translate the surrounding information provided by the direct contact with other cells or the cytokines and other molecules into epigenetic profiles that determine their responses?
2. What is the relevance of the epigenetic alterations that are found in different immune mediated diseases in relation to the aberrant function of these cells?
3. How can we apply the knowledge on the epigenetic dysregulation in immune-mediated disease to the clinics?

KEYWORDS

Epigenetics, DNA methylation, Immune-mediated disease, autoimmune disease, primary immunodeficiency

GROUP MEMBERS

BALLESTAR TARIN, ESTEBAN
Group Leader

RODRÍGUEZ UBREVA, FRANCISCO JAVIER
Senior Researcher

ESTUPIÑAN MORENO, ELKYN FABIAN
Postdoctoral Researcher

TRIGUERO MARTÍNEZ, ANA
Postdoctoral Researcher

CALAFELL SEGURA, JOSEP
PhD Student

CIUDAD GARRIDO, LAURA
Research Specialist Technician

FONDELLI, FEDERICO
PhD Student

GODOY TENA, GERARD
PhD Student

GOMEZ PEREIRA, CRISTINA
PhD Student

GUTIERREZ MINGUEZ, SONIA
PhD Student

JUÁREZ CALVILLO, CELIA DE LOURDES
PhD Student

LINK DOPAZO, LUCÍA
PhD Student

MELBERT, FLORENCE
PhD Student

FERRETÉ BONASTRE, ANNA GUIOMAR
Research Specialist Technician

Epigenetic Therapies

led by María Berdasco

Transversal Programme:
Applied epigenetics

OVERVIEW

Epigenetic therapies aim to modify the epigenome, the set of molecular processes that regulate gene expression without altering the DNA sequence and can change the course of a disease and its phenotype. There are now examples of epigenetic drugs for treating haematological malignancies approved by the United States Food and Drug Administration (FDA). However, the volume of promising preclinical evidence far exceeds the number of epigenetic research projects that have resulted in clinical applications to patients. Therefore, more translational studies that may lead to the development of more specific epigenetic drugs and more robust biomarkers are required.

OUR GOALS

Our research aims to ascertain the therapeutic benefit of targeting epigenetic alterations in cancer together with the epigenetic-based stratification of patients to predict therapy response. To achieve this, we develop research based on three specific aims:

1. Identification of the epigenetic alterations that act as drivers of tumour progression.
2. Validation of epidrugs that can efficiently revert aberrant epigenomes in cancer.
3. Stratification of patients based on their epigenetic profile to predict response to immunotherapy.

OUR CHALLENGES

Through our research, we aim to help answer the following questions:

1. Which epigenetic alternations represent targets for drugs to treat cancer?
2. How can we efficiently treat tumours caused by epigenetic alternations?
3. Who could benefit from therapeutic strategies based on epigenetics?

KEYWORDS

Epigenetic drug, epigenetic editing, epidrug, haematological malignancies, targeted therapies

GROUP MEMBERS

BERDASCO MENENDEZ, MARIA
Group Leader

HEALD, JAMES SIMON
PhD Student

LÓPEZ PATO, MIGUEL
Research Specialist Technician

Immunohematology and Glycobiology

led by Fumiichiro Yamamoto

Transversal Programme:
Preclinical models

OVERVIEW

We study the molecular genetic mechanisms for the expression of genetically incompatible glycan antigens and have thus far revealed several potential mechanisms, including the appearance of FORS1 induced by the deletion of exon 3 or 4 of the AT mRNA. Because altered splicing is a hallmark of cancer, this mechanism may be responsible, at least partially, for FORS1 expression in group A and AB individuals.

We also investigate the potential mechanism by which incompatible A antigens appear in group O individuals through complementation by recombination of DNA or trans-splicing of RNA and the expression of FORS1 due to changes in specificity resulting from incorrect intra-Golgi localization of modified glycosyltransferases.

OUR GOALS

Cancer growth indicates that the cancer cell-killing activities of natural immunity against genetically incompatible and/or cryptic glycans are ineffective and insufficient. However, they can be improved through active and/or passive immunization. Therefore, our goals are:

1. To investigate the use of genetically incompatible and/or cryptic glycan antigens as molecular targets for medical intervention.
2. To explore the possibility of using forced expression of genetically incompatible glycans to make cancer cells susceptible to natural immunity.

OUR CHALLENGES

If successful, the active immunization we advocate for could revolutionize the cancer treatment landscape, thereby dramatically reducing the financial burdens on patients and society. Through our research, we aim to answer the following questions:

1. What is the molecular genetic/epigenetic basis of glycan alterations in cancer?
2. Can we use cancer-specific glycans as molecular targets for cancer detection and immunotherapy?
3. Does the minitransfusion/injection of mismatched red blood cells expressing genetically incompatible and/or cryptic glycans improve humoral and cellular immunity against cancer cells expressing cancer-specific glycans?

KEYWORDS

Genetically incompatible glycan antigens, cryptic glycan antigens, cancer immunotherapy, disease susceptibility, ABO polymorphism

GROUP MEMBERS

YAMAMOTO, FUMIICHIRO
Group Leader

CID ROLDÓS, EMILI
Postdoctoral Researcher

YAMAMOTO, MIYAKO
Senior Technician

Regulatory Genomics

led by Tanya Vavouri

Transversal Programme:
Multiscale-omics

OVERVIEW

Our aim is to contribute to a better understanding of gene regulation and the consequences of drug treatments and inter-individual genetic variation in gene expression. Although most of our research is based on data from animal model organisms or cell lines, we hope that, in the long term, the knowledge acquired will increase our understanding about humans.

Extensive aberrant gene expression and genome deregulation are extremely common in cancer, especially haematological forms, and treatments targeting gene regulation pathways are being used for haematological malignancies. Last, but not least, we hope that the data we generate and the analysis methods we develop serve as useful tools for the wider research community.

OUR GOALS

Our research focuses on three main areas:

1. Study the effect of the environment on gene expression changes that are transmitted from parents to their offspring.
2. Describe non-coding RNAs and other non-coding elements that influence gene expression.
3. Understand how epigenetic drugs affect gene expression and chromatin in different genomic contexts.

OUR CHALLENGES

We hope that our research sheds light on the following questions:

1. Which epigenetic mechanisms are involved in the transmission of acquired or variable traits between generations in humans and other animals?
2. Which non-coding DNA elements affect gene expression and therefore potentially phenotype?
3. How drugs (such as those used for the treatment of blood cancers) affect gene expression and the function of the non-coding parts of our genome?

KEYWORDS

Bioinformatics, gene regulation, epigenetic inheritance, germline, genomics.

GROUP MEMBERS

VAVOURI, TANYA
Group Leader

MITJAVILA VENTURA, ADRIÀ
Specialist Technician

Regulatory RNA and Chromatin

led by Sònia Guil

Transversal Programme:
Applied epigenetics

OVERVIEW

We study the emerging roles of noncoding RNAs as key regulators of gene expression in physiological cellular programs and at the onset or during progression of human diseases, with a major focus on tumorigenesis and neurodevelopmental diseases. The research carried out by our group combines biochemical, cellular, and global genomic approaches to dissect mechanisms of gene expression regulation with the participation of ncRNAs, with the aim of revealing molecules of therapeutic/biomarker interest for clinical translation.

Our interest concentrates on the noncoding transcriptome, with the main aim of separating the wheat from the chaff to reveal true biologically relevant molecules and to understand how they are connected to broader gene regulatory networks.

OUR GOALS

Our research aims to:

1. Gain a better understanding of the biological relevance of ncRNAs for an informed use in therapeutic strategies.
2. Identify ncRNA candidates that act as master regulators of oncofetal genes, thereby revealing their validity as biomarkers in human cancer.
3. Developing new experimental tools for research into Rett syndrome.

OUR CHALLENGES

Through our research, we hope to answer the following questions:

1. What is the precise contribution of the non-coding transcriptome to tumour biology?
2. How can we use RNA tools to improve treatment or diagnosis of human disease?
3. How can we better model neurodevelopmental diseases such as Rett syndrome to understand key initial changes in gene expression programs?

KEYWORDS

Noncoding RNAs, cancer epigenetics, gene expression regulation, stem cells, Rett syndrome.

GROUP MEMBERS

GUIL DOMÈNECH, SÒNIA
Group Leader

FERREIRA ALVES, LETICIA
Postdoctoral Researcher

JORGE TORRES, OLGA DE LA CARIDAD
Postdoctoral Researcher

LOUBAT CASANOVAS, JORDINA
Postdoctoral Researcher

SIQUEIRA SOARES, EDILENE
Postdoctoral Researcher

BERGOZZA, MATTIA
PhD Student

CHONGTHAM, ISORCHAND
PhD Student

RAMESH KUMAR, DEEPTHI
PhD Student

SIMKUS, MANTAUTAS
PhD Student

TARRASÓN LARA, ARIADNA
Research Assistant

Lymphoid malignancies

3D Chromatin Organization

led by Biola M. Javierre

Transversal Programme:
Applied epigenetics

OVERVIEW

We are a group of passionate scientists with an insatiable thirst for learning about spatiotemporal architecture of the genome and its role in cell differentiation and function in health and disease.

Although enhancers can be defined through well-characterized features, predicting their target genes at distal location remains challenging due to the high complexity of studying enhancer-promoter interactions, and the large variability according to cell-type and state.

This gap of knowledge is particularly problematic for understanding the molecular mechanisms associated to inherited and de novo acquired mutations and epimutations involved in common human diseases, which are all highly enriched at regulatory elements

OUR GOALS

Our lab's main research goals, which are motivated by this gap in the knowledge, are as follows:

1. To define the cell type-specific 3D chromatin organization in human haematopoietic cells.
2. To identify the altered DNA topology in blood cancer.
3. To prioritize new candidate genes and pathways related to leukaemia and lymphomas.

OUR CHALLENGES

Through our research, we hope to answer the following questions:

> Can the dynamic changes in chromatin interactions shape the transcription decisions controlling haematopoiesis and blood cell function?
> Which are the blood cell-type specific key factors orchestrating genome architecture?
> How does the altered genome architecture drive malignant transformation?
> What is the role of non-coding determinants in cancer predisposition, development and relapse?

KEYWORDS

Genome architecture, spatial-temporal chromatin organization, haematopoiesis, blood cancer, cis non-coding determinants, enhancer-promoter interactions

GROUP MEMBERS

JAVIERRE MARTINEZ, BIOLA M.
Group Leader

FANLO ESCUDERO, LUCIA
Postdoctoral Researcher

GONZALEZ CAPDEVILA, MARC
Postdoctoral Researcher

PLANAS RIVEROLA, AINOA
Postdoctoral Researcher

RIGAU DE LLOBET, MARIA
Postdoctoral Researcher

ROBERT FINESTRA, TERESA
Postdoctoral Researcher

SERRA, FRANÇOIS JOSÉ
Postdoctoral Researcher

TOMÁS DAZA, LAUREANO
Postdoctoral Researcher

ALCALDE MERINO, ÁLVARO
PhD Student

CABRERA PASADAS, MONICA
PhD Student

DE HARO BLÁZQUEZ, RAÚL
PhD Student

LÓPEZ MARTÍ, PAULA
PhD Student

NAVARRO CANSINO, PATRICIA
PhD Student

NIETO-ALISEDA SUTTON, ANDREA AURELIA
PhD Student

URMENETA FLORISTÁN, BLANCA
PhD Student

VALERO MARTINEZ, BLANCA
PhD Student

BYRNE ÁLVAREZ, NICOLÁS
Research Assistant

VIDAL CABALLERO, MIGUEL ANGEL
Research Assistant

Acute Lymphoblastic Leukaemia (ALL)

led by Josep Mª Ribera

Transversal Programme:
Multiscale-Omics

OVERVIEW

Our research focuses on analysing the genomic and epigenomic landscape of patients with adult ALL (acute lymphoblastic leukaemia) to find out genetic alterations that predict patients' response to treatment and to identify new alternative (targeted) therapies to apply to those patients. In this way, we aim to design more personalized treatments to increase the probability of survival of ALL patients.

The group's current research is divided into two main areas, according to the two main subtypes distinguished in ALL, Precursor B-cell acute lymphoblastic leukaemia (BCP-ALL) and T-cell acute lymphoblastic leukaemia (T-ALL).

OUR GOALS

We are convinced that new treatments for ALL patients can be obtained only through basic research. Therefore, our goals are:

1. To identify the genetic alterations leading to treatment resistance and disease recurrence in adult ALL.
2. To accurately define the risk of ALL by genetic analysis at diagnosis and relapse to decide on the most appropriate treatment.

OUR CHALLENGES

Although ALL is a rare form of cancer, it has a huge impact on patients, their relatives, and the health system. To find new therapies and provide new knowledge, our research hopes to:

1. Decipher the genetic complexity of ALL at both diagnosis and relapse.
2. Identify critical genetic lesions in ALL cells that could be targetable with new drugs.

KEYWORDS

Acute lymphoblastic leukaemia, adults, genomic analyses, minimal residual disease, treatment resistance

GROUP MEMBERS

RIBERA SANTASUSANA, JOSEP MARIA
Group Leader

GENESCA FERRER, EULALIA
Postdoctoral Researcher

RIBERA SALAS, JORDI
Postdoctoral Researcher

GONZÁLEZ GIL, CELIA
PhD Student

HARMS, TIAGO ELUNEY ERNESTO
Research Assistant

NIYATI PRAGYA, KENNEDY
Research Assistant

PARK, SEUNGBIHN
Research Assistant

REYNOSO FUENTES, SARA
Research Assistant

VAZQUEZ AVALOS, IDOIA
Research Assistant

OLIVER GARCIA, CARLA
Research Specialist Technician

LOPES, THAYSA
Senior Lab Technician

Cellular Immunotherapy and Gene Therapy

led by Javier Briones

Transversal Programme:
Population studies and clinical trials

OVERVIEW

The Cellular Immunotherapy and Gene Therapy Group is focused on the study of genetically modified T-cells expressing chimeric antigen-specific receptors (CARs) and their clinical application in patients with blood cancer.

The group currently focuses on studying T-cells genetically modified with chimeric antigen-specific receptors (CARs) and their clinical application in patients with blood cancer.

OUR GOALS

Our current lines of research concentrate on the following aspects of cellular immunotherapy:

1. Functional antitumor research into subtypes of memory T-cells.
2. Study of the antitumor efficacy of memory stem T-cells genetically modified with CARs.
3. Development of new CARs targeted against haematological malignancies.
4. Development of clinical immunotherapy trials with CAR T-cells on patients with lymphoid neoplasms.

KEYWORDS

CAR-T; T-Cells; Lymphoid Neoplasms.

GROUP MEMBERS

BRIONES MEJIDE, JAVIER
Group Leader

CABALLERO GONZÁLEZ, ANA CAROLINA
Postdoctoral Researcher

ESCRIBA GARCIA, LAURA
Postdoctoral Researcher

JARA BUSTAMANTE, PAOLA
Senior Lab Technician

MONTSERRAT TORRES, ROSANNA
Senior Technician

Cellular Systems Genomics

led by Elisabetta Mereu

Transversal Programme:
Multiscale-Omics

OVERVIEW

In the interface between genomics, digital pathology, and artificial intelligence ***the Cellular Systems Genomics*** group aims to define the spatiotemporal organization of complex tissues in health and disease, by the identification of key regulatory mechanisms driving heterogeneity in cellular identity and function, particularly in the context of inflammation, inflammatory disorders, and autoimmune diseases.
To address these questions, we will adopt a single-cell perspective, enabling the fine-grained and spatially resolved molecular profiling of tissues.

We will develop new machine learning approaches and open-source tools to unlock molecular mechanisms hidden in large-scale datasets. In a short-term perspective, these methods will help understand disease mechanisms, allowing the stratification of patients based on their molecular and cellular characteristics, ultimately providing new therapeutic targets for their treatments.

OUR GOALS

In the European Pancreas Atlas consortium, we are working to:

1. Build a first version of the Human Cell Atlas of the Pancreas.
2. The integration of distinct single-cell and spatial data types create a comprehensive transcriptional and epigenetic landscape of pancreas cell types within their spatial context.
3. Share user-friendly computational solutions, promoting open science, diversity and supporting an inclusive and collaborative environment.

KEYWORDS

Genomics, inflammation, autoimmunity, single cell, machine learning, computational analysis

GROUP MEMBERS

MEREU, ELISABETTA
Group Leader

BURATIN, ALESSIA
Postdoctoral Researcher

ACERA MATEOS, MARIO
PhD Student

GONZALEZ HERRERO, AITOR
PhD Student

RILL I HINAREJOS, AINA
PhD Student

LI, JESSICA KANGLIN
Lab Assistant Technician

Lymphocyte Development and Disease

led by Maribel Parra

Transversal Programme:
Applied Epigenetics

OVERVIEW

Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children under a year old. Even though the chances of survival in infants suffering from ALL have improved significantly in recent years, an exhaustive study of the mechanisms underlying this disease is still required to make further therapeutic advances.

How specific gene expression programs are selected and maintained, thus resulting in the proper generation of B cells, remains a fundamental question in biology. Conversely, how the aberrant establishment of cell- and lineage-specific gene transcriptional programs leads to the development of B-cell malignancies such as leukaemia and lymphoma also requires extensive research.

OUR GOALS

Our group focuses on:

1. To understand how gene silencing is established during normal and aberrant B-cell differentiation.
2. To transfer our basic knowledge in the epigenetics and transcriptional control of B-cell development to the clinical setting for infant B-ALL and DLBCL patients.
3. To implement a 3D organoid platform for DLBCL patient samples to perform compound library screenings aimed at unveiling new drugs for use in combinatorial therapy with current immunotherapy in a personalized manner.

OUR CHALLENGES

Through our research, we aim to answer the following questions:

1. How do B lymphocytes decide their identity? How is gene silencing established?
2. Why does HDAC7 expression improve the prognosis of some hematological diseases?
3. Why is HDAC7 underexpressed in pro-B-ALLA and DLBCL?
4. How can we restore HDAC7 expression in pro-B-ALL and DLBCL to impair disease progression?
5. Can we implement 3D organoids from DLBCL patients aimed at drug screening towards a precision medicine strategy and immunotherapy improvement?

KEYWORDS

B lymphocyte development; Epigenetics; Transcriptional regulation; HDAC; B cell acute lymphoblastic leukemia (B-ALL); Diffuse large B-cell lymphoma (DLBCL)

GROUP MEMBERS

PARRA BOLA, MARIBEL
Group Leader

DE BARRIOS BARRI, ORIOL
Senior Researcher

GUSI VIVES, MAR
PhD Student

OCON GABARRO, INGRID
PhD Student

SOPHIE DIETZ, ALISSA
PhD Student

COLLAZO OTERO, OLGA
Medium Lab Technician

Lymphoid Neoplasms

led by Tomás Navarro

Transversal Programme:
Population studies and clinical trials

OVERVIEW

Our research unit is composed of professionals with strong clinical and biological backgrounds in lymphoproliferative diseases, with a particular focus on those arising in the context of immune system dysregulation or deficiency, such as in HIV infection. This heterogeneous group includes aggressive lymphomas -such as diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), and primary effusion lymphoma (PEL), as well as proliferative disorders like Castleman disease (CD). Most of the above-mentioned nosological entities are very rare, characterized by complex biology and often excluded from clinical trials. As a result, the understanding of their onset and evolution represents a big challenge for the whole scientific community. As a group, we have already contributed to defining some clinical and biological features of these diseases, including through high-profile international collaborations (Baptista MJ, et al. Histopathology 2022; Hübel K, et al. Hemasphere 2024; Pierson SK, et al. Blood Adv 2025; Verdu-Bou M, et al. Blood Adv 2025 Apr).

We are therefore committed to providing further meaningful contributions in this field that can be translated from bench to bedside.

Our main areas of research are:

> Genomic studies on HIV-related lymphomas.
> Liquid biopsy in aggressive lymphomas.
> Clinical and biological studies on Castleman disease.
> Cytogenetic characterization of aggressive lymphomas.

OUR GOALS

1. To clarify the complex genetic and molecular interactions supporting the development of these challenging lymphoid neoplasms;
2. To identify potential biomarkers with real-world applicability.
3. To guide the design of new targeted therapies, based on the identified aberrations.

OUR CHALLENGES

By achieving the goals outlined above, we firmly believe we can make a meaningful contribution to the international effort aimed at improving the early diagnosis and clinical management of both malignant and non-malignant lymphorative disorders associated with immunosuppression and immune dysregulation. Our translational approach holds the promise of improving the life expectancy of specific subgroups of hematologic patients who, to date, remain particularly challenging to treat.

KEYWORDS

Non-Hodgkin's lymphoma, Hodgkin lymphoma, HIV, Epstein-Barr virus, diagnosis, prognosis, marker, treatment, targeted therapy, early detection

GROUP MEMBERS

NAVARRO FERRANDO, JOSE TOMAS
Group Leader

ORNA MONTERO, ELISA
Senior Researcher

DE AGUIRRE EGAÑA, ITZIAR
Postdoctoral Researcher

SANCHO CIA, JUAN MANUEL
Postdoctoral Researcher

VERDÚ BOU, MIRIAM
Postdoctoral Researcher

FRANCH SARTÓ, MIREIA
PhD Student

QUINTELA VITGES, DAVID
PhD Student

HERNANDEZ RODRIGUEZ, INES
Attending Physician

MESA TUDEL, ALBA
Attending Physician

HUGUET MAS, MARÍA
Specialist Technician

RAMIREZ SERRANO, JOSE LUIS
Specialist Technician

VIÑAS NOGUERA, JORDI
Specialist Technician

JIMÉNEZ PONCE, ARIADNA
Senior Lab Technician

MONTES LEO, NOEMI
Medium Lab Technician

Lymphoma Translational

led by Gaël Roué

Transversal Programme:
Preclinical models

OVERVIEW

Our research is centred on the development of innovative preclinical models of B-cell lymphoma that can be used to unravel the complex role of tumour-lymphoma crosstalk during the development of the disease and the acquisition of refractoriness in current regimens. To that end, we intend to reproduce the original composition and architecture of tumours in the laboratory to carry out a complete transcriptomic and proteomic analysis and develop new pharmacological entities in collaboration with academic experts and clinical-level pharmaceutical companies, all with a view to fostering the bench-to-bedside transfer of new and tailored therapeutic strategies.

OUR GOALS

Our main areas of research are:

1. Development of a patient-derived xenograft platform for the evaluation of new targeted therapies in aggressive B-cell lymphomas.
2. Modulation of the lymphoid microenvironment by intrinsic protein homeostasis in aggressive B-cell lymphoma.
3. How multiomics analysis of paired treatment-naïve and therapy-refractory B-cell lymphoma can help in the design of efficient and personalized therapies.

OUR CHALLENGES

Through our research, we aim to understand the following:

1. To what extent intrinsic protein homeostasis can regulate the complex tumour-stroma crosstalk in different models of aggressive B-cell lymphoma.
2. How germinal centre-derived lymphoma can be sensitized to immune checkpoint blockade therapy.

KEYWORDS

B-cell non-Hodgkin's lymphoma (NHL), tumour modelling, proteostasis, tumour microenvironment, immunotherapy

GROUP MEMBERS

ROUÉ, GAËL
Group Leader

PAVLIUCHENKO, NATALIIA
Postdoctoral Researcher

PROFITOS PELEJA, NURIA
Postdoctoral Researcher

CROSS, STEPHEN
PhD Student

GORJON DE PABLO, GEMA
Lab Technician

Mechanisms of cancer and ageing Lab (South)

led by Salvador Macip

Transversal Programme:
Multiscale-Omics

INTRODUCTION

We study the mechanisms that determine resistance to treatment and relapse in B cell malignancies (especially CLL and DLBCL) and the molecular pathways involved in age-related diseases, with particular emphasis on the role of senescent cells in cancer and ageing phenotypes. We also investigate prognostic/diagnostic markers of ageing and anti-senescent therapies for healthy ageing and as adjuvant treatments for leukaemia.

Since 2008, we are studying combination therapies for B cell malignancies to reduce resistance to treatment and relapse. We are characterizing the mutations that confer resistance to leukaemia cells and looking for markers that could allow the stratification of patients (i.e. finding the right treatment for each patient, in what is called personalized or precision medicine).

OUR GOALS

Through our research, we are trying to answer the following questions:

1. What determines the resistance of B cell malignance to treatments and the eventual relapse, and how can they be prevented?
2. What role do senescent cells play in resistance/relapse of leukaemia and in other age-related diseases?
3. Can anti-senescence drugs be used as adjuvants in leukaemia treatment?

OUR CHALLENGES

We hope to develop new markers for patient stratification and define new combination therapies that can reduce resistance/relapse in B cell malignancies. We want to ameliorate cancer and other age-related diseases.

GROUP MEMBERS

MACIP MARESMA, SALVADOR
Group Leader

MASSIP SALCEDO, MARTA
Senior Researcher

RIUS BONET, JÚLIA
PhD Student

TORRUBIANO BALCELLS, MARTA
Medium Lab Technician

Multiple Myeloma

led by Albert Oriol

Transversal Programme:
Population studies and clinical trials

OVERVIEW

Our clinical research team participates in the main international collaborative phase I to phase III trials establishing the current standards of care, with a particular focus on the optimal combinations of agents with clinically relevant synergies.

Active trials are already focusing on the efficacy of next-generation combinations, including antibody-drug conjugates, T-cell engagers, and CAR-T cells. We are interested in the identification of subjects unlikely to respond to optimized first-line strategies and, therefore, of ideal candidates for such trials with novel immunotherapeutic approaches.

OUR GOALS

Our main goals are:

1. To define standards of treatment that provide a long-lasting response in most individuals.
2. To identify patients who will probably be cured and will safely remain treatment-free.
3. To identify patients who are unlikely to be disease-free for long with current treatments and search for alternative treatment options that can be applied before recurring disease causes organic damage.

OUR CHALLENGES

Through our research, we hope to answer the following questions:

1. What patients are unlikely to obtain prolonged benefits from current standards?
2. Would they benefit from early intervention with alternative agents?
3. Can we identify patients who will potentially be cured or are unlikely to relapse and safely spare them the burden of continuous therapy?

KEYWORDS

Multiple myeloma, synergistic combinations, immuno-drug conjugates, T-cell engagers, CAR-T cells.

GROUP MEMBERS

ORIOL ROCAFIGUERA, ALBERT
Group Leader

CISNEROS SALA, ADELA
Senior Researcher

IBARRA FERNANDEZ, GLADYS
Attending Physician

FERNÁNDEZ NÚÑEZ, OLGA
Specialist Technician

Nuclear Architecture in Leukemia

led by Grégoire Stik

Transversal Programme:
Multiscale-Omics

OVERVIEW

The main goal of our lab is to understand the molecular mechanisms that induce and control the malignancy of leukemic cells. For that, we combine and integrate state-of-the-art genomics technology, genome-engineering tools, optogenetic and advanced microscopy imaging to study gene regulatory network in human leukemic cells.

We focus particularly on the role of the three-dimensional (3D) genome organization in leukemic phenotype and how fusion protein induced by chromosomal translocation can alter the chromatin organization. Beyond our fundamental discoveries, we aim to uncover new targets and biomedical applications for the treatment of lymphoid malignancies.

OUR GOALS

The research in our lab develops around the following axes:

1. Uncovering the biophysical properties of the chimeric E2A-PBX1 oncogene and its role on 3D genome alteration and pathogenesis of B cell acute leukaemia
2. Identification and characterization of genome topology alteration in B cell acute lymphoblastic leukaemia
3. Characterization of transcription factor mutations and their role in 3D genome organization alteration and leukemogenesis

OUR CHALLENGES

The genome is highly organized in the nucleus into various structures including compartments, domains and loops. These structures are crucial to maintain the physical interactions between regulatory regions and gene expression. The comprehensive integration of the 3D genome organization with other layers of the gene regulatory network is therefore crucial to uncover the molecular mechanisms beyond the disease and identify new potential therapeutic targets.

KEYWORDS

Genomics, 3D genome organisation, Acute Lymphoblastic Leukaemia, Transcription Factors, Translocations

GROUP MEMBERS

STIK, GREGOIRE
Group Leader

TOVAR FERNANDEZ, MARIA CAMILA
Postdoctoral Researcher

ERCAN, KUTLU
PhD Student

LOPEZ GARCIA, MARTA
PhD Student

ALCOVERRO BERTRAN, MARC
Senior Lab Technician

FERRE AGUIRRE, ESTEL
Lab Assistant Technician

Stem Cell Biology, Developmental Leukemia and Immunotherapy

led by Pablo Menéndez

Transversal Programme:
Preclinical models

OVERVIEW

Our group is interested in understanding the cellular origin, etiology, and pathogenesis of childhood leukaemia. We aim to ascertain the cell in which mutations occur and we strive to discover which cells are responsible for triggering relapses. Furthermore, we work to identify new therapeutic targets and develop more targeted, less toxic therapies. To achieve this, our laboratory uses various approaches, including genetic studies, epigenetic techniques, and animal models, as well as adoptive cell immunotherapy tools.

OUR GOALS

Our group is currently involved in various lines of research in pursuit of the following objectives:

1. To understand the etiology and pathogenesis of leukaemia in breastfeeding infants.
2. To gain a better understanding of the role of bone marrow (BM) stroma in chemoresistance in acute myeloid leukaemia (AML).
3. To improve adoptive cellular immunotherapies against ALL-B, ALL-T and AML.

Our overall goal is to contribute towards curing 100% of childhood leukaemia or convert them into chronic conditions, without generating lifelong toxicities.

OUR CHALLENGES

Through our research, we aim to:

1. Identify the cellular origin, cellular and molecular mechanisms, and the genetic and epigenetic composition of ALL-B in breastfeeding infants.
2. Contribute to the development of new therapeutic strategies in AML targeted towards reducing the resistance mediated through the BM microenvironment and that are particularly effective against LICs.
3. Develop adoptive cellular immunotherapies against ALL-B, ALL-T and AML using allogeneic T-cells without genome editing to eliminate TCR, CD3 and other molecules that play a role in immunological synapse.

KEYWORDS

Paediatric leukaemia, stem cells, immunotherapy, MLL rearrangements, PDX models

GROUP MEMBERS

MENÉNDEZ BUJÁN, PABLO
Group Leader

BUENO UROZ, CLARA
Associate Researcher

MOLINA CAMPOY, OSCAR
Senior Researcher

...

...

APOSTOLOV, APOSTOL KONSTANTINOV
Postdoctoral Researcher

DIAZ COTES, VICTOR
Postdoctoral Researcher

ESPINOSA AROCA, LADY GIOVANNA
Postdoctoral Researcher

FALGAS COMAMALA, AIDA
Postdoctoral Researcher

FERNÁNDEZ FUENTES, NARCISO
Postdoctoral Researcher

FIDYT, KLAUDYNA PAULINA
Postdoctoral Researcher

MULENS ARIAS, VLADIMIR
Postdoctoral Researcher

ROCA - HO, HELEIA
Postdoctoral Researcher

SAFI, RÉMI
Postdoctoral Researcher

SÁNCHEZ MARTÍNEZ, DIEGO
Postdoctoral Researcher

VELASCO HERNÁNDEZ, TALÍA
Postdoctoral Researcher

VINYOLES VERGES, MERITXELL
Postdoctoral Researcher

CALVO GONZÁLEZ, CRISTINA MIREIA
PhD Student

CYRAN, JULIA SELENA
PhD Student

FRASEZ SORENSEN, JOHANNES
PhD Student

GUERRERO MURILLO, MERCEDES
PhD Student

MESEGUER GIRON, ANGELA
PhD Student

PANISELLO ARANDA, CARLA
PhD Student

RUBIO GAYARRE, ALBA
PhD Student

THAMPI, NAMITHA
PhD Student

TIRADO CABRERA, NÉSTOR
PhD Student

XIMENO PARPAL, PAU
PhD Student

RODRIGUEZ CORTEZ, VIRGINIA CAROLINA
Lab Manager

MARTINEZ MORENO, ALBA
Senior Lab Technician

PANELLI, PATRIZIO
Research Specialist Technician

PERICH PALLARUELO, LAURA
Lab Assistant Technician

Stem Cells and Cancer

led by Anna Bigas

Transversal Programme:
Multiscale-Omics

OVERVIEW

Our research group investigates how to generate and maintain the stem cells in the hematopoietic system under physiological conditions but also how these processes are mimicked by the tumours for their perpetuation. We constantly improve our research by implementing novel technology to understand the process of normal and malignant hematopoietic development. Our research includes basic studies at the molecular level to understand cellular processes in the context of mouse models and human patients.

OUR GOALS

We are currently working on several projects that deal with different functional aspects of normal hematopoietic stem cell regulation as well as leukaemia initiating cells:

1. Generation of hematopoietic stem cells.
2. Understanding T Acute Lymphoblastic Leukaemia (T-ALL) development and T-cell lymphoma.
3. GATA2 deficiency syndrome.
4. Understanding cell transformation.

OUR CHALLENGES

Through our research, we aim to understand the following:

1. What signals are imposed in embryonic HSCs that affect the adult hematopoietic system?
2. What are the molecular mechanisms that impose resistance to treatment in T-ALL cells?
3. What are the basic mechanisms that control cell transformation?

KEYWORDS

Embryonic haematopoiesis, T-ALL, CTCL, GATA2, Notch, NFkB, hematopoietic stem cell, leukemic stem cells.

GROUP MEMBERS

BIGAS SALVANS, ANNA
Group Leader

GARCÍA HERNÁNDEZ, VIOLETA
Postdoctoral Researcher

PANDA, SIMRAN
PhD Student

CANTON DOMINGUEZ, ERIC
Research Assistant

GONZALEZ MIRANDA, JESSICA
Senior Lab Technician

IGLESIAS PIQUERAS, ARNAU
Senior Lab Technician

T-Cell Lymphoma

led by Laura Mondragón

Transversal Programme:
Preclinical models

OVERVIEW

Our research is focused on the better understanding of the molecular mechanisms leading to T cell lymphomas appearance. We will develop our research by determining possible defective mechanisms during thymopoiesis and, by developing preclinical mice models for the study of T cell lymphomas, such as angioimmunoblastic T cell lymphoma.

With this knowledge we expect to design and validate new therapeutic treatments more specific and effective than the ones currently available to improve patient's survival and quality of life.

OUR GOALS

Through our research, we aim to:

1. Make available new therapies to treat angioimmunoblastic T cell lymphoma and reduce mortality in those patients.
2. To improve life expectancy of patient's suffering from this type of disease.
3. Finding new strategies to improve patient's chances to recover from this disease and significantly improve their quality of life.
4. To unveil the molecular mechanisms leading to T cell lymphoma appearance
5. To provide new therapeutic targets to design more specific and effective therapeutic treatments to fight these group of haematological diseases.

OUR CHALLENGES

There are some questions we are trying to answer with our research:

1. When does defects in T cells leading to T cell lymphoma appearance start?
2. Which are the specific T cell populations responsible for T cell lymphoma induction?
3. Can we design more specific and effective therapeutic treatments for this type of disease?

KEYWORDS

thymopoiesis, t cell lineage selection, T cell receptor, T cell activation, lymphoma

GROUP MEMBERS

MONDRAGÓN MARTÍNEZ, LAURA
Group Leader

CHALHOUB, BARBARA
PhD Student

LEIVA YUSTE, DIEGO
PhD Student

LUQUE GARCIA, ANTONIO MIGUEL
Lab Assistant Technician

Myeloid Neoplasms

Chromatin, Metabolism and Cell Fate

led by Marcus Buschbeck

Transversal Programme:
Applied epigenetics

OVERVIEW

We seek to bridge the gap between basic molecular research and translational research by exploring chromatin regulation, in particular the molecular biology of histone variants. We aim to exploit this knowledge for the identification of novel intervention strategies for the treatment of blood cancers. We focus on the continuum of myeloid diseases, ranging from the premalignant expansion of altered clones to chronic myelodysplastic syndromes and acute myeloid leukaemia.

OUR GOALS

Through our research, we aim to gain a better understanding of the epigenetic mechanisms that contribute to the development of blood cancers. Particularly:

1. To mine the chromatin regulatory space to identify novel drug targets that can either help improve current treatments or intercept disease at an early asymptomatic stage.
2. To study histones from the protein core of the nucleosome, particularly the variant macroH2A.

OUR CHALLENGES

Through our research, we hope to answer the following questions:

1. How do epigenetic mechanisms operate on the molecular level?
2. How do chromatin and histone variants contribute to cell fate transitions?
3. How can we exploit this knowledge for the development of novel therapeutic strategies?

KEYWORDS

myelodysplastic syndrome, acute myeloid leukaemia, chromatin, nuclear organization, histone variants

GROUP MEMBERS

BUSCHBECK, MARCUS
Group Leader

CORUJO GARCIA, DAVID
Postdoctoral Researcher

DIESCH, JEANNINE
Postdoctoral Researcher

FARKAS, MARINA
Postdoctoral Researcher

WINKLER, RENÉ
Postdoctoral Researcher

BHATTACHARYA, SHUBHRA ASHISH
PhD Student

BLICKENBERGER, JONATHAN
PhD Student

CHRISTINA, NADYA
PhD Student

DIAS, EVE
PhD Student

MEERS, OLIVER PATRICK
PhD Student

ROQUERO MENDIOLA, PAULA
PhD Student

VALERO LÁZARO, VANESA
Medium Lab Technician

KOUMPROGLOU, RACHIL
Project Manager

Descriptive Epidemiology, Genetics and Cancer Prevention

led by Rafael Marcos Gragera

Transversal Programme:
Population studies and clinical trials

OVERVIEW

One of the main lines of research of the group is the epidemiology of haematological neoplasms, with the aim of determining the incidence, prevalence, and survival of this type of cancer. The results obtained aim to provide useful and reliable information to design and/or improve the appropriate health resources and describe the population trends of this group of diseases.

OUR GOALS

Specifically, our research objectives aim at:

1. Establishing the prevalence, incidence, and survival of myeloid, lymphoid and histiocytosis neoplasms globally and according to the respective subtypes.
2. To analyse the temporal trend of the incidence and survival of haematological neoplasms in the context of the evolving therapeutic background.
3. Determine epidemiological parameters based on sex and age.
4. Carry out etiological studies of haematological neoplasms according to each of the histological subtypes.
5. To study the genetic and environmental risk factors related to haematological neoplasms.
6. Describe the risk factors and epidemiology of multiple myeloma based on its precursor cells.
7. Analyse the associations between comorbidity and the survival of lymphoid and myeloid neoplasms.
8. Evaluate the population effectiveness of new therapies in a real population and the impact on survival.
9. Identify changes in the classification, definition and coding of haematological neoplasms and establish working protocols to have homogeneous tools that allow epidemiological comparisons at the international level.

OUR CHALLENGES

Through our research, we aim to understand the following:

1. What is the incidence of haematological neoplasms in the territory?
2. What is the survival of each of the histological subtypes of neoplasia?
3. How have changes in the coding of haematological neoplasms over time affected the epidemiological determinants of this group of diseases?

KEYWORDS

Incidence, survival, mortality, lymphoid neoplasms, myeloid neoplasms, histiocytosis, haematological neoplasms

GROUP MEMBERS

MARCOS - GRAGERA, RAFAEL
Group Leader

AUÑON SANZ, CARME
Postdoctoral Researcher

OSCA GELIS, GEMMA
Postdoctoral Researcher

SOLANS MARGALEF, MARTA
Postdoctoral Researcher

VILLAVICENCIO OBANDO, ALICIA
Postdoctoral Researcher

PLA GONZÁLEZ, CLÀUDIA
PhD Student

AMEIJIDE SÁNCHEZ, ALBERTO
Research Specialist Technician

ROMAGUERA PALOMÉ, AINA
Research Specialist Technician

SANVISENS BERGÉ, ARANTZAZU
Research Specialist Technician

TRALLERO MORALES, JAN
Research Specialist Technician

PUIGDEMONT GUINART, MONTSE
Specialist Technician

VERDAGUER ROBERTE, MAIKEL
Specialist Technician

VIDAL VILA, ANNA
Specialist Technician

RODON NAVARRO, ESTEVE
Finance Specialist

Epigenetic Control of Haematopoiesis

led by José Luis Sardina

Transversal Programme:
Multiscale-Omics

OVERVIEW

We study how aberrant DNA methylation at distal gene regulatory regions poisons the chromatin to trigger corrupted gene expression signatures in cells, thus eventually leading to the onset and progression of haematological neoplasms. This line of research has implications for a broad spectrum of patients suffering from blood diseases sharing an abnormal genome-wide DNA methylation landscape.

OUR GOALS

Through our research, we aim to:

1. Unravel the different layers of intricated epigenetic information that specify which subsets of genes define the cellular identity in every one of the cells of the hematopoietic system.
2. Apply this knowledge to better understand how and when deleterious transcriptional programs leading to cellular transformation are activated.

OUR CHALLENGES

There is an urgent need for novel therapies for acute myeloid leukaemia, since barely any drugs introduced in the last decades have increased the overall survival its patients. Hence, our research aims to shed light on the following questions:

1. What is the interplay between DNA (hydroxy) methylation and chromatin dynamics at distal gene regulatory regions during hematopoietic cell fate decisions?
2. What are the molecular mechanisms underlying the role of TET2 in the epigenetic control of the chromatin at distal gene regulatory regions during leukaemia onset and progression?
3. What is the role of mRNA methylation-mediated post-transcriptional control in myeloid cell differentiation?

KEYWORDS

DNA methylation; TET enzymes; Chromatin; Haematological malignancies; Stem cells

GROUP MEMBERS

SARDINA ORTEGA, JOSÉ LUIS
Group Leader

CAVIEDES CARDENAS, LISKA RAYEN
Postdoctoral Researcher

FLASCHNER, EMILY ALEXANDRA
PhD Student

LAZARENKOV, ALEKSEY
PhD Student

LOPEZ RUBIO, ANNA VANESSA
PhD Student

MELBERT, FLORENCE
PhD Student

OBIOLS HURTADO, MIREIA
PhD Student

VALCARCEL XIMENIS, GEMMA
PhD Student

Haematological Diagnosis

led by Josep Nomdedéu

Transversal Programme:
Applied epigenetics

OUR RESEARCH

In our lab, we focus on both malignant and non-malignant haemopathologies to offer better diagnostics, understand its biological characteristics, and develop new treatments. We study acute leukaemia multi-omics and platelet pathologies like thrombocytopenia, thrombocytopathies and thrombosis.

OUR GOALS

Through our research, we aim to:

1. Consolidate the characterization of haematological tumours and complex, rare, and genetic noncancerous hematopathologies.
2. Include the results of mass-analysis genomic and proteomic platforms in diagnostic algorithms and establish prognostic factors for hematological disorders.
3. Develop functional cell culture and animal (murine) models.
4. Consolidate cooperation with the GAIT-2 project, especially regarding platelet and other blood cell participation in thrombosis generation.

KEYWORDS

Malignant hemopathologies, thrombocytopathies, thrombosis

GROUP MEMBERS

NOMDEDÉU GUINOT, JOSEP
Group Leader

Haematological Diseases, Transplant and Cell Therapy

led by Jordi Sierra

Transversal Programme:
Population studies and clinical trials

OUR RESEARCH

Our research focuses on the molecular and cellular physiopathology of blood cancers, particularly on acute myeloid leukaemia (LMA) and chronic lymphatic leukaemia (CLL) where we seek to find new treatment options targeting molecular features. Also, we study the prognostic value of clinical and biological features in malignant hemopathies, like LMA and CLL.

We study the transplant of hematopoietic progenitors and its complications and develop new academic CAR-T cells enriched in T-memory stem cells to treat T and B Hodgkin lymphomas.

OUR GOALS

The main goals of our research are:

1. Identify new prognostic parameters for risk and therapeutic stratifications.
2. Molecularly characterize acute myeloid leukaemia and determine the prognostic value of known genes and other genes of uncertain significance.
3. Evaluate targeted therapy in cell lines and animal models (together with Dr. Mangues' group).
4. Reduce toxicity and increase the availability of allogeneic transplants.
5. Preclinical (mouse) and clinical studies on immunotherapy for lymphoproliferative diseases. Development of non-commercial CAR-T cell therapies.

OUR CHALLENGES

It is paramount that we improve the prognosis of haematological patients by using new more precise therapies, and less toxic. Therefore, through our research, we aim to:

1. Improve the genotypic and immunophenotypic characterization of AML and CLL, to identify new prognostic factors and administer targeted therapy.
2. Improve the safety and effectiveness of hematopoietic transplantation and expand the number of patients who can benefit from it.
3. Develop new CAR-T products that enhance the currently commercially available ones.

KEYWORDS

Hematopoietic transplantation, CAR-T cells, Immunotherapy, Acute Myeloid Leukaemia, Chronic Lymphocytic Leukaemia

GROUP MEMBERS

SIERRA GIL, JORDI
Senior Researcher

GARCÍA CADENAS, IRENE
Attending Physician

GARRIDO DIAZ, ANA
Attending Physician

LOPEZ PARDO, JORDI
Attending Physician

MARTINO BOFARULL, RODRIGO
Attending Physician

MIQUELEIZ ALAMOS, SARA
Attending Physician

NOVELLI CANALES, SILVANA
Attending Physician

SAAVEDRA GEROSA, SILVANA
Attending Physician

ARGÜELLO DE TOMAS, MIGUEL
PhD Student

ESQUIROL SANFELIU, ALBERT
Senior Lab Technician

Leukaemia and Immuno-Oncology

led by Laura Belver

Transversal Programme:
Preclinical models

OVERVIEW

Since 2020, our work has focused on the study of the molecular mechanisms driving Juvenile myelomonocytic leukaemia (JMML) and the exploration of alternative therapeutic strategies specifically designed for these patients.
To achieve this, we incorporate different methods into epigenetics, systems biology, functional genomics, and biochemistry, to help address critical questions about the origin and progression of JMML and to identify new therapeutic targets for the treatment of this disease.

OUR GOALS

The specific goals of our research programme are as follows:

1. To create a centralized JMML sample repository and patient-derived xenograft (PDX) collection.
2. To develop a comprehensive molecular analysis of JMML patients to define accurate diagnostic and stratification criteria.
3. To identify new potential therapeutic targets and develop specific therapies for the treatment of JMML.

We are confident that our results will have an important impact on the diagnosis and treatment of JMML by increasing knowledge of the disease and expanding the therapeutic options open to these patients.

OUR CHALLENGES

With our research, we aim to answer the following questions:

1. What is the relevance of non-coding somatic mutations in the generation and development of JMML?
2. Can non-coding mutations predict the prognosis of JMML patients?
3. What are the best therapeutic targets for the development of JMML-specific treatments?

KEYWORDS

Leukaemia, JMML, PTPN11, experimental therapeutics, CAR-T cells, rare diseases, paediatric diseases, sequencing, diagnosis, therapeutic targets, preclinical models, drug discovery

GROUP MEMBERS

BELVER MIGUEL, LAURA
Group Leader

DEBERNARDI, ALICE
Postdoctoral Researcher

MOUALLA, YAHIA
Postdoctoral Researcher

CAMPAGNARI, ANNA
PhD Student

FIÑANA OROÑEZ, CLAUDIA
PhD Student

GÓMEZ MOLINA, NOEL
PhD Student

RUINI, EMILIO
PhD Student

ALONSO MORENO, SANDRA
Senior Lab Technician

SERRACANTA ROCA, ELISABETH
Lab Assistant Technician

LUONG, MAILINH
Lab Assistant Technician

Myelodysplastic Syndromes

led by Francesc Solé

Transversal Programme:
Multiscale-Omics

OVERVIEW

Our research focuses on unravelling the heterogeneity of myelodysplastic syndromes (MDS), mainly using genomic techniques. We study MDS patients who harbor a specific cytogenetic alteration: the deletion of the long arm of chromosome 5. Our aim is to improve the genetic characterization of these patients by studying the impact of adjunct cytogenetic abnormalities on their prognostic stratification; how cytogenetics and mutations can influence the response to lenalidomide treatment; the molecular landscape of MDS through next-generation sequencing techniques; and, finally, intratumoral heterogeneity before and after lenalidomide treatment using single-cell techniques.

OUR GOALS

Through our research, we intend to contribute to a better understanding of MDS from a genomic point of view, contributing to refine the current criteria to diagnose this disease and predict patient outcomes to select the best possible treatment. Hence, our research addresses the following lines:

1. Evaluating the feasibility of using peripheral blood samples to perform genetic analyses (SNP-A and NGS) in MDS.
2. Monitoring mutational burden in low-risk MDS patients using sequential peripheral blood samples to minimize invasive techniques on these patients.
3. Genetic characterization of myelodysplastic syndromes / myeloproliferative neoplasms (MDS/MPN) to define the genetic changes that could contribute to the differential diagnosis and prognostic stratification of these patients.
4. Genetic characterization of therapy-related myeloid neoplasms.
5. Mechanisms of progression from clonal haematopoiesis to MDS.

OUR CHALLENGES

Our research can translate into a more efficient use of public healthcare resources and improve the quality of life for patients. Therefore, we want to shed light on the following questions:

1. How might genomic techniques contribute to refining the current criteria for MDS diagnosis, prognostic stratification, and treatment response?
2. Can peripheral blood samples be useful to monitor MDS patients through next-generation sequencing?
3. Could single-cell studies help us better understand intratumoral heterogeneity and clonal evolution from CHIP to MDS and TRMN (therapy-related myeloid neoplasms)?

KEYWORDS

Myelodysplastic syndromes, chronic myelomonocytic leukaemia, intratumor heterogeneity, myelodysplasia, cytopenia, CHIP, TRMN

GROUP MEMBERS

SOLE RISTOL, FRANCESC
Group Leader

CALVETE TORRES, ORIOL
Postdoctoral Researcher

MESTRE VIÑOLAS, JULIA
PhD Student

MANCINI, ESTEFANIA
Senior Lab Technician

MANZANARES MILEO, ANA
Senior Lab Technician

AKTAN, IPEK YAREN
Lab Assistant Technician

ANDRES MOLINA, CONSTANTINO
Lab Assistant Technician

CHAPARRO GONZALEZ, LOREA
Lab Assistant Technician

RUIZ PÉREZ-HITA, LUCÍA
Lab Assistant Technician

RODRIGUEZ GARCIA, MARIA
Lab Assistant Technician

Myeloid Neoplasms

led by Lurdes Zamora and Blanca Xicoy

Transversal Programme:
Multiscale-Omics

OVERVIEW

Since 2004, our group has been studying MN, with a particular focus on characterizing genetic and epigenetic lesions to find new diagnostic, prognostic and therapeutic markers that could help us better diagnose and treat patients with these diseases. First, we started with karyotype and single nucleotide polymorphism arrays (SNP-A) to help us detect alterations at chromosome level, and we are currently performing studies at gene level (mutational profile studies) and analyzing the impact that telomere size could have on the development of the disease.

OUR GOALS

Our research focuses mainly on the following areas:

1. Chronic myelomonocytic leukaemia (CMML).
2. The classification and prognosis of the group of diseases termed myelodysplastic syndromes (MDS).
3. Chronic myeloid leukaemia (CML).
4. BCR-ABL1 negative classic myeloproliferative neoplasms (MPNs).

OUR CHALLENGES

Our research is highly socially relevant because we promote capacity building, advancing knowledge, help in making informed decisions and improve the health in general terms, with economic benefits for the whole society. Through our research, we aim to answer the following question:

> How can we improve diagnosis, prognosis stratification, treatment response and life expectancy in chronic myelomonocytic leukaemia?

KEYWORDS

Myeloproliferative neoplasms, chronic myeloid leukaemia, myelodysplastic syndromes, MPN/MDS, acute myeloid leukaemia.

GROUP MEMBERS

XICOY CIRICI, BLANCA
Group Leader

ZAMORA PLANA, LURDES
Group Leader

CABEZÓN MARCO, MARTA
Postdoctoral Researcher

MARCÉ TORRA, SÍLVIA
Postdoctoral Researcher

ESTRADA BARRERAS, NATALIA
Postdoctoral Researcher

PALOMO SANCHIS, LAURA
Postdoctoral Researcher

BRIONES MARTÍNEZ, JOSÉ LUIS
Research Assistant

GONZÁLEZ DE MIGUEL, AIDA
Senior Lab Technician

ALBA GONZÁLEZ, LUCÍA
Medium Lab Technician

DOMÍNGUEZ DOMÍNGUEZ, DIANA
Medium Lab Technician

PUIGDEFÀBREGAS HORTA, LLUÍS
Medium Lab Technician

MADALA, MEGHNA
Support Technician

MARTIN MERLEZ, FERNANDA JESÚS
Short-term stay

Myeloid Neoplasms (Clínic)

led by Jordi Esteve

Transversal Programme:
Population studies and clinical trials

OVERVIEW

Myeloid neoplasms are a group of diseases in which the bone marrow produces an abnormal quantity of precursors for red blood cells, platelets, or certain types of white blood cells. This leads to a variety of symptoms and from fatigue to bones fragility and, eventually, to a higher risk of developing Acute Myeloid Leukaemia (AML).
Despite the advances produced during the last decades, not all those diagnosed benefit from efficient therapies. Advancing in the knowledge of myeloid neoplasms is, therefore, paramount to increase both prognosis and survival of patients.

OUR GOALS

Our research group is searching for key molecular features of myeloid neoplasms that could be used as therapeutic targets. We are focusing our efforts towards:

1. Myeloma and other monoclonal gammopathies
2. Mechanisms of progression in monoclonal gammopathies
3. Myeloid neoplasms
4. Lymphoid neoplasms

Also, we are seeking to improve the overall knowledge of the neoplasm microenvironment, the conditions where malignant cells live and proliferate, as well as how the body defences respond to it.

GROUP MEMBERS

ESTEVE REYNER, JORDI
Group Leader

Oncogenesis and Antitumor Drugs

led by Ramon Mangues

Transversal Programme:
Preclinical models

OVERVIEW

Current treatments lack selectivity towards cancer cells, which induces insufficient anticancer activity and produces severe adverse effects that limit their dosage. We are developing self-assembling protein-based nanoparticles for the treatment of haematological and solid cancers that are highly selective in targeting receptors overexpressed in cancer stem cells. They display a wide therapeutic window by avoiding renal clearance while internalizing into and selectively eliminating cancer target cells and enhancing the uptake of the payload drug into cancer tissues, with negligible uptake or toxicity in normal tissues.

We have achieved high antitumor and antimetastatic effects using apoptotic, genotoxic or microtubule inhibitor drugs as payloads, and we are now testing novel payloads that use non-apoptotic cell death mechanisms.

OUR GOALS

The aims of our lab are:

1. To develop nanomedicines that can effectively render cancers that have disseminated or relapsed sensitive to therapy by acquiring resistance to current therapy.
2. Ensure that the repeated administration of these novel nanomedicines induces potent anticancer activity, while maintaining low or absent toxicity in normal tissues.
3. Develop a formulation of amyloid structured inclusion bodies whose capacity for the sustained release of therapeutic nanoparticles into the blood could be subcutaneously administered once a month.

OUR CHALLENGES

Ninety percent of cancer patients die of metastases that do not respond to current treatments. Therefore, patients who develop metastases are considered incurable. Through our research, we aim to answer the following questions:

1. Is the selective elimination of cancer stem cells a relevant clinical target to improve therapy in different cancer types with acquired resistance and disseminated disease?
2. Will protein-based targeted nanoparticles that incorporate non-apoptotic and immunogenic cell death polypeptides increase cure, response and survival rates while reducing side effects once tested in patients?
3. What are the underlying mechanisms that dictate the highly selective accumulation of protein nanoparticles targeting the CXCR4 receptor we observe in cancer tissues?

KEYWORDS

Biotechnology, nanomedicine, targeted drug delivery, oncotherapy, metastases

GROUP MEMBERS

MANGUES BAFALLUY, RAMON
Group Leader

ALBA CASTELLÓN, LORENA
Postdoctoral Researcher

CASANOVA RIGAT, ISOLDA
Postdoctoral Researcher

UNZUETA ELORZA, UGUTZ
Postdoctoral Researcher

CARRASCO DIAZ, LUIS MIGUEL
PhD Student

NAVAS JIMENEZ, LUIS CARLOS
Medium Lab Technician

Transcriptional Dynamics in Leukaemia

led by Sergi Cuartero

Transversal Programme:
Applied epigenetics

OVERVIEW

We study the mechanisms that regulate transcription during hematopoietic differentiation and investigate the leukemogenic potential of mutations in transcriptional regulators and epigenetic modifiers. We are also looking into the role of mutations in proteins that drive the three-dimensional organization of the genome. These mutations alter transcriptional dynamics and can impair normal differentiation.

OUR GOALS

Our main goals are:

1. To understand the role of mutations in hematopoietic transcription factors and chromatin regulators in acute myeloid leukaemia (AML).
2. To characterize the impact of inflammatory signaling on normal hematopoietic differentiation and during leukemic progression.

OUR CHALLENGES

Acute myeloid leukaemia (AML) is the one of the most aggressive forms of leukaemia, and there is an urgent need to find new treatment options. While we now know **what** genes are recurrently mutated in AML, we still do not understand **why** these mutations are malignant. Through our research, we aim to answer the following questions:

1. What transcriptional mechanisms are deregulated in acute myeloid leukaemia?
2. How do inflammatory signals influence leukemic progression?
3. Can we use inflammatory modulation to attenuate the severity of myeloid malignancies?

KEYWORDS

Haematopoiesis; chromatin; AML; MDS; cohesin; inflammation

GROUP MEMBERS

CUARTERO BETRIU, SERGI
Group Leader

LORENZI FARÍAS, LUCÍA
Postdoctoral Researcher

MARTINEZ CEBRIAN, GERARD
Postdoctoral Researcher

CADEFAU FABREGAT, MARIA
PhD Student

JULIA VILELLA, ERIC
PhD Student

PICARDI MORAIS DE CASTRO, CARINI
PhD Student

YERA FERNANDEZ, LAURA
Lab Assistant Technician

Transplantation and immunotherapy

Barcelona Endothelium Team (BET)

led by Enric Carreras

Transversal Programme:
Population studies and clinical trials

OVERVIEW

Our group has extensive experience in the study of the endothelial dysfunction that develops in association with different vascular pathologies, such as the early complications associated with hematopoietic cell transplantation, obesity, chronic kidney disease, thrombotic microangiopathies and sepsis.

We also explore strategies for the protection of this endothelial dysfunction to improve patient health. In this regard, one of our main interests is to evaluate different compounds that potentially exhibit the capacity to protect the endothelium and to decipher their mechanisms of action.

OUR CHALLENGES

Hematopoietic cell transplantation (HCT) has been the major curative therapy for several haematological, metabolic, and neoplastic disorders. However, the efficacy of this procedure is limited by life-threatening complications, the most important of which is graft versus host disease (GvHD), which has a high mortality rate. Through our research, we aim to answer the following questions:

1. What are the pathophysiologic mechanisms that characterize endothelial dysfunction?
2. How can we avoid the vascular complications associated with hematopoietic cell transplantation?
3. Which is the role of the complement system in vascular complications?

OUR GOALS

Our main lines of research are:

1. To characterize the endothelial activation and dysfunction associated with cardiometabolic diseases through in vitro models.
2. To elucidate the mechanisms that lead to endothelial dysfunction.
3. To investigate agents with potential protective effects on the endothelium to prevent complications.
4. To find soluble markers with prognostic and diagnostic value for vascular complications.
5. To study complement pathways and complement deficiencies in thrombotic microangiopathies.
6. To assess platelet physiology and alterations of haemostasis by using perfusion devices to explore adhesive and cohesive properties of platelets under flow conditions.

KEYWORDS

Endothelium, Inflammation, Diagnostic and prognostic markers, Thrombotic microangiopathies (TMA), Drugs

GROUP MEMBERS

CARRERAS PONS, ENRIC
Group Leader

DIAZ RICART, MARIBEL
Postdoctoral Researcher

YOUSSEF, LINA
Postdoctoral Researcher

DE MONER RAFEL, BLANCA
PhD Student

MARTÍNEZ SÁNCHEZ, JÚLIA
PhD Student

RAMOS LOPEZ, ALEX
PhD Student

ESCRIBANO SERRAT, SILVIA
Attending Physician

Blood Stem Cell Identity

led by Vincenzo Calvanese

Transversal Programme:
Multiscale-Omics

OVERVIEW

Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells through their core properties of self-renewal and multilineage engraftment ability. As a result, bone marrow and cord blood transplantation provide a life-saving treatment for blood cancer and other diseases. Our goal is understanding the establishment and maintenance of human HSC properties, as determined by chromatin-mediated gene regulation. We investigate how microenvironment and metabolism influence HSC function, and how to generate or maintain HSCs in vitro while preserving their stemness.

Classically used as a lifesaving leukaemia treatment, HSCs also represent a key tool for gene therapy of genetic and other diseases. Yet, practical limitations render these therapies unfeasible or unsuccessful for many patients. To overcome these hurdles, we aim to understand the molecular bases of HSC function and to create a reliable source of HSCs for therapy from pluripotent stem cells (PSCs).

OUR GOALS

The Blood Stem Cell Identity Lab pursues the following research lines:

1. Molecular dissection of the self-renewal program in HSC.
2. Investigation of developmental pathways of functional HSC generation.
3. Development of new strategies for HSC-based therapy.

Establishment and maintenance of self-renewal ability is not only one of the most interesting questions in modern stem cell biology, with clear connections to aging and disease: it also holds the key to immense potential for clinical applications. By using our background in gene regulation and epigenetic modulation in stem cell biology, cancer, and aging, we aim to learn more general lessons regarding stem cells and their future potential in medicine.

OUR CHALLENGES

Through our research, we are trying to answer the following questions:

1. What are the fundamental mechanisms sustaining self-renewal in HSC?
2. How are HSC properties acquired during human development?
3. How can we generate and preserve functional human HSC in a dish?

GROUP MEMBERS

CALVANESE, VINCENZO
Group Leader

GARCIA PEREZ, ANGELICA
Scientific Coordinator

PERROD, CHIARA
Senior Researcher

AGUADE GORGORIO, JULIA
Postdoctoral Researcher

MADRIGAL AVILES, ADRIAN
Postdoctoral Researcher

BUNCE, HOLLIE MAY
PhD Student

WEN, YUNQIANQIAN
PhD Student

BARCLAY, JUSTIN ANDREW
Senior Lab Technician

MEROÑO RAFEL, MARTA
Lab Assistant Technician

Haematology Research

led by David Gallardo

Transversal Programme:
Population studies and clinical trials

OVERVIEW

The research group in haematology is devoted to clinical and translational trials in haematology, focused on diagnosis, prognosis, and the development of new therapies to treat haematological malignancies such as leukaemia and myelomas.

The group uses a variety of approaches such as genetic studies of the immune response, pharmacogenomics in response to treatment, analysis of polymorphisms as disease predictors and the study of cell populations using flow cytometry for the characterization of residual disease.

OUR GOALS

Through our research, we aim to:

1. Investigate biological, clinical, and epidemiological aspects of haematological diseases.
2. Carry out translational research projects focused on finding prognostic factors or treatment response predictors.
3. Carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national and international cooperative groups.

KEYWORDS

Haematology, myeloblastic leukaemia, multiple myeloma, chronic lymphatic leukaemia, residual disease

GROUP MEMBERS

GALLARDO GIRALT, DAVID
Group Leader

ANGONA FIGUERAS, ANNA
Attending Physician

BLANCO BLANCO, ANTONIO
Attending Physician

BUCH VILLA, JOAN
Attending Physician

BUSTINS TARRATS, ANNA
Attending Physician

CERDÀ SABATER, MARIA
Attending Physician

COLL JORDA, ROSA
Attending Physician

CRUZ GARCÍA, DAVID
Attending Physician

DÍAZ SANTA, JOHANA
Attending Physician

GARZÓN MORENO, ANA
Attending Physician

GONZÁLEZ MONTES, YOLANDA
Attending Physician

KELLEHER, NICHOLAS
Attending Physician

LLOPIS PUIGMARTÍ, FRANCISCA
Attending Physician

LLOVERAS GUELQUE, NATALIA
Attending Physician

MOSTACEDO MARASOVI, SILVIA
Attending Physician

RONCERO VIDAL, JOSEP
Attending Physician

SANTOS CARVAJAL, NAZLY
Attending Physician

SITGES ARRIAGA, MARTA
Attending Physician

TUSET ANDÚJAR, ESPERANZA
Attending Physician

VELARDE LÓPEZ DE AYALA, Mª PILAR
Attending Physician

VILA BOU, JORDI
Attending Physician

RODRÍGUEZ ROMANOS, ROCÍO
Specialist Technician

CASADO PUERTAS, LORENA
Administrative Assistant

Stem Cell Transplantation and Cellular Immunotherapy

led by Álvaro Urbano-Ispizua

Transversal Programme:
Population studies and clinical trials

OVERVIEW

We conduct research into cell immunotherapy treatments for patients with advanced malignant blood disorders, who tend to have a very short life expectancy. To treat such patients, we develop CAR-T and CAR-NK therapies based on adding chimeric antigen receptors (CAR) to cells of the immune system, such as T-lymphocytes and NK cells, respectively. CARs help recognize and attack tumour cells exclusively, specifically, and effectively, thereby preventing an autoimmune response and reducing secondary effects on healthy cells.

OUR GOALS

The basic aims of the lab are:

1. Study what happens at the molecular level between CAR-T and CB-NK cells throughout the process of recognizing, contacting, and attacking tumour
2. To examine what happens within the environment of the cells when they meet tumour cells.

Through our research, we aim to achieve the best possible scenario: to cure patients and ensure that they do not relapse.

OUR CHALLENGES

If we manage to enhance the efficacy of the CAR-T therapy and its permanence in patients to protect them from relapses, this breakthrough could be applied to patients with types of cancer other than MM. Therefore, through our research we hope to answer the following questions:

1. How are tumour cell resistance mechanisms against immune cells developed?
2. How can these tumour cell resistance mechanisms against immune cells be avoided?
3. How can the persistence and efficacy of CART cell treatment be increased?

KEYWORDS

Multiple myeloma, B-cell malignancies, chimeric antigen receptors, T lymphocytes, NK cells, cord blood-derived NK cells, haematological malignancies, B-cell maturation antigen

GROUP MEMBERS

URBANO - ISPIZUA, ALVARO
Group Leader

Core Facilities

Advanced Microscopy Unit

The Advanced Microscopy Platform offers cutting-edge services in fluorescence (laser and conventional light source), bright field microscopy and High-performance Slide Scanner and Image analysis. The Platform offers a unique opportunity for internal and external researchers to take advantage of advanced technologies without costly investments in equipment.

Services

CONFOCAL MICROSCOPY
Leica Stellaris 8

- WLL white laser; up to 8 excitation lines between 440-790 nm. You can work with any fluorochrome excited in this range and ensure maximum excitation efficiency
- Solid state laser 405 nm
- TauSense – rapid analysis of fluorescence lifetimes. Allows the separation of fluorochromes and auto-fluorescence
- Spectral Detectors – 4 high sensitivity and contrast HyD S detectors for general applications
- Super-resolution module: confocal images up to 100 nm XY resolution
- Galvometric (high quality up to 8096 x 8096) and Resonant (8000 lines/second 1024 x 1024, 28 images/second 512 x 512) duo scanning
- Leica AFC (Adaptive Focus Control) focus correction system
- Motorized stage for mosaic and multi-position experiments
- Objectives:
  - HC PL APO 10x/0.40 W.D. 2.2mm (dry)
  - HC PL FLUOTAR 20x/0.75 W.D. 0.62mm (dry)
  - HC FLUOTAR L 25x/0.95 W VISIR (water) Long working distance, for thick specimens HC PL APO 40x/1.25 CORR CS2 (Glycerol). Long working distance, thick specimens
  - HC PL APO 40x/1.30 CS2 (oil)
  - PL APO 63x/1.40 (oil)

HIGH PERFORMANCE SCANNING FOR BRIGHTFIELD AND FLUORESCENT SAMPLES
Zeiss Axioscan 7

- High-performance Slide Scanner for Fluorescence (from 405nm to 647nm) and Brightfield
- Z-stack scanning.
- 100 slides in a single run

EPIFLUORESCENCE (CONVENTIONAL) AND BRIGHTFIELD MICROSCOPY
Leica DM4

- Epifluorescence and brightfield microscopy
- Objectives: 5X, 10X, 20X, 40X and 63X dry objectives. 100X oil immersion

Olympus BX23

- High quality brightfield for clinical sample analysis
- Motorized Stage
- Objective: 10x Dry; High performance UPlanSApo 100X/1.40 Oil Immersion

IMAGE ANALYSIS
Workstation PC Hewlett Packard
256 RAM Windows 10 PRO for Workstations Software:

- IMARIS 10.1.1 (Including Imaris Stitcher, Imaris File converter and Imaris Viewer)
- AIVIA 12.0
- LASX
- Fiji 64 bits
- Zen Blue Lite

GROUP MEMBERS

GREGO BESSA, JOAQUIM
Postdoctoral Researcher

Bioinformatics Unit

The Bioinformatics Unit at IJC provides both internal and external researchers with high-quality computational analysis services covering all project aspects related to clinical and biological data. This includes experimental design and data analysis for microarray experiments and Next Generation Sequencing, statistical consulting, data integration, interpretation and reporting, as well as software development and data management.

The unit further provides training workshops on different bioinformatics related topics, such as working in a Linux environment, the use of high-performance computing (HPC) resources, the R programming language, working with containers, best practices, etc., and supervises students.

General services

- Data analysis, including consulting on experimental design and selection of the appropriate workflow and tools, data visualizations, report generation
- Custom analyses and tailored software development
- Data management, transfer/submission from/to public repositories (GEO, SRA, EGA)
- Support for grant and project proposal writing
- Supervision of students, bioinformatics training

Genomics

- Genotyping and variant calling from whole-exome sequencing (WES), whole genome sequencing WGS, amplicon sequencing and SNP microarrays

Transcriptomics

- Differential expression analysis from RNA-seq (polyA, totalRNA) and miRNA, mRNA microarrays, target prediction
- Analysis of alternative splicing from RNA-seq
- Variant calling (e.g., RNA editing) from RNAs-eq

Epigenomics

- Analysis of 5mC and 5hmC DNA methylation by microarray (450K, EPIC, mouse), or NGS (whole-genome bisulfite sequencing (WGBS), reduced-representation bisulfite sequencing (RRBS)
- Chromatin analysis by ChIP-seq, DNAse-seq, ATAC-seq

Epitranscriptomics

- Analysis of RNA Protein binding by CLIP-seq (binding and motif prediction)

GROUP MEMBERS

MERKEL, ANGELIKA
Core Facility Leader

LARIO CRESPO, EMILIO
Specialist Technician

VILARDELL LLADO, MARINA
Specialist Technician

Cell Immortalisation Unit

The Cell Immortalisation Unit of the Josep Carreras Leukaemia Research Institute offers immortalisation of B lymphocytes through infection with Epstein–Barr virus (EBV). This is considered the method of choice for generating lymphoblastoid cell lines (LCLs).

Cell culture is an essential tool to study the fundamentals of genetic background variables. The development of precision medicine has driven its use in the development and testing of drug safety. Infection of B lymphocytes with Epstein–Barr virus (EBV), which leads to cell immortalisation, is considered the method of choice for generating lymphoblastoid cell lines (LCLs). Following successful LCL production, various parameters must be evaluated in EBV-transformed B-cells, including temperature, serum concentration, type of culture medium, and CO_2 concentration. Our unit can produce LCLs and optimise their conditions.

Applications

- This immortalisation technology enables rapid, efficient, and reliable production of unlimited numbers of personalised cells
- To produce control material for rare genetic disorders
- Lymphocyte immortalisation technique let to preserve of DNA, RNA, and proteins samples, that appears to be a valid strategy for further studies
- To determine optimised condition for reliable and reproducible LCLs from different sources.
- Testing drugs analysis
- Allows us to have enough biological sample without having to access the patient again

Cytogenetics Unit

The Cytogenetics Unit in collaboration with the Hematology Service from Hospital ICO-Germans Trias i Pujol (Badalona) is responsible for analytical tests belonging to the Hematology Service from samples of whole blood, serum, plasma, urine, body fluids, bone marrow, lymph nodes, spleen, and tumour masses. The available analysis includes Cytogenetics (karyotype), FISH and SNP-microarrays (in collaboration with Unit of Microarrays from IJC).

The Cytogenetics Unit includes the Laboratory of Cytogenetics of the Institut Català d'Oncologia (ICO) from Badalona. The Unit process more than 3000 samples per year from ICO Badalona, from ICO Girona and ICO Bellvitge.

Services

Services

- Karyotype of cell lines
- Blood karyotype
- Bone marrow karyotype
- Karyotype of different tissues
- FISH from commercial probe (technique and interpretation, acquired by the platform)
- FISH from commercial probe (technique and interpretation, acquired by the client)
- Advice on karyotyping and/or FISH techniques
- Use of the "Metafer Slide Scanning Platform with Slide Feeder x 80" equipment Use of the software "Ikaros" (chromosome analyser) and "Isis" (FISH capturer)

GROUP MEMBERS

GRANADA FONT, ISABEL
Core Facility Leader

GRAU CAT, JAVIER
Postdoctoral Researcher

JURADO TAPIADOR, REBECA
Senior Lab Technician

VILLENA PERMANYER, M CARMEN
Senior Lab Technician

SANTAFÉ COLLADO, ENCARNACIÓ
Lab Assistant Technician

Genomics Unit

The Genomics Unit focuses on the application of high throughput genomic and epigenomic technologies to support cutting-edge biomedical research.

The facility houses specialized equipment to provide genomic services to the IJC community as well as to external customers.

We have long standing experience in genome-wide characterization of DNA methylation profiles using Illumina Infinium Technology (Human MethylationEPIC v2.0 and Mouse Methylation BeadChips).

We offer different levels of service depending upon user needs, including experimental design, sample quality control, processing, and basic data analysis.

Services

Array-based applications
- DNA Methylation analysis
- SNP Genotyping and CNV analysis

Equipment: Illumina iScan with Autoloader system & TECAN Freedom EVO liquid-handling robot

Next Generation Sequencing (NGS) applications
- Targeted resequencing
- Small genome sequencing
- Metagenomics (16S rRNA)

Equipment: Illumina MiSeqDX (for diagnostic testing)

Pyrosequencing applications
- Quantitative analysis of DNA methylation levels
- Determination of DNA variant allele frequencies (SNPs/ indels)

Equipment: Qiagen PyroMark Q48 Autoprep System

DNA isolation from a range of sample types (primary cells, cell lines, frozen and paraffin-embedded tissues)

Nucleic acid quantification and **quality control** assessment

GROUP MEMBERS

PLUVINET ORTEGA, RAQUEL
Core Facility Leader

ARRIBAS JORBA, CARLES
Senior Lab Technician

MARTIN JIMENEZ, ANNA
Lab Assistant Technician

Microarrays Unit

The Microarrays Unit (UM) is a service focused on DNA and RNA microarray solutions towards a personalized medicine and participates in the Cytogenetic European Quality Assessment (CEQA).

Molecular cytogenetics

Microarray studies can offer various solutions for cytogenetic applications:

- Detection of whole genome gains and losses at a high resolution.
- Analysis of whole genome absences of heterozygosity.
- SNPs genotyping and genome-wide association studies.
- RNA Analysis Solution

Gene expression profile studies on either human or mouse are suitable for:

- Detection of genes and pathways involved in diseases, treatment responses and biological processes.
- Predictive models based on gene expression profiles.
- Pharmacogenomics and toxicogenomics studies.
- Alternative splicing detection.
- Classification of samples on gene signatures.
- Analysis of miRNA.
- Microarray analysis on compromised samples with degraded and/or low quantity samples.
- Quality sample analysis

In addition, to the microarray procedure we also offer:

- DNA and RNA quantification and quality control analysis.
- Optical genome mapping (OGM) (Bionano) to detect structural and copy number alterations at a high resolution.
- Hand made FISH probes from the CHORI BAC collection.

High throughput qPCR

The Biomark HD system is a high throughput qPCR that runs IFCs in either real-time or end-point read modes, bringing PCR solutions to a range of applications. The 48x48 Dynamic Array combines up to 48 samples and 48 assays, generating 2304 different assays in one single run. The 96x96 Dynamic Array combines up to 96 samples and 96 assays, generating 9216 different assays. In addition, the FLEXsix IFC incorporates six 12x12 partitions that can be organized in any configuration, in up to six separate experimental runs.

Applications

- Genotyping
- Targeted Gene expression
- Digital PCR

Equipment

- Affymetrix/Thermofisher Research Platform: GCS3000 with autoloader
- Agilent Bioanalyzer 2100
- NanoDrop 2000 Spectrophotometer
- Saphyr (Bionano) equipment for OGM. Renting

GROUP MEMBERS

MALLO FAJULA, MARIA DEL MAR
Core Facility Leader

DE HARO CAMPS, NURI
Senior Lab Technician

ABEL CAMPOS, MARIA
Lab Assistant Technician

TIJERO SANTOS, JESSICA
Support Technician

Proteomics Unit

The Proteomics Unit of the Josep Carreras Leukaemia Research Institute provides state-of-the-art mass spectrometry-based proteomics services, identifying, quantifying, and characterizing proteomes, proteins, and their post-translational modifications. We offer proteomics services to Institute scientists as well as outside public and private organizations, run by a highly committed team.

Services

The Proteomics Cores Resource provides a wide range of mass spectrometry services:

- Differential Proteomics expression using label-free or label-based techniques (e.g., TMT)
- Identification and localization of Post-Translational Modifications (e.g., phosphorylation, ubiquitinylation, acetylation, and methylation)
- Protein-protein interaction (i.e., Pull-down, BioID, Crosslink)
- Extracellular vesicles from liquid samples (plasma and saliva) and cells
- Targeted protein-peptide identification and quantification
- Top Down (intact protein)
- Monodimensional SDS-PAGE
- Protein and AND/RNA extraction by FastPrep-24 5G bead beater
- Process automation-standardization by Robot Biomeik5 (Proteomics, Genomics, and basic research)
- Data analysis (differential expression and system biology) and Scientific support

We encourage you to consult with us before starting your proteomics experiment. We will assist you in designing the best experiment to meet your objectives.

Equipment & Resources

The Proteomics Core is equipped with an **Exploris 480 mass spectrometer** (Thermo Scientific) and two chromatographs, **Evosep One** (Evosep) **and Vanquish Neo** (Thermo Scientific), offering a versatile pipeline depending on sample analysis requirements, and a robust computational infrastructure and software.

Additionally, the core offers a process automation-standardization service by means of **Robot Biomeik5** (Beckman) and **FastPrep-24 5G** bead beating grinder and lysis system (MP Biomedical).

GROUP MEMBERS

DE LA TORRE GÓMEZ, CAROLINA
Core Facility Leader

BRENELLI DE LIMA, TATIANI
Postdoctoral Researcher

DIAZ PEÑA, RAMON
Postdoctoral Researcher

ESPINOSA ALCANTUD, MARIA DOLORES
Postdoctoral Researcher

BECH SERRA, JOAN JOSEP
Research Specialist Technician

DIAZ RIERA, ELISA
Senior Lab Technician

JARNE SANZ, IGNASI
Senior Lab Technician

ARDILA FERNANDEZ, DUBERNEY
Lab Assistant Technician

Sample Handling Circuit Unit

The Josep Carreras Leukaemia Research Institute (IJC) location ICO-GTP houses the Germans Trias i Pujol Hospital and Institute (IGTP-HUGTP) Sample Handling Circuit Unit, which manages the processing and storage of voluntarily donated samples of haematological neoplasms.

The samples are stored in the collection entitled "IJC Leukaemia and other blood diseases Sample Collection". The IJC Sample Handling Unit receives the bulk of its samples from the Catalan Institute of Oncology at the Germans Trias i Pujol Hospital (ICO-HUGTP, Badalona). Samples received from other hospitals are processed in an identical way.

The technical staff of the IJC have created a database of patients, donors and samples received and processed according to required specifications for the tracking of each sample in the collection. The staff verify the quality, security and tracking of the data and samples throughout the process and starting at extraction. Every year the Unit process and cryopreserve approximately 1000 samples from patients with hematologic cancers.

GROUP MEMBERS

ARANDA CEBRIAN, JESSICA
Senior Lab Technician

RUIZ CORTÉS, ROCÍO
Senior Lab Technician

GONZALEZ ALEMAN, YLENIA
Lab Assistant Technician

Single Cell Unit

The Single Cell Unit aims to provide scientific services to the Josep Carreras Institute community and is equipped with cutting-edge technology to apply single-cell technology to basic and translational genomic and transcriptomic studies. Single Cell approaches allow us to identify cell populations that are impossible to isolate with less resolute technologies previously used, such us bulk sequencing, allowing to characterize cell populations and thus identify differences at the genetic and phenotypic level within tumour tissues.

These techniques can, therefore, reveal the cellular heterogeneity of tumours and help identify cells resistant to standard treatments or more prone to proliferate.

The Single Cell Unit is equipped with 2 Chromium Controller (10x Genomics), for single cell analysis at the transcriptomic level, a Nikon ECLIPSE Ti Series inverted microscope and a CytAssit equipment (10X Genomics), for spatial transcriptomics at tissue level and a Tapestri platform (Mission Bio), for single cell analysis at the genomic and proteomic level.

These technologies provide a comprehensive, scalable solution for cell characterization, gene expression profiling and DNA sequencing of up to tens of thousands of cells.

Services

ChromiumTM Controller (10x Genomics):
- Single-cell RNA-seq (gene expression)
- Single-cell RNA-seq (gene expression) + Feature Barcoding
- Single-cell Immune profiling (GEX 5' + TCR/BCR)
- Single-cell ATAC-seq
- Single-cell Multiome (ATAC + GEX)

Spatial Transcriptommics (10X Genomics):
- Visium Spatial Gene Expression for Fresh-Frozen (FF) tissues
- Visium Spatial Gene Expression FFPE tissues
- Visium CytAssist Spatial Gene Expression for FF & FFPE tissues

Tapestri Platform (Mission Bio):
- Single-cell targeted DNA-seq (mutation analysis)
- Single-cell targeted DNA-seq (mutation analysis + CNV analysis)
- Single-cell DNA-seq + cell-surface protein analysis

GROUP MEMBERS

MATA GARCIA, CATERINA
Core Facility Leader

TOFACCHI, ELENA
PhD Student

LÓPEZ JIMÉNEZ, LIDIA
Senior Lab Technician

BOURACHED SILVA, NOUR AL YOUSSEF
Medium Lab Technician

GARCIA TERCERO, LAURA
Medium Lab Technician

Management Units

Management

The Management team contributes to the development of general policy and strategic planning. It enables and translates the scientific vision and strategic objectives of the Institute into a clearly articulated operational strategy. It also manages and coordinates the financial control of the centre.

GROUP MEMBERS

FELIU FRASNEDO, EVARIST
President of the Management Commission

GARRIDO ANGLADA, ANA
Strategy Director

BOIX MONTEMAYOR, HEURA
Economic Development Manager

Business Development Unit (Middle East)

The ME Business Development Manager is in charge of the Institute's growth strategy in the Middle East Region. She analyses and identifies new opportunities for the Institute to expand by developing partnerships with key international actors in the health and research sector of the ME region.

GROUP MEMBERS

EL-GHAUCHE EL-HALLAK, RANIA
International Business Development Manager

Communication Unit

Passionate about spreading the latest discoveries of our scientists and bring their research efforts closer to society, in any form. The unit strives to keep our partners closer and updated, and to foster the staff's sense of belonging.

GROUP MEMBERS

DÍAZ LÓPEZ, HELENA
Communication Manager

BADAL SOLER, MARTI
Communication Specialist

BERZOSA FERNÁNDEZ, BEA
Communication Specialist

OLMO GONZÁLEZ, AINOA
Communication Specialist

Data Management Unit

Aimed at delivering and maintaining all necessary infrastructure to efficiently keep institutional data available at all levels: strategic, technical, administrative and for transparent accountability in front of local or international management bodies.

GROUP MEMBERS

CARRIO REIG, MARTA
Data Manager

DE HIGES ALBERICH, PAU TADAYUKI
Data Specialist

Finance Unit

Its mission is to keep track of the actual finance situation of the Institute, rigorously and transparently, to support data driven strategic decision making in the short, medium, and long run.

GROUP MEMBERS

CALONGE CORTÉS, MARIA CRISTINA
Finance Manager

AMADO BALLANO, ERIKA
Finance Specialist

CARPALLO LOAYSSA, LYDIA
Finance Specialist

FINESTRES MARTINEZ, XAVIER
Finance Specialist

MURE FERNANDEZ, MIREIA
Finance Specialist

VILANOVA CUADRA, YAIZA
Finance Specialist

MATOS BERGADA, LAURA
Administrative Assistant

MATOS SILVA, AWILDA
Support Technician

FERNÁNDEZ GARCÍA, SANDRA
Recepcionist

Human Resources Unit

Its mission is to plan, organize and execute all processes related to the professional development of the staff and their commitment with the organization, within the framework of current regulations, including training opportunities and occupational risk prevention.

GROUP MEMBERS

CHICO GENEROSO, LETICIA B.
HR Manager

GARTNER, ELISA
HR Specialist

LATORRE REQUELME, IRENE
HR Specialist

OLMOS CHICO, GUILLERMO FEDERICO
HR Specialist

PAZ SOLDAN VASQUEZ, JUAN FRANCISCO
HR Specialist

SOUIRJI GOMEZ, SOFIA
HR Specialist

VARGAS SOLETO, BRIAN
HR Specialist

VERA SANCHEZ, MIREIA
HR Specialist

Infrastructure Unit

This Unit assures the proper functioning of all the facilities of the Institute. It coordinates facility maintenance and janitorial services and guarantees efficient and effective delivery of logistics for on-site activities.

GROUP MEMBERS

SÁNCHEZ-COLLADO PALMA, LIDIA DE LAS MERCEDES
Infrastructre Manager

ALONSO BELTRAN, DOMINGO
Specialist Technician

CARPANESE, ALESSANDRO
Specialist Technician

LEOTTA MARZABAL, ADRIAN
Specialist Technician

XICOLA MIQUEL, IVAN
Specialist Technician

LOPEZ GONZALEZ, CARLOS
General Services

PEREZ GARCIA, MARIA ISABEL
Recepcionist

Innovation Unit

In order to promote, maintain and invigorate knowledge and technology transfer at the Institute the main objectives of the Innovation Unit are: to establish a culture of innovation, valorisation and translation of results among professionals; to promote the effective transfer of the research results for the benefit of health especially for leukaemia patients, and to align the technology produced with the market and the industry.

To this end, the Innovation Unit explores the development of collaborative projects with centres and companies; providing specific training actions to research staff and management to improve and enhance the efficiency of public-private co-operation; systematizing communication both internally and externally; giving support to research in terms of intellectual property and innovation-related competitive calls, developing regulations according to current legislation, and promoting the diffusion and commercialization of its technology portfolio.

GROUP MEMBERS

RIERA GUERRA, ANNA
Innovation Manager

GINES MOLINA, ALBA
Project Manager

IT Unit

The unit's objective is to support the Institute's staff in the use and purchasing of IT components -hardware, software, and systems and keep the institutional IT systems online and secure while ensuring its efficiency.

GROUP MEMBERS

JUBANY LÓPEZ, MARC
IT Manager

ALCANTÁRA RUIZ, JOSE ANTONIO
IT Specialist

CONTRERAS PEÑA, FRANCISCO
IT Specialist

MONTERDE ROMERO, JOSE
IT Specialist

ESPAÑA GRAU, ROGER
Support Technician

Lab Management Unit

Its aim is to support researchers in their daily work in laboratories so that their research can be carried out with the best equipment, in the best state and with maximum safety.

GROUP MEMBERS

PEREZ LADAGA, ALBERT
Lab Manager

GARCIA FERRAN, ALBA
Senior Lab Technician

MORENO ZAMBRANA, ELISABET
Lab Assistant Technician

Purchasing Unit

The unit's aim is to optimize purchasing at the institutional level according to the legal framework for public research bodies, to be more efficient, fast, and agile, avoid unnecessary costs and save resources for research.

GROUP MEMBERS

REYES IBORRA, LAIA
Purchasing Manager

MONTSERRAT SANCHEZ, QUIQUE
Public Procurement Specialist

ALVAREZ MOYANO, JESSICA
Purchasing Specialist

BLANCO RUIZ, RUTH
Purchasing Specialist

CARMONA ORTIZ, MINERVA
Purchasing Specialist

VERGÉS COLOMINAS, ANNA
Purchasing Specialist

Research Grants Unit

Its objective is the attraction of public and private competitive funding, both nationally and internationally, as well as the proactive management of the granted research projects. They support researchers throughout the life cycle of projects, from the detection of opportunities, the preparation of proposals and the training of research consortiums, to the management of projects in all areas beyond the economic.

GROUP MEMBERS

MANCUSO PONCE, CHIARA
Acting Research Grants Manager

BENAVIDES RUIZ, ANTONIA PILAR
Project Manager

COMAS RODRIGUEZ, YASMINA
Project Manager

DE LA ROSA LOPEZ, BRISA MILAGROS
Project Manager

DEL RIO PASCUAL, MARIA DEL PILAR
Project Manager

GARCIA GALAN, MARIA JESUS
Project Manager

LAFUENTE QUINTANA, VALENTIN
Project Manager

LAGUNAS VILA, LAIA
Project Manager

MARGARYAN, MELINE
Project Manager

MARTIN NUÑEZ, MARTA
Project Manager

MARTINEZ ESCRIBANO, BEATRIZ
Project Manager

PADIAL MELIÁN, VERÓNICA
Project Manager

RODRIGUEZ AYUSO, NURIA
Project Manager

SORO ARNAIZ, INES
Project Manager

DOLSET VILLALOBOS, SARAI
Support Technician

Strategic Projects Unit



The unit develops projects deemed institutional and strategic for the Institute, including initiatives to boost institutional impact and foster international alliances. It also participates in excellence accreditations and the development of internal policies that adhere to international standards. These initiatives aim to enhance the Institute's strategic and international positioning in line with the Strategic Plan.

GROUP MEMBERS

GIL GUIÑON, ESTEL
Strategic Projects Manager

SPINOSA, VITTORIA
Project Manager

Support Unit

The Support Unit supports the governing bodies of the Institute in daily administrative tasks, agendas as well as in travel procedures.

GROUP MEMBERS

MARIN MANZANERA, ESPERANZA
Management Assistant

FARRÉ VIADER, LAURA
Support Technician

GONZALEZ RUIZ, PATRICIA
Support Technician

IZQUIERDO SÁNCHEZ, IRMA
Administrative Assistant

Communication

Selected Press Releases

March

The Josep Carreras Leukaemia Research Institute is accredited as a Severo Ochoa Centre of Excellence. The Ministry of Science, Innovation and Universities has awarded, by resolution of provisional concession, the prestigious Severo Ochoa Centre of Excellence accreditation to the Josep Carreras Institute, in recognition of its excellence, national and international scientific impact and capacity to attract talent, among others.

https://www.carrerasresearch.org/en/news/the-josep-carreras-leukaemia-research-institute-is-accredited-as-a-severo-ochoa-centre-of-excellence

June

Researchers discover a protein's function that can open the door to the generation of blood stem cells in the laboratory to treat leukaemia and other diseases. A scientific team led by Dr Anna Bigas, from the Josep Carreras Institute and the Hospital del Mar Research Institute has described the role of the IκBa protein in the differentiation process of haematopoietic cells. This is an important step towards being able to generate these types of cells in the lab, preventing them from differentiating and turning into other cells too early.

https://www.carrerasresearch.org/en/news/researchers-discover-a-proteins-function-that-can-open-the-door-to-the-generation-of-blood-stem-cells-in-the-laboratory-to-treat-leukaemia-and-other-diseases

Sant Pau Lays the Cornerstone of the New Advanced Therapies Unit, in collaboration with the Josep Carreras Institute. The new Advanced Therapies Unit at the Sant Pau Research Institute will be a strategic resource, by enabling the development and manufacture of personalised biological medicines within the same hospital

facilities for the treatment of its patients. This project has been made possible through the collaboration with the Josep Carreras Leukaemia Research Institute, the Josep Carreras Leukaemia Foundation and the support from the Blood and Tissue Bank (BST).

https://www.carrerasresearch.org/en/news/sant-pau-lays-the-cornerstone-of-the-new-advanced-therapies-unit-in-collaboration-with-the-josep-carreras-institute

July

A new proteogenomics analysis of high-grade gliomas offers hints on tumour evolution. Researcher Kathleen J. Imbach, a member of the Cancer Immunogenomics Group at the Josep Carreras Leukaemia Research Institute, has co-authored the last paper of the international Clinical Proteomic Tumour Analysis Consortium. The research uses the new proteogenomics perspective to uncover the deep molecular features of high-grade gliomas, a type of brain tumours, such as glioblastoma and IDH-mutant grade 4 astrocytoma, and found that tumour evolution may share common features.

https://www.carrerasresearch.org/en/news/a-new-proteogenomics-analysis-of-high-grade-gliomas-offers-hints-on-tumour-evolution

August

RNA hijacking sustains the development of acute myeloid leukaemia. New evidence shows that in Acute Myeloid Leukaemia cells, RNA molecules from tumour suppressor genes are hijacked by the cell's RNA processing centres, the P-bodies, effectively silencing its antitumour effects. The evidence, presented at the prestigious journal Nature Cell Biology by an international team of researchers, offers a new perspective to better understand malignant transformation in Acute Myeloid Leukaemia cells. Members of the Epigenetic Control of Haematopoiesis group at the Josep Carreras Leukaemia Research Institute, headed by Dr. José Luis Sardina, co-led the research.

https://www.carrerasresearch.org/en/news/rna-hijacking-sustains-the-development-of-acute-myeloid-leukaemia

September

Low oxygen levels in tumours could enhance some of the body's immune responses against cancer. Researchers from the Epigenetics and Immune Disease lab at the Josep Carreras Leukaemia Research Institute have found evidence that low oxygen levels in tumours could actually enhance some of the body's immune responses against cancer, in contrast with the general paradigm that hypoxia exclusively helps cancer progression. Their findings identified a macrophage subpopulation displaying more potent immune responses under low oxygen concentrations in tumours.

https://www.carrerasresearch.org/en/news/low-oxygen-levels-in-tumours-could-enhance-some-of-the-bodys-immune-responses-against-cancer

Haematological tumours are the fifth most common cancers in Spain. In the Blood Cancer Month, which is celebrated throughout September, the Spanish Network of Cancer Registries (REDECAN) and the Spanish Society of Haematology and Haemotherapy (SEHH) have presented at a press conference the report 'Blood cancer figures in Spain incidence estimates for 2025 and survival analysis'.

https://www.carrerasresearch.org/en/news/haematological-tumours-are-the-fifth-most-common-cancers-in-spain

October

Described the Epigenetic Hallmarks that define Cancer. Dr. Manel Esteller, researcher at the Josep Carreras Leukaemia Research Institute, coordinated an international team of experts aimed at defining the key Epigenetic Hallmarks common to all cancer cells. The team concluded that malignant transformation requires some degree of six different epigenetic features, from changes in the DNA methylation status to large rearrangements in the cell's nucleus

https://www.carrerasresearch.org/en/news/described-the-epigenetic-hallmarks-that-define-cancer

Understanding the maturation of white blood cells to find new therapies against lymphoblastic leukaemia. Researchers from the Chromatin Biology lab at the Josep Carreras Leukaemia Research Institute just discovered a fundamental mechanism controlling B-lymphocyte maturation in the bone marrow. Defects in this process lead to B-cell Acute Lymphoblastic Leukaemia, the most common childhood blood cancer. This new knowledge may open the door to developing new drugs targeting the B-cell maturation main players, such as the protein SIRT7, of the sirtuin family.

https://www.carrerasresearch.org/en/news/understanding-the-maturation-of-white-blood-cells-to-find-new-therapies-against-lymphoblastic-leukaemia

Intrinsic factors of the CAR-T cells may play a major role on its clinical success. Researchers from the Josep Carreras Leukaemia Research Institute have found that the efficacy of varnicel, a CAR-T infusion product for B-ALL patients, is highly dependent on intrinsic features of the CAR-T cells themselves and their progression within the patient. In a recent study published at Cell Reports Medicine the team identified three key success markers the CD4:CD8 ratio, exhaustion signals and the expansion of gamma-delta cytotoxic T-cells. Taken together, the results may help reaching higher complete remission rates and sustained disease-free survival in the near future.

https://www.carrerasresearch.org/en/news/intrinsic-factors-of-the-car-t-cells-may-play-a-major-role-on-its-clinical-success%0D

Scientific Dissemination

The Josep Carreras Leukaemia Research Institute is a public institution with a strong commitment towards society. On this regard, the Institute is constantly seeking for new ways of disseminating the results and impacts of our research.

During 2024, the Communication Unit has been strengthening all the **communication channels** of the institute, either online (IJC institutional website and social media profiles) and offline channels (direct contact with our publics). As a result, there has been a significant growth in our audience while keeping the fundamental presence of the institute among our traditional publics, like the **InstiCiència** visits programme and the summer internships for high school students. The project **"A handful of science"**, funded by La Caixa Foundation, has already visited the paediatric units of three of the main Catalan hospitals during 2024, and plan to visit four more by mid-2025.

In addition to the specific programmes mentioned above, the institute participated in the main scientific dissemination events in Barcelona and Catalonia through talks and workshops. These actions are indicated in the list below:

> "Barcelona Science Festival", organized by the City Council through the Barcelona Institute of Culture (ICUB).
> "European Research Night", organized by the Catalan Association for Scientific Communication with funding from the European programme MSCA.
> "#100tifiques", organized by the FCRi and the BIST: networking and talks in schools by researchers from the centre on the day of Women and Girls in Science, February 11th.
> "Fira STEAM Badalona". An event organized by the Badalona City Council, Educational department, targeting primary and secondary school students.
> "Saló de l'ensenyament", organised by the Generalitat de Catalunya. An event targeting high-school and college students.

It is worth mentioning that all the Conferences and Seminars organized by the Institute are hybrid events with online streaming. These talks are delivered by national and international speakers and have the aim to facilitate access to the latest developments in leukaemia research.

The Josep Carreras Institute has maintained its collaboration with the Josep Carreras Foundation, with whom we have close ties. Every year, the Josep Carreras Foundation celebrates the Unstoppable Day and the Week against Leukaemia, organizing activities for patients, relatives and civil society. Researchers from the Josep Carreras Leukaemia Research Institute participated in the 2024 edition of the Unstoppable Day as experts in round tables and lectures aimed at informing the public.

Facts & figures

Innovation

The Josep Carreras Institute is committed to bringing the cure of leukaemia and other haematological malignancies to patients. To do so and contribute to society and country's progress, it fosters the generation of new knowledge together with the development of new therapies and technologies.

In 2024, the results of our research in terms of innovation were as follows:

98
Active Innovation Projects

17
Patent families Portfolio
(53% Licensed)

2
Active Spin-offs
Leukos Biotech & OneChain Immunotherapeutics

105
New innovation-related agreements signed in 2024

2,36M€
2,36M€ raised through Innovation related Agreements

In terms of technology transfer, over this last period, the Institute has managed 98 innovation projects and 17 patent families. It currently has 2 active spin-offs, both with products in clinical phases: Leukos Biotech and OneChain Immunotherapeutics. In 2024, 105 innovation contracts worth 2.36 million euros were signed.

The Innomed programme, launched in 2024, was promoted by the Germans Trias i Pujol Research Institute (IGTP) and, in addition to IJC, includes other innovation units from research and healthcare centres around the Can Ruti Campus (IrsiCaixa, Guttmann Institute, Catalan Institute of Oncology (ICO), Germans Trias i Pujol Research Institute (IGTP), Germans Trias Hospital (HUGTiP) and the Maresme Health Consortium (CSdM). This programme aims to share knowledge, skills and resources to promote innovation and technology transfer in health. Its launch was made possible thanks to the support of ITEMAS, the platform of the Carlos III Health Institute (ISCIII).

Another significant achievement in 2024 was the treatment of the first patient in the CARxALL clinical trial by OneChain Immunotherapeutics, a spin-off of the Josep Carreras Institute and ICREA. The trial is evaluating OC-1, an innovative CAR-T therapy for a rare and aggressive subtype of leukaemia. It is being conducted at the Hospital Clínic and the Hospital Sant Joan de Déu in Barcelona and is open to paediatric and adult patients from all over the world. The other IJC spin-off, Leukos Biotech S.L., in collaboration with AOP Health, has treated its first patient with the new drug AOP208. This drug targets tumour stem cells by blocking a particular conformation of the serotonin 1b receptor, which controls essential metabolic pathways. The study was carried out at the UITM-CaixaResearch of the Vall d'Hebron Institute of Oncology (VHIO) as part of the SERONCO-1 phase 1 trial.

The innovation unit has promoted different strategic initiatives throughout the year, such as the Framework Agreement for the Tendering of Industrial Protection Services that brings together 8 research centres and 16 agencies and represents an innovative and ecosystem model in the management of Intellectual Property, placing value and not price at the centre Additionally, the Unit has created a new internal guide for pricing services with companies that allows optimizing and streamlining collaboration between research groups and collaborating companies.

Teaching and Training

International Congresses

Emerging Leaders in Biomedicine – 26 September 2024
The 2nd edition of the Emerging Leaders in Biomedicine Symposium, held at the Vall d'Hebron Institute of Oncology (VHIO), consolidated the event as a meeting point for the next generation of leaders in cancer research. The conference aimed to create a space for networking, sharing cutting-edge research and fostering scientific collaborations between senior postdoctoral researchers and junior group leaders in Barcelona.

This initiative is promoted by eight Catalan research centres: the Josep Carreras Leukaemia Research Institute (IJC), the Vall d'Hebron Institute of Oncology (VHIO), the Institute of Bioengineering of Catalonia (IBEC), the Centre for Genomic Regulation (CRG), the Institute of Molecular Biology of Barcelona (IBMB-CSIC), the Department of Medicine and Life Sciences (MELIS) of the Pompeu Fabra University, the Institute of Biomedicine of the University of Barcelona (IBUB), and the Barcelona Institute of Biomedical Research (IRBB).



"Updates on Genetics and Epigenetics of Haematological Malignancies: From Knowledge to Applications" – 20-22 November 2024
Five years after its first international Symposium, the Josep Carreras Leukaemia Research Institute organized a new international gathering on the latest advancements in haematology research. Coordinated by Dr Anna Bigas, Dr Laura Belver, Dr Marcus Buschbeck and Dr Manel Esteller, the Symposium brought together more than 150 participants and an exceptional panel of international speakers, with the aim to foster scientific collaboration between leading scientists and clinicians in the field of leukaemia and lymphoma. The programme featured the most cutting-edge fields of haemato-oncology, as cell biology, immunology, genetics, epigenetics and computational biology, among others.

Distinguished, Invited and Open Lectures

The Institute has the pleasure to receive national and international well-renowned researchers in the cancer research-related field. They deliver a 1-hour lecture on their research, career, and findings, which is open to all the Institute and the scientific community.

Young Researchers Seminars (32)

The Young Researchers Seminars are 20-min talks given by our PhD Students and young Postdoctoral Investigators, in which they explain an aspect of their research to their IJC fellows and respond to their questions. This is the perfect opportunity for them to practice an activity that they will have to face not only in their thesis defence, but also on numerous occasions throughout their research career.

Thesis read (16)

Predoctoral researchers in 2024 (121 researchers - 97,89 FTE)

Courses and Seminars

January

Invited Lecture: "Digital twins: dreams and realities" Dr Alfonso Valencia, Barcelona Supercomputing Center. Barcelona, Spain

February

Distinguished Lecture: "Genome Stability in Aging and Inheritance: New insights from C. elegans" Prof Björn Schumacher, Institute for Genome Stability in Aging and Disease, Medical Faculty, University of Cologne. Cologne, Germany

Open Lecture: "Your Research Shapes the Future of Hematology" Dr Francesco Cerisoli, European Hematology Association (EHA). The Hague, Netherlands

Invited Lecture: "Crosstalk between innate and adaptive immune system during aging" Dr Maria Mittelbrunn, Centro de Biología Molecular Severo Ochoa (CBMSO). Madrid, Spain

March

Invited Lecture: "Leveraging genetic mouse models for precision prevention in pancreatic cancer" Dr Francisco Real, Spanish National Cancer Research Centre-CNIO

April

Invited Lecture: "New Trends in Adoptive Cell Immunotherapy for Cancer" Dr Luis Álvarez-Vallina, Spanish National Cancer Research Centre (CNIO). Madrid, Spain

Training Course: NEXT, New Generation Diagnosis in Leukemia Training Course Spanish Society of Hematology and Hemotherapy (SEHH), Dr Francesc Solé and Dr Eulàlia Genescà

Invited Lecture: "Fueling Cancer: Exploring the Role of Metabolism in Tumorigenesis" Dr Guadalupe Sabio, Spanish National Cancer Research Centre (CNIO). Madrid, Spain

May

Conference: InfoDay Core Facilities Campus Can Ruti Core Facilities Unit Managers of the Campus Can Ruti

Open Lecture: "The dialog between the integrated stress response and Innate immunity: the special case of theAB5 subtilase cytotoxin" Dr Philippe Pierre, Centre d'Immunologie de Marseille-Luminy (CIML). Marseille, France

June

Conference: PhD Day 2024 Campus Can Ruti PhD Committee

Open Lecture: "Team Science at scale: the Cancer Grand Challenges initiative" Dr Lorenzo de la Rica, Cancer Grand Challenges. London, United Kingdom

Conference: Innomed Awards Innovation Units of the Campus Can Ruti

September

Congress: Emerging Leaders in Biomedicine Josep Carreras Leukaemia Research Institute (IJC), Vall d'Hebron Institute of Oncology (VHIO),

Institute of Bioengineering of Catalonia (IBEC), Centre for Genomic Regulation (CRG), Institute of Molecular Biology of Barcelona (IBMB- CSIC), Department of Medicine and Life Sciences (MELIS) of the Pompeu Fabra University, Institute of Biomedicine of the University of Barcelona (IBUB), and Barcelona Institute of Biomedical Research (IRBB)

October

Invited Lecture: "Improving the outcome of patients receiving CAR T-cell therapy" Dr Pere Barba, Vall d'Hebron Institute of Oncology (VHIO). Barcelona, Spain

Distinguished Lecture: "Nuclear and mitochondrial functions of the methyltransferase KMT9 control prostate tumour growth" Dr Roland Schüle, Centre for Biological Signaling Studies (BIOSS). Centre for Clinical Research, University Medical Center Freiburg. Freiburg, Germany

November

Training Course: Ethics Gender Diversity in Research & Innovation Workshop IMMERGE Marie Skłodowska-Curie Actions (MSCA) Doctoral Networks (DN)

Invited Lecture: "Linking metabolism and anti-cancer functions of dendritic cells" Dr Stefanie Wculek, Barcelona Institute of Biomedical Research (IRBB). Barcelona, Spain

Training Course: Preceptorship: Advances in Acute Lymphoblastic Leukaemia Dr Josep Maria Ribera

Congress: Updates on Genetics and Epigenetics of Haematological Malignancies: From Knowledge to Applications Josep Carreras Leukaemia Research Institute (IJC), Dr Anna Bigas, Dr Laura Belver, Dr Marcus Buschbeck and Dr Manel Esteller

Invited Lecture: "The opposing effect of clonal hematopoiesis in stemness and immunity" Dr Hector Huerga Encabo, The Francis Crick Institute. London, United Kingdom

December

Invited Lecture: "Hallmarks and vulnerabilities of metastatic cancer cells" Dr Victoria Sanz-Moreno, Institute of Cancer Research (ICR). London, United Kingdom



Financial Data

The funding model of the Institute is partially supported by the Josep Carreras Foundation. In addition, it receives funding from the Government of Catalonia and is based on competitive funding for its research activities. In 2024 there was an increase of 9.99% in revenue from public funds and the provision of services. In terms of expenditure, this increased by 6.04% compared to the previous year.

	2023	2024	
Incomes	**20.986.155**	**23.083.287**	**9,99**
Contributions from the Generalitat	3.995.614	4.328.809	
Other transfers (FIJC)	1.000.000	1.000.000	
Services	3.113.573	3.807.892	
Project	11.548.593	13.400.915	
Overheads	1.328.375	545.670	
Operational expenses	**19.014.537**	**20.163.727**	**6,04**
Staffing costs	4.548.863	4.554.768	
Information technologies services	159.580	184.723	
Communication	43.087	23.781	
Building maintenance	984.782	740.135	
Laboratories maintenance	255.726	265.774	
Research support (travel, càterings...)	87.281	20.499	
Project	11.190.297	12.619.171	
Scientific-technical services (Platforms)	930.587	1.190.122	
Biobank	13.330	15.837	
Management support services	257.353	228.892	
Other	329.067	234.580	
VAT prorata	87.232	56.281	
Reimbursement of subsidies and other management losses	127.351	29.164	
Result of the activity	**1.971.618**	**2.919.560**	
Extraordinary result	**0**	**0**	
Operating income	**1.971.618**	**2.919.560**	
Financial performance	**-823.882**	**-1.114.123**	
Result before amortization	**1.147.737**	**1.805.436**	
Amortization	**-2.216.913**	**-2.224.265**	
Result	**-1.069.176**	**-418.828**	

Awards

Dr. Laura Belver

Lupus Innovation Awards by the **Lupus Research Alliance** to develop a new cell therapy targeting Systemic Lupus Erythematosus (SLE)

https://www.carrerasresearch.org/en/news/dr-laura-belver-receives-one-of-the-prestigious-lupus-innovation-awards-from-the-lupus-research-alliance

Dr. Manel Esteller

Award of the **Royal National Academy of Medicine (RANME**) for his contributions to medicine, especially for his discoveries in epigenetics in health and disease, mainly in the oncology field

https://www.carrerasresearch.org/en/news/dr-manel-esteller-awarded-by-the-royal-national-academy-of-medicine-

Award of the **Research Award of the Royal National Academy of Pharmacy (RANF)** for his research in anti-cancer drugs that change the genetic expression of tumour cells

https://www.carrerasresearch.org/en/news/dr-manel-esteller-receives-the-royal-national-academy-of-pharmacy-award-for-his-work-on-drugs-that-change-gene-expression

Recognition as the **best researcher working in the Genetics field in Spain** by the 2024 Edition of the **Ranking of Best Scientists of Research.com**

https://www.carrerasresearch.org/en/news/dr-manel-esteller-recognized-with-the-genetics-leader-award-2024-

Burdinola Research Award by the **Burdinola Society**, distinguishing his research in the area of new therapeutic strategies, active ingredients, and molecular targets in medicine

https://www.carrerasresearch.org/en/news/dr-manel-esteller-receives-the-burdinola-research-award

Recognition among the most influential researchers in the world across all scientific disciplines in the annual list of **Stanford University**

https://www.carrerasresearch.org/en/news/dr-manel-esteller-considered-among-the-most-relevant-scientists-worldwide-according-to-the-stanford-university

E-nnova Health 2024 Award in Big Data and Artificial Intelligence for a Spatial Expression-Based Diagnosis by **Diario Médico** and **Correo Farmacéutico**

https://www.carrerasresearch.org/en/news/dr-manel-esteller-receives-the-e-nnova-health-2024-award-in-big-data-and-artificial-intelligence-for-a-spatial-expression-based-diagnosis%0D

Dr. Biola M. Javierre

Argonauta Award as the best young researcher of the year by the **PharmaMar Foundation**

https://www.carrerasresearch.org/en/news/dr-biola-m-javierre-receives-the-pharmamar-foundations-2024-argonauta-award-for-best-young-researcher

Dr. Pablo Menéndez

Appointment as new member of the Board of Directors of the **International Society for Experimental Hematology**

https://www.carrerasresearch.org/en/news/dr-pablo-menendez-new-member-of-the-board-of-directors-of-the-international-society-for-experimental-hematology%0D

Dr. Montse Sanchez-Cespedes

Fred R. Hirsch Award in Translational Medicine by the **International Association for the Study of Lung Cancer (IASLC)** for her contributions to understanding some of the genetic mechanisms involved in the onset of lung cancer

https://www.carrerasresearch.org/en/news/dr-montse-sanchez-cespedes-receives-the-fred-r-hirsch-award-in-translational-medicine

Dr. Esteban Ballestar, Dr. Enric Carreras, Dr. Manel Esteller, Dr. Josep Maria Ribera, Dr. Montse Sanchez-Cespedes, Dr. Fumiichiro Yamamoto and Dr. Ciril Rozman

Recognition among the world's most prominent professionals in the scientific field according to the **Scopus database** by **Elsevier**

https://www.carrerasresearch.org/en/news/researchers-from-the-josep-carreras-institute-among-the-most-relevant-on-an-international-level-according-to-elsevier-

Competitive Grants and Active Projects

Management

Type: Project
2023 Ministerio de Ciencia e Innovación, CENTROS DE EXCELENCIA SEVERO OCHOA Y DE UNIDADES DE EXCELENCIA MARÍA DE MAEZTU 2023
Manager: FELIU FRASNEDO, EVARIST
Unit: Management
Reference: CEX2023-001258-S
Start Date: 01/04/2024 - **End Date:** 31/03/2028

Cancer Epigenetics

Manel Esteller

Type: Project
2019 European Commission, MSCA-RISE-2019
Marie Skłodowska-Curie Actions – Research and Innovation Staff
Exchange
PI: ESTELLER BADOSA, MANEL - BERDASCO MENENDEZ, MARIA
Group: Cancer Epigenetics
Reference: 872391
Title: DevelOpmeNt of Cancer RNA TherapEutics
Start Date: 01/05/2020 - **End Date:** 30/04/2024
27/08/2024

Type: Project
2018 Cancer Research UK, Accelerator Award 2018
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: A29372/GEACC19003CED
Title: PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma
Start Date: 01/04/2020 - **End Date:** 30/11/2024
28/02/2026

Type: Project
2017 Cancer Research UK, Accelerator Award 2017
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: A26825/GEACC18004TAB
Title: Colorectal Cancer Stratified Medicine Network
Start Date: 02/08/2019 - **End Date:** 31/10/2023
31/10/2024

Type: HR
2019 Ministerio de Ciencia e Innovación, Ayudas para contratos predoctorales para la formación de doctores (FPI)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: PRE2019-089958
Title: Disrupción epigenética y genética de las modificaciones del RNA en cáncer
Start Date: 01/08/2020 - **End Date:** 31/07/2024

Type: Project
2021 Fundació La Marató de TV3, Marató TV3: COVID-19
PI: FERRER AGUILAR, GERARDO
Group: Cancer Epigenetics
Reference: 202131-32
Title: Síndrome inflamatòria multisistèmica associada a COVID-19 en nens (MIS-C): bases genètiques, epigenètiques i immunopatogèniques.
Start Date: 23/09/2021 - **End Date:** 22/09/2024

Type: HR
2020 Ministerio de Ciencia e Innovación, AYUDAS JUAN DE LA CIERVA FORMACIÓN 2020
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: FJC2020-044658-I
Title: Single cell analysis of clonal heterogeneity in myelodysplastic syndromes treated with azacitidine
Start Date: 01/07/2022 - **End Date:** 30/06/2024

Type: Project
2021 Fundació "La Caixa", CAIXARESEARCH HEALTH 2022
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: HR22-00732
Title: Somatic mutations and clonal hematopoiesis as predictors and drivers of heart failure progression
Start Date: 01/10/2022 - **End Date:** 30/09/2025

Type: Project
2021 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2021
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: PID2021-125282OB-I00
Title: Uso de aproximaciones de célula única para decifrar la epigenómica del cáncer y las epidrogas
Start Date: 01/09/2022 - **End Date:** 31/08/2025

Type: Project
2021 Ministerio de Ciencia e Innovación, AYUDAS A PROYECTOS ESTRATÉGICOS ORIENTADOS A LA TRANSICIÓN ECOLÓGICA Y A LA TRANSICIÓN DIGITAL 2021
PI: MUSULÉN PALET, EVA - José Aneiros Fernández
Group: Cancer Epigenetics
Reference: TED2021-131248B-I00
Title: AlgoRitmoS de aprEndizaje Profundo en el diagnóstico de adenomas y del cáNcer cOlorrectal precoz
Start Date: 01/12/2022 - **End Date:** 30/11/2024 30/09/2025

Type: HR
2021 European Commission, MSCA COFUND 2021
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 101081298
Title: FCAECC Fellowship programme for talented researchers in cancer
Start Date: 01/09/2023 - **End Date:** 31/08/2028

Type: Network
2016 Instituto de Salud Carlos III, INCORPORACIÓN DE NUEVAS **ÁREAS** TEMÁTICAS Y NUEVOS GRUPOS CIBER
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: CB16/12/00312
Title: Centro de Investigación Biomédica en Red Cáncer
Start Date: 01/01/2017 - **End Date:** 31/12/2025

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 2021 SGR 01494
Title: Grup d' Epigenètica del Càncer
Start Date: 01/01/2022 - **End Date:** 31/12/2024 30/06/2025

Type: Project
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, AJUTS D'INDÚSTRIA DEL CONEIXEMENT PER A L'ANY 2021 (LLAVOR I PRODUCTE)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 2021 PROD 00020
Title: Desenvolupament i validació d'una signatura de metilació del DNA per la predicció de la resposta a ta teràpia cel·lular receptor d'antigen quimèric (CAR) de cèl·lules T
Start Date: 19/10/2022 - **End Date:** 18/04/2024 18/07/2024

Type: Project
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, AJUTS PER A PROJECTS DE VALORITZACIÓ I TRANSFERÈNCIA DE CONEIXEMENT DESENVOLUPATS PER INNOVADORS EN ESTADES EN ENTITATS DEL SISTEMA DE RECERCA I INNOVACIÓ DE CATALUNYA (INNOVADORS) PER A L'ANY 2021
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 2021 INNOV 00011
Title: Spin-off per comercialitzar línies cel·lulars immortalizades de limfòcits
Start Date: 07/12/2022 - **End Date:** 23/04/2024

Type: Project
2022 Ministerio de Ciencia e Innovación, PRUEBA DE CONCEPTO 2022
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: PDC2022-133476-I00
Title: Estudio de validación y valorización en el mercado de EPICART, una firma para predecir la respuesta a la terapia de células CAR-T
Start Date: 01/12/2022 - **End Date:** 30/11/2024 05/02/2025

Type: Project
2022 Ministerio de Ciencia e Innovación, CONCESIÓN DIRECTA DE SUBVENCIONES A DIVERSAS ENTIDADES PARA EL DESARROLLO DE PROYECTOS DE CIENCIA DE EXCELENCIA
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Title: Proyecto Proteoma del Cáncer
Start Date: 01/01/2022 - **End Date:** 31/12/2024

Type: HR
2022 Instituto de Salud Carlos III, Convocatoria y ayudas de la Acción Estratégica en Salud
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: IHMC22/00035
Title: Epitranscriptomic regulation of DNA methylation in Acute myeloid leukemia
Start Date: 01/04/2023 - **End Date:** 31/03/2025

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 2023 INV-2 00011 (200011TC5)
Title: Grup de recerca Epigenètica del Càncer
Start Date: 01/09/2023 - **End Date:** 30/09/2024

Type: HR
2022 Fundación Científica de la Asociación Española Contra el Cáncer, INVESTIGADOR AECC 2023
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: INVES234765FERR
Title: Revolutionizing Precision Medicine in Leukemia Patients
Start Date: 01/12/2023 - **End Date:** 30/11/2026

Type: HR
2023 Ministerio de Ciencia e Innovación, Ayudas para contratos predoctorales para la formación de doctores 2022 (FPI 2022)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: PRE2022-105015
Title: USO DE APROXIMACIONES DE CELULA UNICA PARA DESCIFRAR LA EPIGENOMICA DEL CANCER Y LAS EPIDROGAS
Start Date: 01/11/2023 - **End Date:** 15/09/2027

Type: HR
2023 Ministerio de Universidades, CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE PROFESORADO UNIVERSITARIO-FPU 2022
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: FPU22/01655
Title: Estudios de epigenética del cáncer a nivel de célula **única**
Start Date: 01/01/2024 - **End Date:** 31/05/2027

Type: Project
2023 Fundación Mutua Madrileña, AYUDAS A PROYECTOS DE INVESTIGACIÓN EN SALUD 2023
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: AP183262023
Title: Identificación de determinantes de respuesta a quimioinmunoterapia en biopsia líquida, en pacientes con cáncer microcítico de pulmón.
Start Date: 06/10/2023 - **End Date:** 05/10/2026

Type: Project
2023 European Commission, RESEARCH AND INNOVATION ACTIONS SUPPORTING THE IMPLEMENTATION OF THE MISSION ON CANCER
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 101136622
Title: TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS
Start Date: 01/12/2023 - **End Date:** 30/11/2028

Type: Project
2023 Fundación Científica de la Asociación Española Contra el Cáncer, RETO AECC 70% SUPERVIVENCIA
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Title: Neoadjuvant-adjuvant immunotherapy and cancer vaccines to improve survival in hepatocellular carcinoma
Start Date: 01/11/2024 - **End Date:** 31/10/2030

Type: HR
2021 Fundación Científica de la Asociación Española Contra el Cáncer, POSTDOCTORAL AECC
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: POSTD211413AREN
Title: OVERCOMING CANCER IMMUNOTHERAPY RESISTANCE: NEW COMBINATORIAL STRATEGIES TO IMPROVE IMMUNOTHERAPIES
Start Date: 01/10/2023 - **End Date:** 30/06/2025

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, AJUTS JOAN ORÓ PER A LA CONTRACTACIÓ DE PERSONAL INVESTIGADOR PREDOCTORAL EN FORMACIÓ (FI 2024)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: 2024 FI-1 00954
Title: Overcoming Cancer Immunotherapy Resistance
Start Date: 01/06/2024 - **End Date:** 31/05/2027

Type: Award
2023 Fundación San Rafael, PREMIO RAFAEL HERVADA A LA INVESTIGACIÓN BIOMÉDICA 2023
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Title: Aplicaciones de la Inteligencia Artificial en la medicina de vanguardia usando la epigenómica
Start Date: 27/11/2023 - **End Date:** 27/11/2024

Type: Award
2023 Real Academia Nacional de Medicina de España, PREMIO REAL ACADEMIA NACIONAL DE MEDICINA DE ESPAÑA 2023
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Start Date: 01/02/2024 - **End Date:** 28/02/2024

Type: Network
2023 European Commission, EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY - COST ACTION 2023
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: OC-2023-1-26592
Title: Targeting Cell Senescence to Prevent Age-Related Diseases
Start Date: 03/10/2024 - **End Date:** 02/10/2028

Type: Project
2023 FinRett, IV CONVOCATORIA DE AYUDAS A LA INVESTIGACIÓN EN SÍNDROME DE RETT DE FINRETT
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Title: Investigate the spatial epigenome of the respiratory pacemaker: Seeking insights for addressing breathing and swallowing disturbances in Rett Syndrome
Start Date: 31/01/2024 - **End Date:** 30/01/2025

Type: Project
2023 Fundació "La Caixa", CAIXARESEARCH HEALTH CALL 2024
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: HR24-00788
Title: Brain Inflammation in adrenoleukodystrophy: from drivers to treatments
Start Date: 01/12/2024 - **End Date:** 30/11/2027

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2023 (CPP23)
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: CPP2023-010525
Title: NUEVAS ESTRATEGIAS COMBINATORIAS Y BIOMARCADORES DE RESPUESTA A INHIBIDORES DE HDAC6 PARA EL TRATAMIENTO DEL CÁNCER.
Start Date: 01/07/2024 - **End Date:** 30/06/2027

Type: HR
2024 Ajuntament de Sant Boi de Llobregat, PREMIS MANEL ESTELLER D'INICIACIÓ A LA RECERCA BIOMÈDICA
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Reference: RGE/2024/002403
Title: Understanding the biological differences & mechanisms of resistance of TCBs vs CAR T cells in solid and haematological tumours to find new vulnerabilities to improve cancer immunotherapies
Start Date: 16/10/2024 - **End Date:** 15/10/2026

Type: Mobility
2024 Instituto de Salud Carlos III, ACCIONES DE FORMACIÓN CIBERONC 2024. II CONVOCATORIA FORMACIÓN
PI: ESTELLER BADOSA, MANEL
Group: Cancer Epigenetics
Title: Simposio "Updates on Genetics and Epigenetics of Haematological Malignancies: From Knowledge to Applications"
Start Date: 01/10/2024 - **End Date:** 15/11/2024

Cancer Genetics

Montse Sanchez - Cespedes

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: SANCHEZ CESPEDES, MONTSE
Group: Cancer Genetics
Reference: PID2020-114541RB-I00
Title: *Análisis funcional de la inactivación de complejos involucrados en la represión transcripcional en el desarrollo del cáncer de pulmón. (TRARECAN)*
Start Date: 01/09/2021 - **End Date:** 31/08/2024
28/02/2025

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: SANCHEZ - CESPEDES, MONTSE
Group: Cancer Genetics
Reference: 2021 SGR 01377
Title: Cancer Genetics
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: HR
2021 Ministerio de Universidades, CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE PROFESORADO UNIVERSITARIO-FPU 2021
PI: SANCHEZ CESPEDES, MONTSE
Group: Cancer Genetics
Reference: FPU21/00047
Title: Inactivación genética de moléculas involucradas en la represión transcripcional: análisis funcional y papel en el desarrollo del cáncer de pulmón
Start Date: 01/01/2023 - **End Date:** 30/04/2025

Type: HR
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, CONVOCATÒRIA DELS AJUTS JOAN ORÓ PER A LA CONTRACTACIÓ DE PERSONAL INVESTIGADOR PREDOCTORAL EN FORMACIÓ (FI 2023)
PI: SANCHEZ CESPEDES, MONTSE
Group: Cancer Genetics
Reference: 2023 FI-1 00667, 2024 FI-2 00667
Title: Estudio de los factores que determinan la evasión tumoral del reconocimiento inmunológico y respuesta a inmunoterapia.
Start Date: 01/05/2023 - **End Date:** 30/04/2026

Type: Mobility
2023 Ministerio de Ciencia e Innovación, AYUDAS COMPLEMENTARIAS DE MOVILIDAD DESTINADAS A BENEFICIARIOS DEL PROGRAMA DE FORMACIÓN DEL PROFESORADO UNIVERSITARIO (FPU)
PI: SANCHEZ - CESPEDES, MONTSE
Group: Cancer Genetics
Reference: EST24/00262
Title: Obtención de datos experimentales (usando la técnica CUT&RUN) y análisis bioinformático del perfil epigenético de elementos genómicos altamente repetitivos en modelos celulares de cáncer de pulmón para la caracterización del efecto a nivel epigenómico de la pérdida de expresión de ATF7IP.
Start Date: 31/08/2024 - **End Date:** 29/10/2024

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: SANCHEZ - CESPEDES, MONTSE
Group: Cancer Genetics
Reference: PID2023-150559OB-I00
Title: Contribución de las alteraciones en factores epigenéticos al desarrollo del cáncer de pulmón y oportunidades de nuevas vías terapéuticas
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Type: Mobility
2024 European Molecular Biology Organization, SCIENTIFIC EXCHANGE GRANTS 2024
PI: MORILLAS VIÑUALES, JUAN
Group: Cancer Genetics
Title: Characterization of ATF7IP's role in the onco-exaptation of transposable elements in lung cancer
Start Date: 01/06/2024 - **End Date:** 30/06/2024

Cancer Heterogeneity and Hierarchies

Verónica Rodilla

Type: HR
2018 Ministerio de Economia y Competitividad, Ramón y Cajal
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: RYC2018-024099-I
Title: In vivo models to study cellular hierarchies and cancer
Start Date: 01/05/2020 - **End Date:** 30/04/2025

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: PID2020-114647RA-I00
Title: Estudio de linajes celulares en cáncer de mama para entender las dinámicas de crecimiento tumoral y su plasticidad celular
Start Date: 01/09/2021 - **End Date:** 31/08/2024

Type: HR
2021 Departament de Salut, Generalitat de

Catalunya, Subvencions per a la contractació de personal investigador en formació (PIF-SALUT)
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: SLT017/20/000140
Title: Estudis clonals per entendre les jerarquies i plasticitat cel·lular en el càncer de mama
Start Date: 15/07/2021 - **End Date:** 31/12/2024

Type: Project
2021 Fundació d'Estudis i Recerca Oncològica, III PROYECTO FERO-GHD en Cáncer de Mama 2021
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: PFERO2021.01
Title: Defining new biomarkers for an improved diagnosis and better treatment of choice.
Start Date: 01/06/2021 - **End Date:** 31/05/2023 31/12/2024

Type: Project
2021 Fundación Científica de la Asociación Española Contra el Cáncer, LAB AECC 2021
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: LABAE211626RODI
Title: Tumor heterogeneity comprehension for an improved diagnosis and treatment choice for Triple Negative Breast Cancer (TNBC)
Start Date: 01/12/2021 - **End Date:** 30/11/2024 30/11/2025

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS JUAN DE LA CIERVA FORMACIÓN
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: FJC2021-047741-I
Title: Tumor heterogeneity comprehension for an improved diagnosis and treatment choice for Triple Negative Breast Cancer (TNBC)
Start Date: 01/01/2023 - **End Date:** 17/11/2024

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: RODILLA BENITO, VERÓNICA
Group: Cancer Heterogeneity and Hierarchies
Reference: PID2023-150280OB-I00
Title: Desentrañando el papel del linaje luminal en la progresión tumoral del cáncer de mama triple negativo
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Cancer immunogenomics

Eduard Porta

Type: Project
2020 Fundación Científica de la Asociación Española Contra el Cáncer, LAB AECC 2020
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: LABAE20038PORT
Title: Un mapa molecular y celular del cáncer de vejiga para guiar el tratamiento neoadyuvante
Start Date: 01/12/2020 - **End Date:** 30/11/2023 31/05/2024

Type: HR
2019 Ministerio de Ciencia e Innovación, Subprograma de ayudas para contratos Ramon y Cajal
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: RYC2019-026415-I
Title: RYC Eduard Porta
Start Date: 01/09/2021 - **End Date:** 31/08/2026

Type: HR
2021 Fundació "La Caixa", BECAS DE DOCTORADO INPhINIT RETAINING 2022
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: 118772
Title: Harnessing Multi-omic Data Integration to Decode Molecular Patterns in Cancer
Start Date: 16/10/2022 - **End Date:** 15/10/2025

Type: HR
2021 Fundació "La Caixa", BECAS DE DOCTORADO INPhINIT RETAINING 2022
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: 122913
Start Date: 16/10/2022 - **End Date:** 15/10/2025

Type: Project
2021 European Commission, A COMPETITIVE HEALTH-RELATED INDUSTRY 2022
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: 101095717
Title: Scaling Up secure Processing, Anonymization and generation of Health Data for EU cross border collaborative research and Innovation
Start Date: 01/01/2023 - **End Date:** 31/12/2025

Type: Project
2022 Asociación Española de Investigación sobre el Cáncer, III AYUDA DE inVESTIGACIÓN EN CÁNCER FERO- ASEICA
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: BFERO2022.06
Title: Mapping the activity of Cancer Hallmarks to predict the success of cancer treatments
Start Date: 01/01/2023 - **End Date:** 31/12/2024
31/07/2025

Type: HR
2022 European Commission, MSCA COFUND 2022
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: 101126667
Title: The Ramon Llull-AIRA Postdoctoral Programme
Start Date: 01/09/2024 - **End Date:** 31/08/2029

Type: HR
2023 Fundación Científica de la Asociación Española Contra el Cáncer, AECC TALENT 2024
PI: PORTA PARDO, EDUARD
Group: Cancer immunogenomics
Reference: 101081298
Title: Deciphering the spatial architecture of B-Cell lymphomas
Start Date: 01/11/2024 - **End Date:** 31/10/2027

Cancer Metabolism

Lucas Blas Pontel

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS PARA CONTRATOS RAMÓN Y CAJAL 2021
PI: PONTEL MILOCH, LUCAS BLAS
Group: Cancer Metabolism
Reference: RYC2021-032395-I
Title: The role of metabolism in disease aetiology
Start Date: 01/01/2023 - **End Date:** 31/12/2027

Type: Project
2022 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2022
PI: PONTEL MILOCH, LUCAS BLAS
Group: Cancer Metabolism
Reference: DJCLS 04 R/2023
Title: Metabolic drivers of age-related leukemia: mechanisms and therapeutic opportunities
Start Date: 01/04/2024 - **End Date:** 31/03/2027

Type: Project
2021 Ministerio de Ciencia e Innovación, PLAN COMPLEMENTARIO DE BIOTECNOLOGÍA APLICADA A LA SALUD DEL PLAN DE RECUPERACIÓN, TRANSFORMACIÓN Y RESILIENCIA
PI: PONTEL MILOCH, LUCAS BLAS
Group: Cancer Metabolism
Title: Precision Medicine in FA: drug screening to identify a mutation specific drug
Start Date: 31/01/2023 - **End Date:** 31/12/2024

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: PONTEL MILOCH, LUCAS BLAS
Group: Cancer Metabolism
Reference: PID2022-136694NB-I00
Title: Multifaceted Roles of Cellular Nucleophiles in Hematopoietic Tumors
Start Date: 01/09/2023 - **End Date:** 31/08/2026

Chromatin Biology Laboratory

Alejandro Vaquero

Type: Project
2020 Fundación Científica de la Asociación Española Contra el Cáncer, Proyectos Estratégicos AECC 2020
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: PROYE20042VAQU
Title: Descifrando el papel de SIRT7 en el desarrollo de linfocitos B y la formación de Leucemias

Start Date: 01/12/2020 - **End Date:** 30/11/2023
31/05/2024

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: PID2020-117284RB-I00
Title: PAPEL DE LAS SIRTUÍNAS EN LA REGULACIÓN EPIGENÉTICA Y LA INTEGRIDAD GENÓMICA EN RESPUESTA A ESTRÉS Y SU IMPLICACIÓN EN CÁNCER Y ENVEJECIMIENTO (SIREPINOME)
Start Date: 01/09/2021 - **End Date:** 31/08/2024

Type: HR
2021 European Commission, MSCA POSTDOCTORAL FELLOWSHIPS 2021
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: 101065013
Title: Role of the SIRT7-NPM-c-Myc pathway in lung cancer
Start Date: 01/09/2023 - **End Date:** 31/08/2025

Type: HR
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per a la contractació de personal investigador novell (FI-2022)
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: 2022 FI_B 00924, 2023 FI-2 00924, 2024 FI-3 00924
Title: Role of sirtuins in epigenetic regulation and genome integrity in stress respnse and their implication in cancer and aging
Start Date: 01/07/2022 - **End Date:** 30/06/2025

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: 2021 SGR 01378
Title: Grup de biologia de la cromatina
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: HR
2022 Ministerio de Ciencia e Innovación, AYUDAS JUAN DE LA CIERVA 2022
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: JDC2022-049753-I
Title: Brassinosteroid-mediated stem cell divisions in response to DNA damagein Arabidopsis thaliana
Start Date: 01/01/2024 - **End Date:** 31/12/2025

Type: Project
2023 Ministerio de Ciencia e Innovación, PROGRAMA SCREENTECH - PLAN COMPLEMENTARIO DE BIOTECNOLOGÍA APLICADA A LA SALUD
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: P9134
Title: Identificación de moduladores de la actividad ADPribosiltransferasa de Sirtuínas con potencial uso terapéutico
en Leucemias
Start Date: 01/09/2023 - **End Date:** 31/08/2024

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: VAQUERO GARCÍA, ALEJANDRO
Group: Chromatin Biology Laboratory
Reference: PID2023-148760OB-I00
Title: ESTUDIO DEL PAPEL DE LAS SIRTUINAS EN LA RESPUESTA ESTRÉS, ENVEJECIMIENTO Y CANCER (SIRTRESS)
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Endothelial Pathobiology and Microenvironment

Mariona Graupera

Type: Project
2020 European Commission, H2020_MSCA_ITN-2020 Marie Skłodowska-Curie Actions – Innovative Training Networks
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 955951
Title: Deconstructing the evolution of metastasis
Start Date: 01/03/2021 - **End Date:** 28/02/2025

Type: HR
2020 European Commission, H2020 - MSCA - IF-

2020 Marie Skłodowska-Curie Actions - Individual Fellowship
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 101026227
Title: PIK3CA-Related Overgrowth Spectrum: molecular mechanisms and preclinical modelling of PIK3CA VARIANTs
Start Date: 01/09/2022 - **End Date:** 31/08/2024

Type: Project
2020 Leducq Foundation, Transatlantic Networks of Excellence Program 2020
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 21CVD01
Title: Brown Fat and Cardiovascular Health: Genetic Determinants and Molecular Mechanisms
Start Date: 01/01/2022 - **End Date:** 31/12/2026

Type: Project
2020 Worldwide Cancer Research, March 2020 grant round
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 21-0159
Title: Identifying properties of tumour suppressive pericytes for cancer therapy
Start Date: 01/03/2021 - **End Date:** 31/08/2024 31/12/2024

Type: Project
2020 European Commission, H2020_MSCA_ITN-2020 Marie Skłodowska-Curie Actions – Innovative Training Networks
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 955534
Title: PI3K/PTEN-related monogenic disease to understand cancer.
Start Date: 01/07/2021 - **End Date:** 30/06/2025

Type: Project
2019 PTEN Research Foundation, 2020 call
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: IJC-21-001
Title: Preclinical investigation of vascular malformations in PTEN hamartoma tumour syndrome
Start Date: 01/05/2021 - **End Date:** 31/08/2024 30/04/2025

Type: Project
2018 Fundación Científica de la Asociación Española Contra el Cáncer, GRUPOS TRASLACIONALES AECC
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: GCTRA18006CARR
Title: *Vulnerabilities of Tumour and Stroma Interactions in Castration-Naïve Metastatic Prostate Cancer*
Start Date: 01/04/2021 - **End Date:** 30/09/2023 30/09/2024

Type: Project
2020 Fundació "La Caixa", Health Research 2021
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: HR21-00046
Title: Decoding the paracrine control of metabolic fitness by endothelial nutrient signaling
Start Date: 01/12/2021 - **End Date:** 30/11/2024 30/11/2025

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: PID2020-116184RB-I00
Title: PIK3CA variants in PROS: cracking the Code of pathogenesis
Start Date: 01/09/2021 - **End Date:** 31/08/2024 28/02/2025

Type: Project
2021 Fundació "La Caixa", CAIXARESEARCH HEALTH 2022
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: HR22-00316
Title: Understanding and promoting the growth and regenerative functions of blood vessels in heart disease
Start Date: 01/12/2022 - **End Date:** 30/11/2025

Type: HR
2022 Institució Catalana De Recerca i Estudis Avançats, ICREA SENIOR CALL 2022
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Title: Icrea Senior Call 2022
Start Date: 01/01/2023 - **End Date:** 31/12/2029

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 2021 SGR 01320
Title: Patofisiologia de l'endoteli i metabolisme
Start Date: 01/01/2022 - **End Date:** 31/12/2024

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS CONTRATOS PREDOCTORALES PARA FORMACIÓN DOCTORES (FPI)
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: PRE2021-099260
Title: LAS VARIANTES DE PIK3CA IN PROS: DESCIFRANDO EL CODIGO DE PATOGENESIS
Start Date: 01/09/2022 - **End Date:** 30/08/2025

Type: Network
2022 Ministerio de Ciencia e Innovación, REDES DE INVESTIGACIÓN 2022
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: RED2022-134397-T
Title: Systemic and cellular interactions between cancer and metabolic signaling
Start Date: 01/06/2023 - **End Date:** 31/05/2025

Type: Project
2022 Fundació "La Caixa", CAIXARESEARCH HEALTH CALL 2023
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: HR23-00090
Title: Applying DNA and optical barcoding to study endothelial progenitor cells in physiology and disease
Start Date: 31/12/2023 - **End Date:** 30/12/2026

Type: HR
2022 Ministerio de Ciencia e Innovación, AYUDAS PARA CONTRATOS RAMÓN Y CAJAL 2022
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: RYC2022-035574-I
Title: Understanding the genetic and molecular landscape of endothelial-intrinsic disorders towards modelling and therapeutic intervention
Start Date: 01/09/2024 - **End Date:** 31/08/2029

Type: Project
2023 Fundació d'Estudis i Recerca Oncològica, V PROYECTO FERO-GHD EN CANCER DE MAMA 2023
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: PFERO2023.01
Title: Identifying angiokines that promote BCa metastatic growth in bone
Start Date: 15/10/2023 - **End Date:** 14/10/2025

Type: Project
2022 Ministerio de Ciencia e Innovación, JOINT TRANSNATIONAL CALL ON CARDIOVASCULAR DISEASES: RESEARCH TARGETING DEVELOPMENT OF INNOVATIVE THERAPEUTIC STRATEGIES IN CARDIOVASCULAR DISEASE (CARDINNOV)
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: ERA4HEALTHCVD-122
Title: Understanding and repairing GNAQ-mutant blood vessels
Start Date: 01/05/2024 - **End Date:** 30/04/2027

Type: Project
2023 Fundació la Marató de TV3, MARATÓ TV3: SALUT CARDIOVASCULAR
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: 202319 30 31
Title: Decoding the Endothelial cell intrinsic mechanisms causing portosinusoidal hyperTENSION
Start Date: 11/03/2024 - **End Date:** 11/03/2027

Type: HR
2023 Fundació "La Caixa", POSTDOCTORAL JUNIOR LEADER FELLOWSHIPS - RETAINING CALL 2024
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: LCF/BQ/PR24/12050025
Title: Mapping PIK3CA mutant clonal behaviors in development to understand the onset of PIK3CA-related congenital pathologies
Start Date: 16/12/2024 - **End Date:** 15/12/2027

Type: Project
2023 Fundación Científica de la Asociación Española Contra el Cáncer, PROYECTOS COORDINADOS AECC 2024
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: PRYCO247223GOMI
Title: Decoding metastasis-ENDothelial co-dependencies in bone (metEND)
Start Date: 01/12/2024 - **End Date:** 30/11/2029

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: PID2023-152319OB-I00
Title: Generando el mapa de carreteras de los clones mutantes de PIK3CA que forman malformaciones linfáticas
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, Proyectos de Colaboración Internacional PCI2024-1
PI: GRAUPERA GARCIA - MILA, MARIONA
Group: Endothelial Pathobiology and Microenvironment
Reference: PCI2024-153458
Title: Understanding and repairing GNAQ-mutant blood vessels
Start Date: 01/05/2024 - **End Date:** 30/04/2027

Epigenetics and immune disease
Esteban Ballestar

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: BALLESTAR TARIN, ESTEBAN
Group: Epigenetics and immune disease
Reference: PID2020-117212RB-I00
Title: Entendiendo el papel de la Comunicación Celular en el Sistema Inmune en la Desregulación Epigenética en Inflamación (InflaEpiTalk)
Start Date: 01/09/2021 - **End Date:** 31/08/2024

Type: Project
2021 Fundació "La Caixa", CAIXARESEARCH HEALTH 2022
PI: BALLESTAR TARIN, ESTEBAN
Group: Epigenetics and immune disease
Reference: HR22-00668
Title: Uncovering the Differentiation Determinants and Dynamics of Congenital Susceptibility to Infections
Start Date: 01/09/2022 - **End Date:** 31/08/2025

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: BALLESTAR TARIN, ESTEBAN - SARDINA ORTEGA, JOSÉ LUIS
Group: Epigenetics and immune disease
Reference: 2021 SGR 01213
Title: Epigenètica i Malaltia Immunitària
Start Date: 01/01/2022 - **End Date:** 31/12/2024 30/06/2025

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS CONTRATOS PREDOCTORALES PARA FORMACIÓN DOCTORES (FPI)
PI: BALLESTAR TARIN, ESTEBAN
Group: Epigenetics and immune disease
Reference: PRE2021-098003
Title: ENTENDIENDO EL PAPEL DE LA COMUNICACION CELULAR EN EL SISTEMA INMUNE EN LA DESREGULACION EPIGENETICA EN INFLAMACION
Start Date: 01/08/2022 - **End Date:** 31/07/2026

Type: Project
2022 European Commission, MSCA DOCTORAL

NETWORKS 2022
PI: BALLESTAR TARIN, ESTEBAN - SARDINA ORTEGA, JOSE LUIS
Group: Epigenetics and immune disease
Reference: 101119927
Title: Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches
Start Date: 01/01/2024 - **End Date:** 31/12/2027

Epigenetic therapies

Maria Berdasco

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: BERDASCO MENENDEZ, MARIA
Group: Epigenetic therapies
Reference: PID2022-139279OB-I00
Title: Preclinical study of the use of epigenetic inhibitors as a personalized therapy for acute myeloid leukaemia patients carrying NUP98 gene fusions
Start Date: 01/09/2023 - **End Date:** 31/08/2026 I

Regulatory Genomics

Tanya Vavouri

Type: Project
2019 Ministerio de Ciencia, Innovación y Universidades, Generación del Conocimiento
PI: VAVOURI, TANYA
Group: Regulatory Genomics
Reference: PID2019-111676GB-I00
Title: La evolución de nuevos ARN que interactúan con PIWI en mamíferos
Start Date: 01/06/2020 - **End Date:** 31/05/2023 31/05/2024

Type: HR
2022 Fundació "la Caixa", BECAS DE DOCTORADO INPhINIT INCOMING 2022
PI: VAVOURI, TANYA SOULTANA
Group: Regulatory Genomics
Reference: 120917
Title: The effect of transposable elements on gene regulation in mammals
Start Date: 01/11/2022 - **End Date:** 31/10/2025

Regulatory RNA and chromatin

Sònia Guil

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin
Reference: 2021 SGR 01309
Title: RNA regulador i cromatina
Start Date: 01/01/2022 - **End Date:** 31/12/2024 30/06/2025

Type: Project
2022 FinRett, III CONVOCATORIA DE AYUDAS A LA INVESTIGACIÓN EN SÍNDROME DE RETT DE FINRETT
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin
Title: Caracterización de la actividad de unión al RNA de la proteína MECP2 salvaje y mutante para mejorar la terapia de reemplazo génica para el síndrome de Rett
Start Date: 01/04/2023 - **End Date:** 31/03/2024 30/06/2024

Type: Project
2022 International Rett Syndrome, RETT SYNDROME INNOVATION AWARD 2022
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin
Reference: 4005
Title: Development of a mechanism to regulate the ectopic expression of a MeCP2 vector
Start Date: 15/12/2022 - **End Date:** 14/12/2024 14/06/2025

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin
Reference: PID2022-142829OB-I00
Title: Estudio del repertorio de dianas RNA de la proteina de union a metil-DNA MeCP2: papel en

la fisiopatologia del sindrome de Rett y utilidad como herramientas terapeuticas
Start Date: 01/09/2023 - **End Date:** 31/08/2026

Type: Project
2022 Ministerio de Ciencia e Innovación, PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2022
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin
Reference: CPP2022-009793
Title: Efecto de HDAC6i en un modelo murino del Síndrome de Rett
Start Date: 01/04/2023 - **End Date:** 31/03/2026

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, AJUTS JOAN ORÓ PER A LA CONTRACTACIÓ DE PERSONAL INVESTIGADOR PREDOCTORAL EN FORMACIÓ (FI 2024)
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin **Reference:** 2024 FI-1 00331
Start Date: 01/07/2024 - **End Date:** 30/06/2027

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: GUIL DOMÈNECH, SÒNIA
Group: Regulatory RNA and chromatin **Reference:** PREP2022-000681
Title: Estudio del repertorio de dianas de RNA de la proteína de unión a metil-DNA MeCP2: papel en la fisiopatología del síndrome de Rett y utilidad como herramientas terapéuticas
Start Date: 01/02/2024 - **End Date:** 31/01/2028

3D Chromatin Organization

Biola M. Javierre

Type: HR
2019 Ministerio de Ciencia e Innovación, Ayudas para contratos predoctorales para la formacion de doctores (FPI)
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: PRE2019-088005
Title: Organización dinámica 3D de la cromatina en la hematopoyesis humana: descripción de nuevos genes asociados a enfermedades hematológicas.
Start Date: 01/08/2020 - **End Date:** 31/07/2024

Type: Project
2020 Wellcome LEAP Inc, Human Organs, Physiology, and Engineering (HOPE)
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: HOPE-2021-2754490174
Title: Engineering human B cells: accelerating modelling of disease, drug screenings and translation of cancer immunotherapy
Start Date: 01/04/2021 - **End Date:** 31/03/2024

Type: Project
2021 Fundación Científica de la Asociación Española Contra el Cáncer, LAB AECC 2021
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: LABAE21981JAVI
Title: Enfoque multiómico para mejorar el manejo terapéutico de la leucemia linfoblástica aguda de células T
Start Date: 01/12/2021 - **End Date:** 30/11/2024
31/05/2025

Type: Project
2021 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2021
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: PID2021-125277OB-I00
Title: Descifrando el papel y la regulación de la arquitectura del genoma espacio-temporal en la linfomagénesis de células B
Start Date: 01/09/2022 - **End Date:** 31/08/2025

Type: HR
2022 Instituto de Salud Carlos III, CONTRATOS MIGUEL SERVET
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: CP22/00127
Start Date: 01/01/2023 - **End Date:** 31/12/2027

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)

PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: 2021 SGR 00771
Title: Leukemia 3D epigenomics
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: HR
2022 Fundación Científica de la Asociación Española Contra el Cáncer, AYUDAS PREDOCTORALES AECC 2023
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: PRDBA233916ALCA
Title: Deciphering the role and regulation of spatial-temporal genome architecture in B cell lymphomagenesis
Start Date: 01/12/2023 - **End Date:** 30/11/2026

Type: Network
2022 Ministerio de Ciencia e Innovación, REDES DE INVESTIGACIÓN 2022
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: RED2022-134768-T
Title: Red de Regulación Genómica/ Regulatory Genomics Network – R2G
Start Date: 01/06/2023 - **End Date:** 31/05/2025

Type: Project
2022 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2022
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: DJCLS 18 R/2023
Title: Deciphering the Oncogenic Role of the PRC1 Complexes Through Integration of Functional and Spatial Genomics in Diffuse Large B-cell Lymphoma
Start Date: 01/06/2024 - **End Date:** 31/05/2026

Type: Project
2022 Fundació "La Caixa", CAIXARESEARCH HEALTH CALL 2023
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: HR23-00060
Title: Deciphering relapse in B-cell acute lymphoblastic leukemia
Start Date: 31/12/2023 - **End Date:** 30/12/2026

Type: HR
2020 Ministerio de Universidades, CONVOCATORIA DE AYUDAS PARA LA FORMACIÓN DEL PROFESORADO UNIVERSITARIO - FPU 2020
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: FPU20/03798
Title: FPU 2020
Start Date: 01/01/2023 - **End Date:** 30/11/2025

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: 2023 INV-2 00011 (200011TG1)
Title: 3D Genome Organization
Start Date: 16/06/2023 - **End Date:** 15/06/2025

Type: HR
2023 Ministerio de Ciencia e Innovación, Ayudas para contratos predoctorales para la formación de doctores 2022 (FPI 2022)
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: PRE2022-102463
Title: Descifrando el papel y la regulacion de la arquitectura del genoma espacio temporal en la linfomagenesis de celulas B
Start Date: 01/12/2023 - **End Date:** 30/11/2027

Type: HR
2023 Fundación Científica de la Asociación Española Contra el Cáncer, AECC TALENT 2024
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Title: Dissecting the role of Silencers in Acute Lymphoblastic Leukaemia to improve its clinical management
Start Date: 01/10/2024 - **End Date:** 30/09/2027

Type: Mobility
2023 Ministerio de Ciencia e Innovación, AYUDAS COMPLEMENTARIAS DE MOVILIDAD DESTINADAS A BENEFICIARIOS DEL PROGRAMA DE FORMACIÓN DEL PROFESORADO UNIVERSITARIO (FPU)
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: EST24/00286

Title: FPU2020
Start Date: 15/04/2024 - **End Date:** 14/07/2024

Type: Project
2024 Fundación BBVA, BECAS LEONARDO A INVESTIGADORES Y CREADORES CULTURALES 2024
PI: JAVIERRE MARTINEZ, BIOLA M.
Group: 3D Chromatin Organization
Reference: LEO24-1-12202
Title: Decoding how silencers orchestrate normal and malignant cell differentiation
Start Date: 01/10/2024 - **End Date:** 31/03/2026

Acute lymphoblastic leukemia

Josep Maria Ribera

Type: Project
2019 Instituto de Salud Carlos III, Proyectos de investigación en Salud GENESCA
PI: FERRER, EULALIA - RIBERA SANTASUSANA, JOSEP MARIA
Group: Acute lymphoblastic leukemia
Reference: PI19/01828
Title: Uso de la Secuenciación de Nueva Generación (NGS) como única herramienta genómica para la mejora del diagnóstico, el pronóstico y el tratamiento de pacientes adultos con leucemia linfoblástica de tipo T
Start Date: 01/01/2020 - **End Date:** 31/12/2022 30/06/2024

Type: Project
2019 European Commission, IMI2-2019-19-01
PI: RIBERA SANTASUSANA, JOSEP MARIA
Group: Acute lymphoblastic leukemia
Reference: 945406
Title: Healthcare alliance for resourceful medicines offensive against neoplasms In hematology – PLUS.
Start Date: 01/10/2020 - **End Date:** 30/09/2023 31/03/2024

Type: Network
2021 Instituto de Salud Carlos III, Redes de Investigación Cooperativa Orientada a Resultados en Salud RIBERA
PI: SANTASUSANA, JOSEP MARIA
Group: Acute lymphoblastic leukemia
Reference: RD21/0017/0029

Title: TERAV (Red de Terapias Avanzadas)
Start Date: 01/01/2022 - **End Date:** 31/12/2024

Type: Project
2021 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2021
PI: GENESCA FERRER, EULALIA
Group: Acute lymphoblastic leukemia
Reference: DJCLS 08 R/2022
Title: Development of innovative therapy strategies to overcome therapy resistance in the Primary therapy for adult T- cell acute lymphatic leukemia (T-ALL).
Start Date: 01/11/2022 - **End Date:** 31/10/2025

Type: Project
2022 Instituto de Salud Carlos III, PROYECTOS DE I+D+I EN SALUD
PI: GENESCA FERRER, EULALIA
Group: Acute lymphoblastic leukemia **Reference:** PI22/01880
Title: Identificación de factores genéticos y no genéticos para predecir recaídas y definir nuevas terapias en la leucemia linfoblástica aguda de células T del adulto (LLA-T)
Start Date: 01/01/2023 - **End Date:** 31/12/2025

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: GENESCA FERRER, EULALIA
Group: Acute lymphoblastic leukemia
Reference: 2023 INV-2 00011 (200011TC6)
Title: T-ALL Team/ALL Research Group
Start Date: 01/09/2023 - **End Date:** 31/08/2025

Type: Project
2022 Fundación Científica de la Asociación Española Contra el Cáncer, ATTRACT 2022 - JOINT INTERNATIONAL CALL FOR RESEARCH ON RARE CANCER DRUG DEVELOPMENT
PI: GENESCA FERRER, EULALIA
Group: Acute lymphoblastic leukemia
Reference: ATTRA236923GENE
Title: A precision medicine randomized trial for patients with relapsed or refractory T-cell Acute Lymphoblastic Leukemia based on a functional approach
Start Date: 01/04/2024 - **End Date:** 31/03/2029

Type: Other
2023 Ministerio de Ciencia e Innovación, ACREDITACIÓN R3
PI: GENESCA FERRER, EULALIA
Group: Acute lymphoblastic leukemia
Reference: CR32023-042176
Start Date: 05/12/2023 - **End Date:** 31/12/2100

Type: HR
2023 Instituto de Salud Carlos III, CONTRATOS PFIS: CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD 2023
PI: GENESCA FERRER, EULALIA
Group: Acute lymphoblastic leukemia
Reference: FI23/00247
Start Date: 01/01/2024 - **End Date:** 31/12/2027

Cellular Systems Genomics

Elisabetta Mereu

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS PARA CONTRATOS RAMÓN Y CAJAL 2021
PI: MEREU, ELISABETTA
Group: Cellular Systems Genomics
Reference: RYC2021-032359-I
Title: Targeting inflammation in the era of single-cell genomics
Start Date: 01/01/2023 - **End Date:** 31/12/2027

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: MEREU, ELISABETTA
Group: Cellular Systems Genomics
Reference: 2021 SGR 01586
Title: Inflammation in Aged Tissue Ecosystems(INFLAM-MATES)
Start Date: 01/01/2022 - **End Date:** 31/12/2024 30/06/2025

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: MEREU, ELISABETTA
Group: Cellular Systems Genomics
Reference: PID2022-137741OA-I00
Title: Unveiling the single-cell transcriptomic and epigenomic regulation of T cell dysfunction in multiple myeloma treatment response (IMMUNOMYELOMICS).
Start Date: 01/09/2023 - **End Date:** 31/08/2026

Type: Project
2023 Asociación Española de Investigación sobre el Cáncer, V AYUDA DE INVESTIGACIÓN EN ONCOLOGÍA ASEICA +QUEUNTRAIL ALCOI
PI: MEREU, ELISABETTA
Group: Cellular Systems Genomics
Title: IMPACT-MM: Immunotherapy Multiomics Precision Analysis for Cancer Treatment in Multiple Myeloma
Start Date: 01/01/2024 - **End Date:** 31/12/2024 31/12/2025

Lymphocyte development and disease

Maribel Parra

Type: Project
2021 Instituto de Salud Carlos III, Proyectos de investigación en Salud (FIS)
PI: PARRA BOLA, MARIBEL
Group: Lymphocyte development and disease
Reference: PI21/01451
Title: Proteïna HDCA7 (repressor transcripcional, tipus Acetona Desacetilasa) clau en la maduració de limfòcits B, com a marcador de prognòstic de MLL-AF4
Start Date: 01/01/2022 - **End Date:** 31/12/2024 31/08/2025

Type: Project
2021 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2021
PI: PARRA BOLA, MARIBEL
Group: Lymphocyte development and disease
Reference: DJCLS 07 R/2022
Title: Precision medicine in infant acute lymphoblastic leukemia: Modulating specific histone deacetylases to improve prognosis
Start Date: 01/10/2022 - **End Date:** 30/09/2025

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS PARA CONTRATOS RAMÓN Y CAJAL 2021
PI: PARRA BOLA, MARIBEL

Group: Lymphocyte development and disease
Reference: RYC2021-031197-I
Title: Targeting epigenetic regulation in early lymphopoiesis: towards precision medicine in B cell malignancies
Start Date: 01/01/2023 - **End Date:** 31/12/2027

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: PARRA BOLA, MARIBEL
Group: Lymphocyte development and disease
Reference: 2021 SGR 01533
Title: Lymphocyte Development and Disease
Start Date: 01/01/2022 - **End Date:** 31/12/2024

Type: Mobility
2023 Ministerio de Educación y Formación Profesional, ESTANCIAS DE PROFESORES E INVESTIGADORES SENIOR EN CENTROS EXTRANJEROS - PROGRAMA FULLBRIGHT
PI: PARRA BOLA, MARIBEL
Group: Lymphocyte development and disease
Reference: PRX22/00572
Title: La cara B de la COVID-19: entender la infección por SARS-CoV-2 para predecir la immunidad humoral en los retos actuales y las perspectivas futuras de la enfermedad y la vacunación
Start Date: 01/06/2024 - **End Date:** 31/08/2024

Type: Project
2023 I-Cerca, 12TH EDITION 2023 - CALL FOR CERCA GÍNJOL PATENTS FUND
PI: DE BARRIOS BARRI, ORIOL
Group: Lymphocyte development and disease
Reference: 2023-12-015 IJC ALL-BePrecise-2
Title: Proteïna HDCA7 (repressor transcripcional, tipus Acetona Desacetilasa) clau en la maduració de limfòcits B, com a marcador de prognòstic de MLL-AF4
Start Date: 01/01/2023 - **End Date:** 31/12/2024

Lymphoma Translational Group
Gaël Roué

Type: Project
2021 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2021
PI: ROUÉ, GAËL
Group: Lymphoma Translational Group
Reference: PID2021-123039OB-C21
Title: Generación de una colección de esferoides organotípicos 3D y de modelos PDX de LDCG completamente anotados para la evaluación preclínica de disruptores del link tumor-estroma
Start Date: 01/09/2022 - **End Date:** 31/08/2025

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: ROUÉ, GAËL
Group: Lymphoma Translational Group
Reference: 2021 SGR 01535
Title: Teràpies personalitzades i bases moleculars dels limfomes agressius de cèl·lules B (TRANSFORB)
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: Project
2023 I-Cerca, 12TH EDITION 2023 - CALL FOR CERCA GÍNJOL PATENTS FUND
PI: ROUÉ, GAËL
Group: Lymphoma Translational Group
Reference: 2023-12-018
Title: A new service platform for the generation of Hematological patient-derived Xenograft using in Ovo technology: enabling reliability and cost-efficiency in the preclinical screening of antitumor therapies.
Start Date: 01/01/2023 - **End Date:** 06/11/2024

Type: Project
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, AJUTS D'INDÚSTRIA DEL CONEIXEMENT 2023, MODALITAT A. LLAVOR
PI: ROUÉ, GAËL
Group: Lymphoma Translational Group
Reference: 2023 LLAV 00120
Title: EmbryoCure: a new platform for the design of in vivo immunocompetent and non-animal xenograft models of hematological cancers
Start Date: 01/02/2024 - **End Date:** 31/07/2024

Nuclear Architecture in Leukemia
Gregoire Stik

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS

PARA CONTRATOS RAMÓN Y CAJAL 2021
PI: STIK, GREGOIRE
Group: Nuclear Architecture in Leukemia
Reference: RYC2021-032384-I
Title: Identifying the role of the biophysical properties of the chimeric E2A-PBX1 transcription factor on 3D genome alteration and pathogenesis of B-ALL leukemia
Start Date: 01/01/2023 - **End Date:** 31/12/2027

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: STIK, GREGOIRE
Group: Nuclear Architecture in Leukemia
Reference: 2023 INV-2 00011 (200011TG4)
Title: Nuclear Architecture in Leukemia.
Start Date: 01/07/2023 - **End Date:** 30/06/2025

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: STIK, GREGOIRE
Group: Nuclear Architecture in Leukemia
Reference: PID2022-140859OA-I00
Title: Uncovering the biomolecular properties of the chimeric oncogene E2A-PBX1 and its role on 3D genome alteration of B cell acute lymphoid leukaemia
Start Date: 01/09/2023 - **End Date:** 31/08/2026

Stem cell biology, developmental leukemia and immunotherapy

Pablo Menéndez

Type: Project
2018 European Commission, H2020-SC1-BHC-2018-2020 (Topics 2018)
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 825749
Title: Childhood Leukaemia: Overcoming distance between South America and Europe Regions
Start Date: 01/01/2019 - **End Date:** 31/12/2023
31/03/2024

Type: HR
2012 Institució Catalana De Recerca i Estudis Avançats, ICREA Senior Call 2012
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Start Date: 01/01/2023 - **End Date:** 31/12/2029

Type: HR
2019 Ministerio de Universidades, Ayudas para la formación de profesorado universitario (FPU)
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: FPU19/00039
Title: Explorando células efectoras alogénicas para inmunoterapia en leucemia aguda
Start Date: 01/11/2020 - **End Date:** 31/03/2024

Type: Project
2020 Deutsche José Carreras Leukämie Stiftung, Forschungsprojekte (R 20) 2020
PI: MENÉNDEZ BUJÁN, PABLO - VELASCO HERNÁNDEZ, TALÍA
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: DJCLS 15R/2021
Title: Acute Myeloid Leukemia initiating cells: contribution of hypoxia/HIF pathway to chemoresistance and relapse
Start Date: 15/02/2022 - **End Date:** 14/02/2025
30/06/2025

Type: HR
2021 Fundación Científica de la Asociación Española Contra el Cáncer, Investigador AECC
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: INVES211226MOLI
Title: Contribución de la inestabilidad cromosómica en el desarrollo de la leucemia linfoblástica aguda infantil con aneuploidías.
Start Date: 01/12/2021 - **End Date:** 24/11/2024
30/11/2025

Type: Project
2021 Fundación Científica de la Asociación Española Contra el Cáncer, Proyectos generales AECC
PI: BUENO UROZ, CLARA
Group: Stem cell biology, developmental leukemia and immunotherapy

Reference: PRYGN211192BUEN
Title: INMUNOTERAPIA REDIRIGIDA DE CELULAS-T UNIVERSAL DE ULTIMA GENERACIÓN PARA LEUCEMIA AGUDA
Start Date: 01/12/2021 - **End Date:** 30/11/2024
31/05/2025

Type: Project
2021 Fundació "La Caixa", CaixaImpulse Validate 2021
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: LCF/TR/CI21/52650003
Title: CARIT4ES - Tailored adoptive CAR T-cell Immunotherapy for Ewing Sarcoma
Start Date: 20/12/2021 - **End Date:** 19/12/2023
19/03/2024

Type: HR
2021 Instituto de Salud Carlos III, Contratos Predoctorales de formacion en investigación (PFIS)
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: FI21/00161
Title: TIM3, A promising novel immunotherapeutic target for de novo and relapsed b-cell acute lymphoblastic.
Start Date: 01/01/2022 - **End Date:** 31/12/2024

Type: Project
2021 Ministerio de Ciencia e Innovación, Proyectos de I+D+i en líneas estratégicas, en colaboración público-privada 2021
PI: BUENO UROZ, CLARA
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: PLEC2021-007518
Title: RECREACIÓN DEL NICHO EMBRIONARIO PARA LA PRODUCCIÓN DE CÉLULAS MADRE HEMATOPOYÉTICAS Y SUS DERIVADOS EN GASTRULOIDES HUMANOS
Start Date: 01/12/2021 - **End Date:** 30/11/2025

Type: HR
2020 Ministerio de Ciencia, Innovación y Universidades , Ayudas para contratos predoctorales en el marco del Plan Estatal de I+D+i (FPI)
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: PRE2020-092778
Title: TIM3, UNA NUEVA Y PROMETEDORA DIANA INMUNOTERAPEUTICA EN LEUCEMIA LINFOBLASTICA AGUDA BDE NOVO Y EN RECAIDA
Start Date: 01/08/2021 - **End Date:** 31/07/2025

Type: Project
2021 European Commission, TOOLS AND TECHNOLOGIES FOR A HEALTHY SOCIETY 2021
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 101057250
Title: RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY
Start Date: 01/06/2022 - **End Date:** 31/05/2025

Type: HR
2021 European Commission, MSCA POSTDOCTORAL FELLOWSHIPS 2021
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 101068558
Title: Contribution of Lipid Droplets to the pathogenesis and chemoresistance of Acute Myeloid Leukemia
Start Date: 01/09/2023 - **End Date:** 28/02/2026

Type: Project
2022 Fundación Merck Salud, AYUDAS MERCK DE INVESTIGACIÓN 2022
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: MERCK 2022
Title: Desarrollo de una innovadora inmunoterapia adoptiva de células CAR-T para sacorma de Ewing
Start Date: 10/07/2022 - **End Date:** 15/06/2025

Type: Project
2021 European Science Foundation, FIGHT KIDS CANCER 2021-2
PI: MENÉNDEZ BUJÁN, PABLO - PARRA BOLA, MARIA ISABEL
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 21-FKC-EOI-020
Title: Finding a cure for MLL-rearranged infant acute lymphoblastic leukemia
Start Date: 15/01/2023 - **End Date:** 31/12/2024
31/12/2025

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS JUAN DE LA CIERVA FORMACIÓN
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: FJC2021-046789-I
Title: Next generation T-cell redirected immunotherapy for acute lymphocytic leukemia
Start Date: 01/01/2023 - **End Date:** 31/12/2024

Type: Project
2021 Ministerio de Ciencia e Innovación, PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2021
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: CPP2021-008508
Title: Desarrollo de una nueva terapia CAR-T dirigida a CD1a para el tratamiento de leucemias/linfomas de células T CD1a+
Start Date: 01/03/2022 - **End Date:** 28/02/2025
30/09/2025

Type: Project
2021 Ministerio de Ciencia e Innovación, PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2021
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: CPP2021-008676
Title: Desarrollo de una nueva tecnología de ingeniería genética aplicada en una terapia CAR-T
Start Date: 01/06/2022 - **End Date:** 31/05/2025

Type: Project
2022 Fundación Uno Entre Cien Mil , IX BECA "Unoentrecienmil" PARA LA INVESTIGACIÓN EN EL **ÁREA** DE LA LEUCEMIA INFANTIL 2022
PI: BUENO UROZ, CLARA
Group: Stem cell biology, developmental leukemia and immunotherapy
Title: Novel and innovative therapeutic strategies for patients with childhood B acute lymphoblastic leukemia harboring MLL rearrangements
Start Date: 26/07/2022 - **End Date:** 25/07/2024

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 2021 SGR 00887
Title: Stem cell biology, developmental leukemia and immunotherapy
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: Project
2021 European Commission, European Commission, Proof of Concept Grants 2021 (ERC-2021-PoC)
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 101100665
Title: Byspecific CAR T-cells for the treatment of CD22/CD19 positive cancer
Start Date: 01/07/2023 - **End Date:** 31/12/2024
31/03/2025

Type: Project
2022 Ministerio de Ciencia e Innovación, PROYECTOS DE I+D+i EN LÍNEAS ESTRATÉGICAS, EN COLABORACIÓN PÚBLICO-PRIVADA 2022
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: PLEC2022-009416
Title: Desarrollo de una inmunoterapia innovadora adoptiva de células CAR-T para sarcoma de Ewing
Start Date: 01/11/2022 - **End Date:** 31/10/2025

Type: HR
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, AJUTS A DOCTORATS INDUSTRIALS MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 2022 DI 43
Title: Development of new CAR-T treatment for glioblastoma multiforme
Start Date: 01/10/2022 - **End Date:** 30/09/2025

Type: Project
2022 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2022
PI: BUENO UROZ, CLARA
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: DJCLS 02 R/2023
Title: Exploring the role of lipid droplets in the

pathogenesis and chemoresistance of AML
Start Date: 01/01/2024 - **End Date:** 31/12/2026

Type: Project
2022 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2022
PI: MOLINA CAMPOY, OSCAR
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: DJCLS 15 R/2023
Title: Clonal heterogeneity and leukemia-initiating stem cell-driven pathophysiology of aneuploid childhood B cell acute lymphoblastic leukemia
Start Date: 01/01/2024 - **End Date:** 31/12/2026

Type: Project
2022 Fundación Científica de la Asociación Española Contra el Cáncer, PROYECTOS GENERALES AECC 2023
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: PRYGN234975MENE
Title: Células T□□ (V□1) alogénicas, HLA-independientes, redirigidas contra las dianas CCR9 y CD1a con un CAR dual para leucemia linfoblástica T en recaída/refractaria
Start Date: 01/12/2023 - **End Date:** 30/11/2026

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 2023 INV-2 00011 (200011TC3)
Title: Stem cell biology, developmental leukemia and immunotherapy.
Start Date: 16/06/2023 - **End Date:** 15/06/2025

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: MENÉNDEZ BUJÁN, PABLO - MOLINA CAMPOY, OSCAR
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: PID2022-142966OB-I00
Title: Chromosome instability and leukemia-initiating stem cell-driven pathophysiology of aneuploid childhood B-cell acute lymphoblastic leukemia.
Start Date: 01/09/2023 - **End Date:** 31/08/2026

Type: Project
2022 Ministerio de Ciencia e Innovación, PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2022
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: CPP2022-009759
Title: Desarrollo de una terapia CAR-T dual dirigida a CD1a/CCR9 para el tratamiento de la leucemia linfoblástica aguda de células T R/R
Start Date: 01/10/2023 - **End Date:** 30/09/2026

Type: Project
2022 European Commission, EIC TRANSITION 2022
PI: MENENDEZ BUJAN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: 101113067
Title: Next generation, off-the-shelf CD1a/CCR9-directed CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
Start Date: 01/04/2023 - **End Date:** 31/03/2026

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: MENÉNDEZ BUJÁN, PABLO
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: PREP2022-000674
Title: Inestabilidad cromosómica y patofisiología de las células iniciadoras de leucemia en la leucemia linfoblástica aguda pediátrica con aneuploidías
Start Date: 01/02/2024 - **End Date:** 31/01/2028

Type: Project
2024 Fundación Uno Entre Cien Mil , XI BECA FUNDACIÓN UNOENTRECIENMIL 2024 PARA LA INVESTIGACIÓN EN EL ÁREA DE LA LEUCEMIA INFANTIL
PI: BUENO UROZ, CLARA - LOPEZ MILLAN, MARIA BELEN
Group: Stem cell biology, developmental leukemia and immunotherapy
Title: Defining Immunutherapy-based pioneering

therapeutic strategies for infant B-ALL patients
Start Date: 28/08/2024 - **End Date:** 28/08/2026

Type: Project
2024 Fundación Eugenio Rodríguez Pascual, Ajudas de investigació biomèdicas (2024)
PI: BUENO UROZ, CLARA
Group: Stem cell biology, developmental leukemia and immunotherapy
Reference: FERP-2024-166
Title: Estrategias terapéuticas pioneras basadas en inmunoterapia para LLA-B del lactante
Start Date: 17/12/2024 - **End Date:** 16/12/2026

Stem Cells and Cancer

Anna Bigas

Type: HR
2021 European Commission, MSCA POSTDOCTORAL FELLOWSHIPS 2021
PI: BIGAS SALVANS, ANNA - Cuartero BETRIU, SERGI
Group: Stem Cells and Cancer
Reference: 101068212
Title: Identification and characterization of long non-coding RNAs as drivers of stemness in hematopoietic stemcells and leukemia.
Start Date: 01/01/2023 - **End Date:** 31/12/2024

Type: Project
2021 Deutsche José Carreras Leukämie Stiftung, DJCLS PROJECT CALL 2021
PI: BIGAS SALVANS, ANNA
Group: Stem Cells and Cancer
Reference: DJCLS 14 R/2022
Title: Establishment of preclinical models of the juvenile myelomonocytic leukemia to develop new therapeutic approaches for high risk patients
Start Date: 01/10/2022 - **End Date:** 30/09/2025

T cell lymphomas

Laura Mondragón

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: MONDRAGÓN MARTÍNEZ, LAURA
Group: T cell lymphomas
Reference: PID2020-116049RA-I00
Title: Papel de Apaf-1 en la maduración de los timocitos TCR-gd y el desarrollo de linfomas - RAINCOAT
Start Date: 01/09/2021 - **End Date:** 31/08/2024
28/02/2025

Type: HR
2019 Ministerio de Ciencia e Innovación, Subprograma de ayudas para contratos Ramon y Cajal
PI: MONDRAGÓN MARTÍNEZ, LAURA
Group: T cell lymphomas
Reference: RYC2019-026522-I
Start Date: 01/04/2021 - **End Date:** 31/03/2026
08/10/2026

Type: Project
2022 Leukemia Research Foundation, Hollis Brownstein Research Grants Program - New Investigator Blood Cancer Research Grant Program (Leukemia, Lymphoma, Myeloma, MDS)
PI: MONDRAGÓN MARTÍNEZ, LAURA
Group: T cell lymphomas
Title: New therapeutic approach for treating angioimmunoblastic T cell lymphoma based on the discovery of a new Tfh population
Start Date: 01/10/2022 - **End Date:** 30/09/2023
31/03/2024

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: MONDRAGÓN MARTÍNEZ, LAURA
Group: T cell lymphomas
Reference: PID2023-149829OB-I00
Title: Cambio de linaje en células T e inhibición de la muerte celular en el origen del linfoma angioinmunoblástico de células T
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Chromatin, Metabolism and Cell Fate

Marcus Buschbeck

Type: Project
2019 Fundació La Marató de TV3, Marató 2019: Càncer

PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: 201907-30-31
Title: Explorant i explotant les variants d'histones com a dianes terapèutiques en la leucèmia mieloide aguda
Start Date: 20/01/2021 - **End Date:** 19/01/2024
31/01/2024

Type: Project
2020 European Commission, H2020_MSCA_ITN-2020 Marie Skłodowska-Curie Actions – Innovative Training Networks
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: 953407
Title: Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.
Start Date: 01/01/2021 - **End Date:** 31/12/2024

Type: HR
2019 Ministerio de Ciencia e Innovación, Ayudas para contratos predoctorales para la formacion de doctores (FPI)
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: PRE2019-088529
Title: Regulacion de la arquitectura tridimensional de la cromatina por parte de las variantes de histona macroh2a y su capacidad de unir metabolitos.
Start Date: 01/10/2020 - **End Date:** 30/09/2024

Type: HR
2021 Deutsche Forschungsgemeinschaft, Walter Benjamin Abroad Fellowship 2021
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: WI 5839/1-1
Title: Exploring epigenetic modulation in bone marrow stroma as novel therapeutic approach to prevent leukaemia
Start Date: 01/05/2022 - **End Date:** 30/04/2024

Type: HR
2022 Fundación Científica de la Asociación Española Contra el Cáncer, INVESTIGADOR AECC 2022
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: INVES223200DIES
Title: A functional approach to accelerate the development of combinatorial drug therapies in blood cancers
Start Date: 01/11/2022 - **End Date:** 31/10/2025

Type: Project
2021 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2021
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: PID2021-126907NB-I00
Title: Regulación de potenciadores de la expresión génica y detección de metabolitos por parte de variantes de histonas
Start Date: 01/09/2022 - **End Date:** 31/08/2025

Type: Project
2022 Fundación Científica de la Asociación Española Contra el Cáncer, PROYECTOS GENERALES AECC 2022
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: PRYGN222668BUSC
Title: Re-educación epigenética del estroma en el microambiente de la médula **ósea** como enfoque terapéutico en la prevención de cáncer de sangre
Start Date: 01/12/2022 - **End Date:** 30/11/2025

Type: HR
2021 European Commission, MSCA COFUND 2021
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: 101081347
Title: Carreras Postdoc Program Empowering Future Leaders to Fight Blood Cancers
Start Date: 01/01/2023 - **End Date:** 31/12/2027

Type: HR
2021 European Molecular Biology Organization, EMBO POSTDOCTORAL FELLOWSHIPS 2021 (Spring evaluation)
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: ALTF 81-2022
Title: Elucidating the role of the histone variant macroH2A1.2 as a metabolic sensor in cell fate
Start Date: 01/08/2022 - **End Date:** 31/07/2024

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i

de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: 2021 SGR 00260
Title: Chromatin, metabolism and cell fate
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: HR
2022 European Commission, MSCA POSTDOCTORAL FELLOWSHIPS 2022
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: 101108823
Title: Elucidating the role of macroH2A1.2 histone variant as a metabolic sensor in the epigenetic regulation of leukaemia cell fate
Start Date: 01/08/2024 - **End Date:** 31/07/2026

Type: HR
2023 Ministerio de Ciencia e Innovación, Ayudas para contratos predoctorales para la formación de doctores 2022 (FPI 2022)
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: PRE2022-102083
Title: REGULACION DE POTENCIADORES DE LA EXPRESION GENICA Y DETECCION DE METABOLITOS POR PARTE DE VARIANTES DE HISTONAS
Start Date: 01/01/2024 - **End Date:** 31/12/2027

Type: HR
2022 European Commission, MSCA COFUND 2022
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: 101126688
Title: Enabling the next generation in search of blood cancer cures
Start Date: 01/09/2024 - **End Date:** 31/08/2029

Type: Project
2023 Fundació "La Caixa", CAIXAIMPULSE HEALTH INNOVATION CALL 2024
PI: BUSCHBECK, MARCUS
Group: Chromatin, Metabolism and Cell Fate
Reference: CI24-10180
Title: Molecular glue degraders for a novel drug target in acute myeloid leukemia
Start Date: 31/12/2024 - **End Date:** 30/12/2026

Epigenetic Control of Haematopoiesis

José Luis Sardina

Type: HR
2019 Instituto de Salud Carlos III, Contratos Miguel Servet - Tipo 1
PI: SARDINA ORTEGA, JOSÉ LUIS
Group: Epigenetic Control of Haematopoiesis
Reference: CP19/00176
Title: Role of TET2 in chromatin structure regulation during the onset and development of myeloid malignancies
Start Date: 01/01/2020 - **End Date:** 31/12/2024
22/04/2025

Type: Project
2019 Ministerio de Ciencia, Innovación y Universidades, Retos Investigación
PI: SARDINA ORTEGA, JOSÉ LUIS
Group: Epigenetic Control of Haematopoiesis
Reference: PID2019-111243RA-I00
Title: Descifrando el impacto de TET2 sobre la estructura de la cromatina en el inicio leucémico
Start Date: 01/06/2020 - **End Date:** 31/05/2023
31/05/2024

Type: HR
2020 Ministerio de Ciencia, Innovación y Universidades , Ayudas para contratos predoctorales en el marco del Plan Estatal de I+D+i (FPI)
PI: SARDINA ORTEGA, JOSÉ LUIS
Group: Epigenetic Control of Haematopoiesis
Reference: PRE2020-093881
Title: Descifrando el impacto de tet2 sobre la estructura de la cromatina en el inicio leucémico.
Start Date: 01/08/2021 - **End Date:** 31/07/2025

Type: Project
2023 Ministerio de Ciencia e Innovación, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022
PI: SARDINA ORTEGA, JOSÉ LUIS
Group: Epigenetic Control of Haematopoiesis
Reference: PID2022-140376OB-I00
Title: Dissecting the DNA Methylation Underpinnings of Healthy and Malignant Myeloid Lineage Ageing
Start Date: 01/09/2023 - **End Date:** 31/08/2026

Type: Other
2023 Ministerio de Ciencia e Innovación, ACREDITACIÓN R3
PI: SARDINA ORTEGA, JOSÉ LUIS

Group: Epigenetic Control of Haematopoiesis
Reference: CR32023-041341
Start Date: 05/10/2023 - **End Date:** 31/12/2100

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: SARDINA ORTEGA, JOSÉ LUIS
Reference: 2021 SGR 01213
Title: Epigenètica i Malaltia Immunitària
Start Date: 01/01/2022 – **End Date:** 31/12/2024
30/06/2025

Type: Projecte
2022 European Commission, MSCA DOCTORAL NETWORKS 2022
PI: SARDINA ORTEGA, JOSE LUIS
Reference: 101119927
Title: Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches
Start Date: 01/01/2024 – **End Date:** 31/12/2027

Leukemia and Immuno-Oncology

Laura Belver

Type: Project
2020 Fundació d'Estudis i Recerca Oncològica, BECA FERO EN INVESTIGACIÓN ONCOLÓGICA TRASLACIONAL 2020
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: BFERO2020.03
Title: Molecular pathways and targeted therapies in Juvenile Myelomonocytic Leukemia
Start Date: 01/12/2020 - **End Date:** 30/11/2022
30/06/2025

Type: HR
2020 Govern d'Andorra, Ajuts de tercer cicle de l'any 2020 - Modalitat 1 - Nous ajuts
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: AJT-PRS2000176
Title: Mecanismes oncogènics en la Leucèmia Mielomonocítica Juvenil i teàpies dirigides pel seu tractament
Start Date: 02/01/2021 - **End Date:** 01/01/2024

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: PID2020-117645RA-I00
Title: Impacto funcional de las mutaciones no codificantes asociadas a enhancers en Leucemia Mielomonocítica Juvenil
Start Date: 01/09/2021 - **End Date:** 31/08/2024

Type: HR
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per a la contractació de personal investigador novell (FI-2022)
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: 2022 FI_B 00595, 2023 FI-2 00595, 2024 FI-3 00595
Title: Analysis of the functional impact of non-coding mutations in Juvenile Myelomonocytic Leukemia
Start Date: 01/04/2022 - **End Date:** 31/03/2025

Type: HR
2020 Ministerio de Ciencia e Innovación, Subprograma de ayudas para contratos Ramon y Cajal
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: RYC2020-029400-I
Title: Genetics and molecular mechanisms in hematologic malignancies
Start Date: 01/01/2022 - **End Date:** 31/12/2026

Type: Project
2022 Fundación Federación Española de Enfermedades Raras, VII CONVOCATORIA DE AYUDAS A LA INVESTIGACIÓN DE FUNDACIÓN FEDER
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Title: Desarrollo de nuevas terapias celulares para el tratamiento de pacientes de lupus eritematoso sistémico
Start Date: 01/01/2023 - **End Date:** 30/06/2024

Type: Project
2022 Fundación Merck Salud, II AYUDA FUNDACIÓN MERCK SALUD-FUNDACIÓN FEDER A LA INVESTIGACIÓN CLÍNICA EN ENFERMEDADES RARAS
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Title: Diseño de terapias celulares para el tratamiento de pacientes de lupus eritematosus sistémico

Start Date: 03/07/2023 - **End Date:** 03/07/2026

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: 2023 INV-2 00011 (200011TC1)
Title: Leucemia e Inmuno-Oncología
Start Date: 16/06/2023 - **End Date:** 15/06/2025

Type: Project
2023 Lupus Research Alliance, LUPUS INNOVATION AWARD 2023
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: 1143347
Title: Development of cell-based therapies targeting DNA-reactive B cells in SLE
Start Date: 15/03/2024 - **End Date:** 14/03/2026

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: BELVER MIGUEL, LAURA
Group: Leukemia and Immuno-Oncology
Reference: PID2023-148276OB-I00
Title: Evaluación de inhibidores de molecula pequeña dirigidos a neutralizar de la actividad oncogénica de SHP2 en cáncer
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Myelodysplastic Syndromes
Francesc Sole

Type: Project
2020 Instituto de Salud Carlos III, Proyectos de investigación en Salud (FIS)
PI: SOLE RISTOL, FRANCESC
Group: Myelodysplastic Syndromes
Reference: PI20/00531
Title: Caracterización genética de las neoplasias mieloides asociadas a tratamiento (Therapy related myeloid neoplasms, TRMN)
Start Date: 01/01/2021 - **End Date:** 31/12/2023
31/12/2024

Type: Project
2020 Deutsche José Carreras Leukämie Stiftung, Forschungsprojekte (R 20) 2020
PI: SOLE RISTOL, FRANCESC
Group: Myelodysplastic Syndromes
Reference: DJCLS 01R/2021
Title: Dissecting the mechanisms of clonal expansion in del(5q) myelodysplastic syndrome to selectively target the disease-initiating hematopoietic stem cells
Start Date: 01/10/2021 - **End Date:** 30/09/2024

Type: Network
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: SOLE RISTOL, FRANCESC
Group: Myelodysplastic Syndromes
Reference: 2021 SGR 00560
Title: Grup de recerca de l'estudi de neoplasies hematològiques
Start Date: 01/01/2022 - **End Date:** 31/12/2024
30/06/2025

Type: HR
2022 Agència de Gestió d'Ajuts Universitaris i de Recerca, CONVOCATÒRIA DELS AJUTS JOAN ORÓ PER A LA CONTRACTACIÓ DE PERSONAL INVESTIGADOR PREDOCTORAL EN FORMACIÓ (FI 2023)
PI: SOLE RISTOL, FRANCESC
Group: Myelodysplastic Syndromes
Reference: 2023 FI-1 00200, 2024 FI-2 00200
Title: Genetic characterization of myelodysplastic syndromes with germline predisposition (gMDS) and therapy- related myeloid neoplasms (TRMN)
Start Date: 01/06/2023 - **End Date:** 31/05/2026

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: SOLE RISTOL, FRANCESC
Group: Myelodysplastic Syndromes
Reference: 2023 INV-2 00011 (200011TG3)

Title: MDS GROUP
Start Date: 01/07/2023 - **End Date:** 30/06/2025

Type: Project
2023 Instituto de Salud Carlos III, PROYECTOS DE I+D+I EN SALUD 2023
PI: SOLE RISTOL, FRANCESC
Group: Myelodysplastic Syndromes
Reference: PI23/00007
Title: Caracterización del paisaje germinal y somático de las neoplasias mieloides asociadas a tratamiento (TRMN)
Start Date: 01/01/2024 - **End Date:** 31/12/2026

Transcriptional Dynamics in Leukemia

Sergi Cuartero

Type: Project
2019 Jérôme Lejeune Foundation, Cycle 2019b-Down syndrome research
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Reference: #1902
Title: Myeloid leukemia in Down syndrome: exploring the interplay between transcriptional regulation and immune signalling
Start Date: 01/04/2020 - **End Date:** 06/01/2023 24/01/2024

Type: Project
2020 Ministerio de Ciencia e Innovación, Retos Investigación 2021
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Reference: PID2020-117950RA-I00
Title: Descifrando el rol de las mutaciones en el complejo de las cohesinas y la estructura 3D del genoma en leucemia mieloide (MYELO-3D)
Start Date: 01/09/2021 - **End Date:** 31/08/2024 31/05/2025

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS PARA CONTRATOS RAMÓN Y CAJAL 2021
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Reference: RYC2021-033018-I
Title: The role of cohesin and 3D genome organization in acute myeloid leukemia
Start Date: 01/01/2023 - **End Date:** 31/12/2027 21/04/2028

Type: Project
2021 American Society of Hematology, ASH GLOBAL RESEARCH AWARD
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Title: Understanding the role of 3D genome organization in myeloid leukemia of Down Syndrome
Start Date: 01/07/2022 - **End Date:** 30/06/2025

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS CONTRATOS PREDOCTORALES PARA FORMACIÓN DOCTORES (FPI)
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Reference: PRE2021-097862
Title: DESCIFRANDO EL ROL DE LAS MUTACIONES EN EL COMPLEJO DE LAS COHESINAS Y LA ESTRUCTURA 3D DEL GENOMA EN LEUCEMIA MIELOIDE
Start Date: 01/08/2022 - **End Date:** 31/07/2026

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Reference: 2023 INV-2 00011 (200011TC4)
Title: Grup de recerca Dinàmica Transcripcional de la Leucèmia
Start Date: 16/06/2023 - **End Date:** 15/06/2025

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: CUARTERO BETRIU, SERGI
Group: Transcriptional Dynamics in Leukemia
Reference: PID2023-151180OB-I00
Title: Estudio del impacto de mutaciones en reguladores transcripcionales en la organización tridimensional del genoma en leucemia mieloide aguda
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Barcelona Endothelium Team

Enric Carreras

Type: HR
2021 Ministerio de Ciencia e Innovación, AYUDAS JUAN DE LA CIERVA FORMACIÓN
PI: CARRERAS PONS, ENRIC
Group: Barcelona Endothelium Team
Reference: FJC2021-048123-I
Title: Deepening in the pathophysiology of the endothelial damage in various pathologies
Start Date: 01/01/2023 - **End Date:** 31/12/2024

Blood Stem Cell Identity

Vincenzo Calvanese

Type: Project
2022 European Commission, ERC CONSOLIDATOR GRANT 2023
PI: CALVANESE, VINCENZO
Group: Blood Stem Cell Identity
Reference: 101088313
Title: Tackling functional maturation for Transplantable hematopoietic stem cell generation
Start Date: 01/01/2024 - **End Date:** 31/12/2028

Type: HR
2023 Ministerio de Ciencia e Innovación, AYUDAS PARA INCENTIVAR LA INCORPORACIÓN DE TALENTO CONSOLIDADO «PROGRAMA ATRAE»
PI: CALVANESE, VINCENZO
Group: Blood Stem Cell Identity
Reference: ATR2023-143555
Title: Corrigiendo el desvio epigenetico en celulas madre adultas de la sangre expandidas en cultivo.
Start Date: 01/09/2024 - **End Date:** 31/08/2027

Type: HR
2023 Fundación Científica de la Asociación Española Contra el Cáncer, AECC TALENT 2024
PI: CALVANESE, VINCENZO
Group: Blood Stem Cell Identity
Reference: TALEN246600AGUA
Title: Dissecting the role of the gene HLF (hepatic leukemia factor) in stemness regulation to identify targeted therapeutic options for AML
Start Date: 01/08/2024 - **End Date:** 31/07/2027

Type: Project
2020 Wellcome Trust, SIR HENRY DALE FELLOWSHIP 2020
PI: CALVANESE, VINCENZO
Group: Blood Stem Cell Identity
Reference: UNS113614
Title: TRANSCRIPTIONAL REGULATION OF SELF-RENEWAL IN HUMAN HAEMATOPOIETIC STEM CELLS
Start Date: 01/04/2024 - **End Date:** 31/03/2026

Type: Project
2024 Ministerio de Ciencia, Innovación y Universidades, PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2023
PI: CALVANESE, VINCENZO
Group: Blood Stem Cell Identity
Reference: PID2023-152341OB-I00
Title: Definición ambiental y espacio-temporal del desarrollo temprano de células madre hematopoyéticas humanas.
Start Date: 01/09/2024 - **End Date:** 31/12/2027

Microarrays

Mar Mallo

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: MALLO FAJULA, MARIA DEL MAR
Unit: Microarrays
Reference: 2023 INV-2 00011 (200011TC2)
Title: Unitat de Microarrays
Start Date: 01/07/2023 - **End Date:** 30/06/2025

Proteomics

Carolina de la Torre

Type: Project
2021 Ministerio de Ciencia e Innovación, AYUDAS A PROYECTOS ESTRATÉGICOS ORIENTADOS A LA TRANSICIÓN ECOLÓGICA Y A LA TRANSICIÓN DIGITAL 2021
PI: DE LA TORRE GÓMEZ, CAROLINA
Unit: Proteomics

Reference: TED2021-130467B-C22
Title: Herramienta inteligente de descubrimiento de nuevos agentes peptídicos bioactivos
Start Date: 01/12/2022 - **End Date:** 30/11/2024

Type: Project
2022 Instituto de Salud Carlos III, AYUDAS DE PROYECTOS DE INVESTIGACIÓN DE MEDICINA PERSONALIZADA DE PRECISIÓN 2022
PI: DE LA TORRE GÓMEZ, CAROLINA
Unit: Proteomics
Reference: PMP22/00004
Title: Caracterización multiómica del carcinoma escamoso de cabeza y cuello mediante biopsia gaseosa y líquida: aplicación diagnóstica, pronóstica y de seguimiento. HN-OMICS
Start Date: 01/01/2023 - **End Date:** 31/12/2025

Single Cell

Caterina Mata

Type: Project
2022 Fundació la Marató de TV3, MARATÓ TV3: SALUT MENTAL
PI: MATA GARCIA, CATERINA
Unit: Single Cell
Reference: 202235-31
Title: Brain and blood coexpression networks using DDR1 as a seed gene in bipolar disorder. Identification of new biomarkers.
Start Date: 31/03/2023 - **End Date:** 30/03/2026

Type: HR
2023 Agència de Gestió d'Ajuts Universitaris i de Recerca, PROGRAMA INVESTIGO DE CONTRACTACIÓ DE PERSONES JOVES DEMANDANTS D'OCUPACIÓ EN LA REALITZACIÓ D'INICIATIVES DE RECERCA I INNOVACIÓ (INVESTIGO 2023)
PI: MATA GARCIA, CATERINA
Unit: Single Cell
Reference: 2023 INV-2 00011 (200011TG2)
Title: Unitat de Single Cell
Start Date: 01/09/2023 - **End Date:** 31/08/2025

Communication Unit

Type: Congress
2024 Ajuntament de Barcelona, CONVOCATÒRIA GENERAL DE SUBVENCIONS PER A PROJECTS, ACTIVITATS I SERVEIS DE DISTRICTE I DE CIUTAT PER A L'ANY 2024
Manager: DÍAZ LÓPEZ, HELENA
Unit: Communication Unit
Reference: 92684771-44
Title: Simposi "Updates in the Genetics and Epigenetics of Hematological Malignancies: from Knowledge to Applications"
Start Date: 01/04/2024 - **End Date:** 31/12/2024

Type: Congress
2024 The Company of Biologists, SCIENTIFIC MEETING GRANTS 2024-1
Manager: DÍAZ LÓPEZ, HELENA
Unit: Communication Unit
Reference: EA1061
Title: Updates in the Genetics and Epigenetics of Hematological Malignancies: From Knowledge to Applications
Start Date: 08/05/2024 - **End Date:** 22/11/2024

Strategic projects

Type: Project
2022 Ministerio de Ciencia e Innovación, AYUDAS PARA LA PREPARACIÓN Y GESTIÓN DE PROYECTOS EUROPEOS 2022
Manager: GIL GUIÑON, ESTEL
Unit: Strategic projects
Reference: GPE2022-001061
Title: Impulsar el potencial del Instituto Josep Carreras para crecer internacionalmente
Start Date: 01/01/2023 - **End Date:** 31/12/2024
30/06/2025

Publications

Indicators

218 **Number of indexed articles published per year**

10,40 **Median Impact Factor per article**

175 **Papers Q1**

98 **Papers D1**

58.070 **Citations at Web of Science** (times cited without self-citations)

32,83 **Citations at Web of Science** (average per item)

2024 Publications

Cancer Epigenetics

Manel Esteller

Noguera-Castells A, Parra J, Davalos V, García-Prieto CA, Veselinova Y, Pérez-Miés B, Caniego-Casas T, Palacios J, Saenz-Sardà X, Englund E, Musulen E, Esteller M.
Epigenetic Fingerprint of the SARS-CoV-2 Infection in the Lung of Lethal COVID-19 Chest. 2024 Apr;165(4):820-824. doi: 10.1016/j.chest.2023.10.032. Epub 2023 Oct 31.
PMID: 37914026 - Citations: 2 [05/03/2025]
IF: 9,5 - QUARTIL 1

Musulen E, Gené M, Cuatrecasas M, Amat I, Veiga JA, Fernández-Aceñero MJ, Chimisana VF, Tarragona J, Jurado I, Fernández-Victoria R, Martínez-Ciarpaglini C, Alenda González C, Zac C, Fernández-Figueras MT, Esteller M. Gastric metaplasia as a precursor of nonconventional dysplasia in inflammatory bowel disease
Hum Pathol. 2024 Jan 15:S0046-8177(23)00233-2. doi: 10.1016/j.humpath.2023.11.011. PMID: 38000679 - Citations: 2 [05/03/2025]
IF: 2,7 - QUARTIL 2

Gallardo-Gómez M, Costas-Ríos L, Garcia-Prieto CA, Álvarez-Rodríguez L, Bujanda L, Barrero M, Castells A, Balaguer F, Jover R, Esteller M, Tardío Baiges A, González-Carreró Fojón J, Cubiella J, De Chiara L.
Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection
Mol Oncol. 2024 Nov;18(11):2696-2713. doi: 10.1002/1878-0261.13573 PMID: 38129291 - Citations: 0 [05/03/2025]
IF: 5 - QUARTIL 1

Vilor-Tejedor N, Genius P, Rodríguez-Fernández B, Minguillón C, Sadeghi I, González-Escalante A, Crous-Bou M, Suárez-Calvet M, Grau-Rivera O, Brugulat-Serrat A, Sánchez-Benavides G, Esteller M, Fauria K, Molinuevo JL, Navarro A, Gispert JD; Alzheimer's Disease Neuroimaging Initiative; ALFA study.
Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum
Alzheimers Dement. 2024 Mar;20(3):1703-1715. doi: 10.1002/alz.13537. Epub 2023 Dec 13. PMID: 38088508 - Citations: 1 [05/03/2025]
IF: 13 - QUARTIL 1

Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic S, Bordone Pittau R, Stathis A, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F.
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Mol Cancer Ther. 2024 Mar 4;23(3):368-380. doi: 10.1158/1535-7163.MCT-23-0068. PMID: 38052765 - Citations: 2 [05/03/2025]
IF: 5,3 - QUARTIL 1

Vazquez BN, Fernández-Duran I, Hernandez Y, Tarighi S, Thackray JK, Espinosa-Alcantud M, Kumari P, Ianni A, Cesaire L, Braun T, Esteller M, Tischfield J, Vaquero A, Serrano L.
SIRT7 and p53 interaction in embryonic development and tumorigenesis
Front Cell Dev Biol. 2024 Jan 3;11:1281730. doi: 10.3389/fcell.2023.1281730. eCollection 2023. PMID: 38234684 - Citations: 1 [05/03/2025]
IF: 4,6 - QUARTIL 1

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, Roue G, Valcárcel D, Molero A, Zamora L, Xicoy B, Palomo L, Acha P, Manzanares A, Tobiasson M, Hellström-Lindberg E, Sole F, Esteller M. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy Cancer Res Commun. 2024 Feb 12;4(2):365-377. doi: 10.1158/2767-

9764.CRC-23-0389.
PMID: 38300528 - Citations: 4 [05/03/2025]
IF: 2 - QUARTIL 3

Macias-Gómez A, Jiménez-Balado J, Fernández-Pérez I, Suárez-Pérez A, Vallverdú-Prats M, Guimaraens L, Vivas E, Saldaña J, Giralt-Steinhauer E, Guisado-Alonso D, Villalba G, Gracia MP, Esteller M, Rodriguez-Campello A, Jiménez-Conde J, Ois A, Cuadrado-Godia E.
The influence of epigenetic biological age on key complications and outcomes in aneurysmal subarachnoid haemorrhage
J Neurol Neurosurg Psychiatry. 2024 Jun 17;95(7):675-681. doi: 10.1136/jnnp-2023-332889. PMID: 38302433 - Citations: 3 [05/03/2025]
IF: 8,7 - QUARTIL 1

Ortega-Alarcon D, Claveria-Gimeno R, Vega S, Kalani L, Jorge-Torres OC, Esteller M, Ausio J, Abian O, Velazquez- Campoy A.
Extending MeCP2 interactome: canonical nucleosomal histones interact with MeCP2 Nucleic Acids Res. 2024 Apr 24;52(7):3636-3653. doi: 10.1093/nar/gkae051.
PMID: 38321951 - Citations: 4 [05/03/2025]
IF: 16,6 - QUARTIL 1

Crespo-García E, Bueno-Costa A, Esteller M.
Single-cell analysis of the epitranscriptome: RNA modifications under the microscope.
RNA Biol. 2024 Jan;21(1):1-8. doi: 10.1080/15476286.2024.2315385. Epub 2024 Feb 18.
PMID: 38368619 - Citations: 2 [05/03/2025]
IF: 3,6 - QUARTIL 2

Ferreté-Bonastre AG, Martínez-Gallo M, Morante-Palacios O, Calvillo CL, Calafell-Segura J, Rodríguez-Ubreva J, Esteller M, Cortés-Hernández J, Ballestar E.
Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus
Ann Rheum Dis. 2024 Jun 12;83(7):865-878. doi: 10.1136/ard-2023-225433. PMID: 38413168 - Citations: 8 [05/03/2025]
IF: 20,3 - QUARTIL 1

Thambyrajah R, Maqueda M, Neo WH, Imbach K, Guillén Y, Grases D, Fadlullah Z, Gambera S, Matteini F, Wang X, Calero-Nieto FJ, Esteller M, Florian MC, Porta E, Benedito R, Göttgens B, Lacaud G, Espinosa L, Bigas A.
Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate
Nat Commun. 2024 Feb 21;15(1):1604. doi: 10.1038/s41467-024-45716-y. PMID: 38383534 - Citations: 5 [05/03/2025]
IF: 14,7 - QUARTIL 1

Noguera-Castells A, Campillo-Marcos I, Davalos V, García-Prieto CA, Valcárcel D, Molero A, Palomo L, Gattermann N, Wulfert M, Chaparro-González L, Solé F, Cabezón M, Jiménez-Lorenzo MJ, Xicoy B, Zamora L, De Stefano A, Casalin I, Finelli C, Follo MY, Esteller M.
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study
Br J Haematol. 2024 May;204(5):1838-1843. doi: 10.1111/bjh.19392. Epub 2024 Mar 12. PMID: 38471524 - Citations: 2 [05/03/2025]
IF: 5,1 - QUARTIL 1

Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M.
Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study Blood Adv. 2024 Jun 11;8(11):2691-2694. doi: 10.1182/bloodadvances.2023012479.
PMID: 38536941 - Citations: 4 [05/03/2025]
IF: 7,4 - QUARTIL 1

Liria Sánchez-Lafuente C, Martinez-Verbo L, Johnston JN, Floyd J, Esteller M, Kalynchuk LE, Ausió J, Caruncho HJ. Chronic corticosterone exposure in rats induces sex-specific alterations in hypothalamic reelin fragments, MeCP2, and DNMT3a protein levels
Neurosci Lett. 2024 May 1:830:137770. doi: 10.1016/j.neulet.2024.137770. Epub 2024 Apr 13.
PMID: 38616004 - Citations: 1 [05/03/2025]
IF: 2,5 - QUARTIL 3

Fernández-Pérez I, Jiménez-Balado J, Macias-Gómez A, Suárez-Pérez A, Vallverdú-Prats M, Pérez-Giraldo A, Viles- García M, Peris-Subiza J, Vidal-Notari S, Giralt-Steinhauer E, Guisado-Alonso D, Esteller M, Rodriguez-Campello A, Jiménez-Conde J, Ois A, Cuadrado-Godia E.
Blood DNA Methylation Analysis Reveals a Distinctive Epigenetic Signature of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Transl Stroke Res. 2024 Apr 23. doi: 10.1007/s12975-024-01252-x. Online ahead of print. PMID: 38649590 - Citations: 2 [05/03/2025]
IF: 3,8 - QUARTIL 1

Yáñez-Bartolomé M, Serra-Camprubí Q, Arenas EJ, Escorihuela M, Castet F, Fabregat-Franco C, Querol J, Arribas J, Peiró S, Macarulla T, Tian TV.

Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models. Methods Mol Biol. 2024 Apr 28;2806:139-151. doi: 10.1007/978-1-0716-3858-3_11. PMID: 38676801 - Citations: 1 [05/03/2025]

Thambyrajah R, Maqueda M, Fadlullah MZ, Proffitt M, Neo WH, Guillén Y, Casado-Pelaez M, Herrero-Molinero P, Brujas C, Castelluccio N, González J, Iglesias A, Marruecos L, Ruiz-Herguido C, Esteller M, Mereu E, Lacaud G, Espinosa L, Bigas A.
IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development Nat Commun. 2024 Jun 1;15(1):4673. doi: 10.1038/s41467-024-48854-5.
PMID: 38824124 - Citations: 3 [05/03/2025]
IF: 14,7 - QUARTIL 1

Jiménez-Balado J, Fernández-Pérez I, Gallego-Fábrega C, Lazcano U, Soriano-Tárraga C, Vallverdú-Prats M, Mola- Caminal M, Rey-Álvarez L, Macias-Gómez A, Suárez-Pérez A, Giralt-Steinhauer E, Rodríguez-Campello A, Cuadrado- Godia E, Ois Á, Esteller M, Roquer J, Fernández-Cadenas I, Jiménez-Conde J.
DNA methylation and stroke prognosis: an epigenome-wide association study Clin Epigenetics. 2024 Jun 6;16(1):75. doi: 10.1186/s13148-024-01690-2. PMID: 38845005 - Citations: 3 [05/03/2025]
IF: 4,8 - QUARTIL 1

Ayllon-Hermida A, Nicolau-Fernandez M, Larrinaga AM, Aparici-Herraiz I, Tintó-Font E, Llorà-Batlle O, Orban A, Yasnot MF, Graupera M, Esteller M, Popovici J, Cortés A, Del Portillo HA, Fernandez-Becerra C.
Plasmodium vivax spleen-dependent protein 1 and its role in extracellular vesicles-mediated intrasplenic infections Front Cell Infect Microbiol. 2024 May 17;14:1408451. doi: 10.3389/fcimb.2024.1408451. eCollection 2024.
PMID: 38828264 - Citations: 1 [05/03/2025]
IF: 4,6 - QUARTIL 1

Santos-Pujol E, Quero-Dotor C, Esteller M.
Clinical Perspectives in Epitranscriptomics Curr Opin Genet Dev. 2024 Aug:87:102209. doi: 10.1016/j.gde.2024.102209. Epub 2024 Jun 1.
PMID: 38824905 - Citations: 3 [05/03/2025]
IF: 3,7 - QUARTIL 2

Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E.
Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment Biomed Pharmacother. 2024 Jul:176:116857. doi: 10.1016/j.biopha.2024.116857. Epub 2024 Jun 7.
PMID: 38850664 - Citations: 3 [05/03/2025]
IF: 6,9 - QUARTIL 1

Giordano A, Rovira M, Veny M, Barastegui R, Marín P, Martínez C, Fernández-Avilés F, Suárez-Lledó M, Domènech A, Serrahima A, Lozano M, Cid J, Ordás I, Fernández-Clotet A, Caballol B, Gallego M, Vara A, Masamunt MC, Giner À, Teubel I, Esteller M, Corraliza AM, Panés J, Salas A, Ricart E.
Cyclophosphamide-free Mobilisation Increases Safety While Preserving the Efficacy of Autologous Haematopoietic Stem Cell Transplantation in Refractory Crohn's Disease Patients J Crohns Colitis. 2024 Oct 15;18(10):1701-1712. doi: 10.1093/ecco-jcc/jjae076.
PMID: 38757210 - Citations: 1 [05/03/2025]
IF: 8,3 - QUARTIL 1

Alves LF, da Silva IN, de Mello DC, Fuziwara CS, Guil S, Esteller M, Geraldo MV. Epigenetic Regulation of DLK1-DIO3 Region in Thyroid Carcinoma Cells. 2024 Jun 8;13(12):1001. doi: 10.3390/cells13121001.
PMID: 38920632 - Citations: 0 [05/03/2025]
IF: 5,1 - QUARTIL 2

Lorenzo-Sanz L, Lopez-Cerda M, da Silva-Diz V, Artés MH, Llop S, Penin RM, Bermejo JO, Gonzalez-Suarez E, Esteller M, Viñals F, Espinosa E, Oliva M, Piulats JM, Martin-Liberal J, Muñoz P.
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma Nat Commun. 2024 Jun 24;15(1):5352. doi: 10.1038/s41467-024-49718-8.
PMID: 38914547 - Citations: 3 [05/03/2025]
IF: 14,7 - QUARTIL 1

Fernandez-Figueras MT, Perez-Muñoz N, Puig L, Posada-Caez R, Ballester Victoria R, Henriquez M, Musulen E. Predictors of Local Invasion in Infiltrative Basal Cell Carcinoma: Tumour Budding Outperforms the WHO Subtyping Acta Derm Venereol. 2024 Jul 2;104:adv40172. doi: 10.2340/actadv.v104.40172.
PMID: 38956962 - Citations: 0 [05/03/2025]
IF: 3,5 - QUARTIL 1

Moragas N, Fernandez-Nogueira P, Recalde-Percaz L, Inman JL, López-Plana A, Bergholtz H, Noguera-Castells A, Del Burgo PJ, Chen X, Sorlie T, Gascón P,

Bragado P, Bissell M, Carbó N, Fuster G.
The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma Breast Cancer Res. 2024 Aug 13;26(1):122. doi: 10.1186/s13058-024-01871-0.
PMID: 39138514 - Citations: 1 [05/03/2025]
IF: 6,1 - QUARTIL 1

Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Domènech-Vivó J, García-Galea E, Moles-Fernández A, Pedretti F, Domènech H, Rodríguez O, Guzmán M, Arenas EJ, Verdaguer H, Calero-Nieto FJ, Talbot S, Tobalina L, Leo E, Lau A, Nuciforo P, Dienstmann R, Macarulla T, Arribas J, Díez O, Gutiérrez-Enríquez S, Forment JV, O'Connor MJ, Albertella M, Balmaña J, Serra V.
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Genome Med. 2024 Aug 26;16(1):107. doi: 10.1186/s13073-024-01370-z.
PMID: 39187844 - Citations: 5 [05/03/2025]
IF: 10,4 - QUARTIL 1

Galassi C, Esteller M, Vitale I, Galluzzi L.
Epigenetic control of immunoevasion in cancer stem cells
Trends Cancer. 2024 Nov;10(11):1052-1071. doi: 10.1016/j.trecan.2024.08.004. Epub 2024 Sep 6.
PMID: 39244477 - Citations: 0 [05/03/2025]
IF: 14,3 - QUARTIL 1

Malla S, Kumari K, García-Prieto CA, Caroli J, Nordin A, Phan TTT, Bhattarai DP, Martinez-Gamero C, Dorafshan E, Stransky S, Álvarez-Errico D, Saiki PA, Lai W, Lyu C, Lizana L, Gilthorpe JD, Wang H, Sidoli S, Mateus A, Lee DF, Cantù C, Esteller M, Mattevi A, Roman AC, Aguilo F.
The scaffolding function of LSD1 controls DNA methylation in mouse ESCs Nat Commun. 2024 Sep 5;15(1):7758. doi: 10.1038/s41467-024-51966-7. PMID: 39237615 - Citations: 1 [05/03/2025]
IF: 14,7 - QUARTIL 1

Martinez-Verbo L, Veselinova Y, Llinàs-Arias P, García-Prieto CA, Noguera-Castells A, Pato ML, Bueno- Costa A, Campillo-Marcos I, Villanueva L, Oliver-Caldes A, Cardus O, Salsench SV, García-Ortiz A, Valeri A, Rojas EA, Barrena N, Gutiérrez NC, Prósper F, Agirre X, Fernández de Larrea C, Martínez-López J, Ferrer G, Esteller M.
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma Leukemia. 2024 Dec;38(12):2722-2726. doi: 10.1038/s41375-024-02419-z. Epub 2024 Sep 24.
PMID: 39322713 - Citations: 0 [05/03/2025]
IF: 12,8 - QUARTIL 1

Esteller M, Dawson MA, Kadoch C, Rassool FV, Jones PA, Baylin SB. The Epigenetic Hallmarks of Cancer Cancer Discov. 2024 Oct 4;14(10):1783-1809. doi: 10.1158/2159-8290.CD-24-0296.
PMID: 39363741 - Citations: 4 [05/03/2025]
IF: 29,7 - QUARTIL 1

Andres Gamez-Garcia, Maria Espinosa-Alcantud, Alberto Bueno-Costa, Elisenda Alari-Pahissa, Anna Marazuela-Duque, Joshua K. Thackray, Chandni Ray, Clara Berenguer, Poonam Kumari, Joan Josep Bech, Thomas Braun, Alessandro Ianni, Jay A. Tischfield, Lourdes Serrano, Manel Esteller, Jose L. Sardina, Carolina De La Torre, Mikael Sigvardsson, Berta N. Vazquez; Alejandro Vaquero
A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5 Nat Immunol. 2024 Dec;25(12):2308-2319. doi: 10.1038/s41590-024-01995-7. Epub 2024 Oct 18.
PMID: 39424985 - Citations: 3 [05/03/2025]
IF: 27,7 - QUARTIL 1

Perron U, Grassi E, Chatzipli A, Viviani M, Karakoc E, Trastulla L, Brochier LM, Isella C, Zanella ER, Klett H, Molineris I, Schueler J, Esteller M, Medico E, Conte N, McDermott U, Trusolino L, Bertotti A, Iorio F.
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts Nat Commun. 2024 Nov 11;15(1):9139. doi: 10.1038/s41467-024-53163-y.
PMID: 39528460 - Citations: 0 [05/03/2025]
IF: 14,7 - QUARTIL 1

Cancer genetics

Montse Sanchez - Cespedes

Saigí M, Mate JL, Carcereny E, Martínez-Cardús A, Esteve A, Andreo F, Centeno C, Cucurull M, Mesia R, Pros E, Sanchez-Cespedes M.
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer
Lung Cancer. 2024 Mar:189:107502. doi: 10.1016/j.lungcan.2024.107502. Epub 2024 Feb 8.
PMID: 38359742 - Citations: 2 [05/03/2025]
IF: 4,5 - QUARTIL 1

Cancer immunogenomics

Eduard Porta

Punzon-Jimenez P, Machado-Lopez A, Perez-Moraga R, Llera-Oyola J, Grases D, Galvez-Viedma M, Sibai M, Satorres-Perez E, Lopez-Agullo S, Badenes R, Ferrer-Gomez C, Porta-Pardo E, Roson B, Simon C, Mas A. Effect of aging on the human myometrium at single-cell resolution
Nat Commun. 2024 Jan 31;15(1):945. doi: 10.1038/s41467-024-45143-z.
PMID: 38296945 - Citations: 8 [05/03/2025]
IF: 14,7 - QUARTIL 1

Thambyrajah R, Maqueda M, Neo WH, Imbach K, Guillén Y, Grases D, Fadlullah Z, Gambera S, Matteini F, Wang X, Calero-Nieto FJ, Esteller M, Florian MC, Porta E, Benedito R, Göttgens B, Lacaud G, Espinosa L, Bigas A.
Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate Nat Commun. 2024 Feb 21;15(1):1604. doi: 10.1038/s41467-024-45716-y.
PMID: 38383534 - Citations: 5 [05/03/2025]
IF: 14,7 - QUARTIL 1

Ruiz-Serra V, Valentini S, Madroñero S, Valencia A, Porta-Pardo E.
3Dmapper: a command line tool for BioBank-scale mapping of variants to protein structures
Bioinformatics. 2024 Mar 29;40(4):btae171. doi: 10.1093/bioinformatics/btae171.
PMID: 38565273 - Citations: 0 [05/03/2025]
IF: 4,4 - QUARTIL 1

Liu J, Cao S, Imbach KJ, Gritsenko MA, Lih TM, Kyle JE, Yaron-Barir TM, Binder ZA, Li Y, Strunilin I, Wang YT, Tsai CF, Ma W, Chen L, Clark NM, Shinkle A, Naser Al Deen N, Caravan W, Houston A, Simin FA, Wyczalkowski MA, Wang LB, Storrs E, Chen S, Illindala R, Li YD, Jayasinghe RG, Rykunov D, Cottingham SL, Chu RK, Weitz KK, Moore RJ, Sagendorf T, Petyuk VA, Nestor M, Bramer LM, Stratton KG, Schepmoes AA, Couvillion SP, Eder J, Kim YM, Gao Y, Fillmore TL, Zhao R, Monroe ME, Southard-Smith AN, Li YE, Jui-Hsien Lu R, Johnson JL, Wiznerowicz M, Hostetter G, Newton CJ, Ketchum KA, Thangudu RR, Barnholtz-Sloan JS, Wang P, Fenyö D, An E, Thiagarajan M, Robles AI, Mani DR, Smith RD, Porta-Pardo E, Cantley LC, Iavarone A, Chen F, Mesri M, Nasrallah MP, Zhang H, Resnick AC, Chheda MG, Rodland KD, Liu T, Ding L; Philadelphia Coalition for a Cure; Clinical Proteomic Tumor Analysis Consortium.
Multi-scale signaling and tumor evolution in high-grade gliomas
Cancer Cell. 2024 Jul 8;42(7):1217-1238.e19. doi: 10.1016/j.ccell.2024.06.004.
PMID: 38981438 - Citations: 5 [05/03/2025]
IF: 48,8 - QUARTIL 1

Cancer metabolism

Lucas Pontel

Rieckher M, Gallrein C, Alquezar-Artieda N, Bourached-Silva N, Vaddavalli PL, Mares D, Backhaus M, Blindauer T, Greger K, Wiesner E, Pontel LB, Schumacher B.
Distinct DNA repair mechanisms prevent formaldehyde toxicity during development, reproduction and aging Nucleic Acids Res. 2024 Aug 12;52(14):8271-8285. doi: 10.1093/nar/gkae519.
PMID: 38894680 - Citations: 4 [05/03/2025]
IF: 16,6 - QUARTIL 1

Chromatin biology laboratory

Alejandro Vaquero

Vazquez BN, Fernández-Duran I, Hernandez Y, Tarighi S, Thackray JK, Espinosa-Alcantud M, Kumari P, Ianni A, Cesaire L, Braun T, Esteller M, Tischfield J, Vaquero A, Serrano L.
SIRT7 and p53 interaction in embryonic development and tumorigenesis
Front Cell Dev Biol. 2024 Jan 3;11:1281730. doi: 10.3389/fcell.2023.1281730. eCollection 2023.
PMID: 38234684 - Citations: 1 [05/03/2025]
IF: 4,6 - QUARTIL 1

Ianni A, Kumari P, Tarighi S, Braun T, Vaquero A.
SIRT7: a novel molecular target for personalized cancer treatment?
Oncogene. 2024 Mar;43(14):993-1006. doi: 10.1038/s41388-024-02976-8. Epub 2024 Feb 21.
PMID: 38383727 - Citations: 12 [05/03/2025]
IF: 6,9 - QUARTIL 1

Latorre J, de Vera N, Santalucía T, Balada R, Marazuela-Duque A, Vaquero A, Planas AM, Petegnief V. Lack of the Histone Deacetylase SIRT1 Leads to Protection against Endoplasmic Reticulum Stress through the Upregulation of Heat

Shock Proteins
Int J Mol Sci. 2024 Mar 1;25(5):2856. doi: 10.3390/ijms25052856.
PMID: 38474102 - Citations: 2 [05/03/2025]
IF: 4,9 - QUARTIL 1

Kumari P, Tarighi S, Fuchshuber E, Li L, Fernández-Duran I, Wang M, Ayoson J, Castelló-García JM, Gámez- García A, Espinosa-Alcantud M, Sreenivasan K, Guenther S, Olivella M, Savai R, Yue S, Vaquero A, Braun T, Ianni A.
SIRT7 promotes lung cancer progression by destabilizing the tumor suppressor ARF
Proc Natl Acad Sci U S A. 2024 Jun 18;121(25):e2409269121. doi: 10.1073/pnas.2409269121. Epub 2024 Jun 13.
PMID: 38870055 - Citations: 6 [05/03/2025]
IF: 9,4 - QUARTIL 1

Tarighi S, Kumari P, Vaquero A, Braun T, Ianni A.
The SIRT7-nucleolus connection in cancer: ARF enters the fray
Mol Cell Oncol. 2024 Jul 17;11(1):2381287. doi: 10.1080/23723556.2024.2381287. eCollection 2024.
PMID: 39036727 - Citations: 0 [05/03/2025]
IF: 2,6 - QUARTIL 3

Andres Gamez-Garcia, Maria Espinosa-Alcantud, Alberto Bueno-Costa, Elisenda Alari-Pahissa, Anna Marazuela-Duque, Joshua K. Thackray, Chandni Ray, Clara Berenguer, Poonam Kumari, Joan Josep Bech, Thomas Braun, Alessandro Ianni, Jay A. Tischfield, Lourdes Serrano, Manel Esteller, Jose L. Sardina, Carolina De La Torre, Mikael Sigvardsson, Berta N. Vazquez; Alejandro Vaquero
A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5 Nat Immunol. 2024 Dec;25(12):2308-2319. doi: 10.1038/s41590-024-01995-7. Epub 2024 Oct 18.
PMID: 39424985 - Citations: 3 [05/03/2025]
IF: 27,7 - QUARTIL 1

Endothelial pathobiology and microenvironment

Mariona Graupera

van Splunder H, Villacampa P, Martínez-Romero A, Graupera M.
Pericytes in the disease spotlight
Trends Cell Biol. 2024 Jan 15:S0962-8924(23)00111-3. doi: 10.1016/j.tcb.2023.06.001.
PMID: 37474376 - Citations: 41 [05/03/2025]
IF: 13 - QUARTIL 1

Cerdà P, Castillo SD, Aguilera C, Iriarte A, Rocamora JL, Larrinaga AM, Viñals F, Graupera M, Riera-Mestre A. New genetic drivers in hemorrhagic hereditary telangiectasia
Eur J Intern Med. 2024 Jan 15:S0953-6205(23)00308-4. doi: 10.1016/j.ejim.2023.08.024.
PMID: 37689549 - Citations: 4 [05/03/2025]
IF: 5,9 - QUARTIL 1

Langbroek GB, Stor MLE, Janssen V, de Haan A, Horbach SER, Graupera M, van Noesel CJM, van der Horst CMAM, Wolkerstorfer A, Huveneers S.
Characterization of Patient-Derived GNAQ Mutated Endothelial Cells from Capillary Malformations
J Invest Dermatol. 2024 Jun;144(6):1378-1388.e1. doi: 10.1016/j.jid.2023.10.033. Epub 2023 Nov 25.
PMID: 38013159 - Citations: 3 [05/03/2025]
IF: 5,7 - QUARTIL 1

Serra F, Nieto-Aliseda A, Fanlo-Escudero L, Rovirosa L, Cabrera-Pasadas M, Lazarenkov A, Urmeneta B, Alcalde-Merino A, Nola EM, Okorokov AL, Fraser P, Graupera M, Castillo SD, Sardina JL, Valencia A, Javierre BM.
p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response Nat Commun. 2024 Apr 1;15(1):2821. doi: 10.1038/s41467-024-46666-1.
PMID: 38561401 - Citations: 8 [05/03/2025]
IF: 14,7 - QUARTIL 1

Ayllon-Hermida A, Nicolau-Fernandez M, Larrinaga AM, Aparici-Herraiz I, Tintó-Font E, Llorà-Batlle O, Orban A, Yasnot MF, Graupera M, Esteller M, Popovici J, Cortés A, Del Portillo HA, Fernandez-Becerra C.
Plasmodium vivax spleen-dependent protein 1 and its role in extracellular vesicles-mediated intrasplenic infections Front Cell Infect Microbiol. 2024 May 17;14:1408451. doi: 10.3389/fcimb.2024.1408451. eCollection 2024.
PMID: 38828264 - Citations: 1 [05/03/2025]
IF: 4,6 - QUARTIL 1

Garcia-Gonzalez I, Rocha SF, Hamidi A, Garcia-Ortega L, Regano A, Sanchez-Muñoz MS, Lytvyn M, Garcia-Cabero A, Roig-Soucase S, Schoofs H, Castro M, Sabata H, Potente M, Graupera M, Makinen T, Benedito R.
iSuRe-HadCre is an essential tool for effective conditional genetics Nucleic Acids Res. 2024 Jul 22;52(13):e56. doi: 10.1093/nar/gkae472. PMID: 38850155 - Citations: 2 [05/03/2025]
IF: 16,6 - QUARTIL 1

Llovera M, Gouveia L, Zorzano A, Sanchis D.
The effects of ENDOG on lipid metabolism may be tissue-dependent and may not require its translocation from mitochondria
Nat Commun. 2024 Aug 21;15(1):7121. doi: 10.1038/s41467-024-51447-x.
PMID: 39169002 - Citations: 0 [05/03/2025]
IF: 14,7 - QUARTIL 1

Conduit SE, Pearce W, Bhamra A, Bilanges B, Bozal-Basterra L, Foukas LC, Cobbaut M, Castillo SD, Danesh MA, Adil M, Carracedo A, Graupera M, McDonald NQ, Parker PJ, Cutillas PR, Surinova S, Vanhaesebroeck B.
A class I PI3K signalling network regulates primary cilia disassembly in normal physiology and disease Nat Commun. 2024 Aug 21;15(1):7181. doi: 10.1038/s41467-024-51354-1.
PMID: 39168978 - Citations: 0 [05/03/2025]
IF: 14,7 - QUARTIL 1

Martinez-Bernabe T, Morla-Barcelo PM, Melguizo-Salom L, Munar-Gelabert M, Maroto-Blasco A, Torrens-Mas M, Oliver J, Roca P, Nadal-Serrano M, Pons DG, Sastre-Serra J
Tumorspheres as In Vitro Model for Identifying Predictive Chemoresistance and Tumor Aggressiveness Biomarkers in Breast and Colorectal Cancer
Biology (Basel). 2024 Sep 15;13(9):724. doi: 10.3390/biology13090724. PMID: 39336151; PMCID: PMC11429065.
PMID: 39336151 - Citations: 1 [05/03/2025]
IF: 3,6 - QUARTIL 1

Epigenetics and immune disease

Esteban Ballestar

Barmada A, Handfield LF, Godoy-Tena G, de la Calle-Fabregat C, Ciudad L, Arutyunyan A, Andrés-León E, Hoo R, Porter T, Oszlanczi A, Richardson L, Calero-Nieto FJ, Wilson NK, Marchese D, Sancho-Serra C, Carrillo J, Presas- Rodríguez S, Ramo-Tello C, Ruiz-Sanmartin A, Ferrer R, Ruiz-Rodriguez JC, Martínez-Gallo M, Munera-Campos M, Carrascosa JM, Göttgens B, Heyn H, Prigmore E, Casafont-Solé I, Solanich X, Sánchez-Cerrillo I, González-Álvaro I, Raimondo MG, Ramming A, Martin J, Martínez-Cáceres E, Ballestar E, Vento-Tormo R, Rodríguez-Ubreva J. Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection
Eur J Immunol. 2024 Jan;54(1):e2350633. doi: 10.1002/eji.202350633. Epub 2023 Oct 20.
PMID: 37799110 - Citations: 3 [05/03/2025]
IF: 4,5 - QUARTIL 2

Carmona EG, Callejas-Rubio JL, Raya E, Ríos-Fernández R, Villanueva-Martín G, Cid MC, Hernández-Rodríguez J,
Ballestar E, Timmermann B, Ortego-Centeno N, Martín J, Márquez A.
Single-cell transcriptomic profiling reveals a pathogenic role of cytotoxic CD4+T cells in giant cell arteritis J Autoimmun. 2024 Jan;142:103124. doi: 10.1016/j.jaut.2023.103124. Epub 2023 Nov 11.
PMID: 37952293 - Citations: 3 [05/03/2025]
IF: 7,9 - QUARTIL 1

Ferreté-Bonastre AG, Martínez-Gallo M, Morante-Palacios O, Calvillo CL, Calafell-Segura J, Rodríguez-Ubreva J, Esteller M, Cortés-Hernández J, Ballestar E.
Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosus Ann Rheum Dis. 2024 Jun 12;83(7):865-878. doi: 10.1136/ard-2023-225433.
PMID: 38413168 - Citations: 8 [05/03/2025]
IF: 20,3 - QUARTIL 1

Wang T, Song D, Li X, Luo Y, Yang D, Liu X, Kong X, Xing Y, Bi S, Zhang Y, Hu T, Zhang Y, Dai S, Shao Z, Chen D, Hou J, Ballestar E, Cai J, Zheng F, Yang JY.
MiR-574-5p activates human TLR8 to promote autoimmune signaling and lupus Cell Commun Signal. 2024 Apr 8;22(1):220. doi: 10.1186/s12964-024-01601-1. PMID: 38589923 - Citations: 4 [05/03/2025]
IF: 8,2 - QUARTIL 1

Díaz-Tejedor A, Rodríguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-Rodríguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, Corchete LA, González-Méndez L, Martín-Sánchez M, Mateos MV, Ocio EM, Garayoa M, Paíno T.
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands
Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718.
PMID: 38731936 - Citations: 0 [05/03/2025]
IF: 4,9 - QUARTIL 1

Estupiñán-Moreno E, Hernández-Rodríguez J, Li T, Ciudad L, Andrés-León E, Terron-Camero LC, Prieto-González S, Espígol-Frigolé G, Cid MC, Márquez A, Martin J, Ballestar E, Ortiz-Fernández L.
Decoding CD4+T cell transcriptome in giant cell

arteritis: Novel pathways and altered cross-talk with monocytes J Autoimmun. 2024 Jun:146:103240. doi: 10.1016/j.jaut.2024.103240. Epub 2024 May 15.
PMID: 38754238 - Citations: 1 [05/03/2025]
IF: 7,9 - QUARTIL 1

Alves M, Gil B, Villegas-Salmeron J, Salari V, Martins-Ferreira R, Arribas Blázquez M, Menéndez Méndez A, Da Rosa Gerbatin R, Smith J, de Diego-Garcia L, Conte G, David Sierra Marquez J, Merino Serrais P, Mitra M, Fernandez Martin A, Wang Y, Kesavan J, Melia C, Parras A, Beamer E, Zimmer B, Heiland M, Cavanagh B, Cipolat R, Morgan J, Teng X, Prehn JHM, Fabene P, Bertini G, Artalejo AR, Ballestar E, Nicke A, Olivos-Oré LA, Connolly NM, Henshall DC, Engel T.
Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice Brain Behav Immun. 2024 Aug:120:121-140. doi: 10.1016/j.bbi.2024.05.023. Epub 2024 May 20. PMID: 38777288 - Citations: 6 [05/03/2025]
IF: 8,8 - QUARTIL 1

Castellini-Pérez O, Povedano E, Barturen G, Martínez-Bueno M, Iakovliev A, Kerick M, López-Domínguez R, Marañón C, Martín J, Ballestar E; PRECISEADS Clinical Consortium; PRECISEADS Flow Cytometry Study Group; Borghi MO, Qiu W, Zhu C, Shankara S, Spiliopoulou A, de Rinaldis E, Carnero-Montoro E, Alarcón-Riquelme ME.
Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants NPJ Genom Med. 2024 Jul 16;9(1):38. doi: 10.1038/s41525-024-00420-0.
PMID: 39013887 - Citations: 1 [05/03/2025]
IF: 4,7 - QUARTIL 1

Martins-Ferreira R, Calafell-Segura J, Chaves J, Ciudad L, Martins da Silva A, Pinho E Costa P, Leal B, Ballestar E.
Purinergic exposure induces epigenomic and transcriptomic-mediated preconditioning resembling epilepsy-associated microglial states iScience. 2024 Jul 20;27(8):110546. doi: 10.1016/j.isci.2024.110546. eCollection 2024 Aug 16.
PMID: 39184445 - Citations: 0 [05/03/2025]
IF: 4,6 - QUARTIL 1

de la Calle-Fabregat C, Calafell-Segura J, Gardet M, Dunsmore G, Mulder K, Ciudad L, Silvin A, Moreno-Càceres J, Corbí ÁL, Muñoz-Pinedo C, Michels J, Gouy S, Dutertre CA, Rodríguez-Ubreva J, Ginhoux F, Ballestar E.
NF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment
Sci Adv. 2024 Sep 20;10(38):eadq5226. doi: 10.1126/sciadv.adq5226. Epub 2024 Sep 18.
PMID: 39292770 - Citations: 4 [05/03/2025]
IF: 11,7 - QUARTIL 1

Fondelli F, Willemyns J, Domenech-Garcia R, Mansilla MJ, Godoy-Tena G, Ferreté-Bonastre AG, Agúndez-Moreno A, Presas-Rodriguez S, Ramo-Tello C, Ballestar E, Martínez-Cáceres E.
Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis
J Clin Invest. 2024 Nov 1;134(21):e178949. doi: 10.1172/JCI178949.
PMID: 39287981 - Citations: 0 [05/03/2025]
IF: 13,3 - QUARTIL 1

Martínez-López J, Ortiz-Fernandez L, Estupiñán-Moreno E, Kerick M, Andrés-León E, Terron-Camero LC, Carnero- Montoro E, Barturen G, Beretta L, Almeida I; PRECISESADS Clinical Consortium; Alarcón-Riquelme ME, Ballestar E, Acosta-Herrera M, Martín J
A strong Dysregulated Myeloid Component in the Epigenetic Landscape of Systemic Sclerosis: An Integrated DNA Methylome and Transcriptome Analysis
Arthritis Rheumatol. 2024 Oct 28. doi: 10.1002/art.43044. Online ahead of print.
PMID: 39468422 - Citations: 1 [05/03/2025]
IF: 11,4 - QUARTIL 1

Rodríguez-Ubreva J , Calafell-Segura J , Calvillo CL , Keller B , Ciudad L , Handfield LF , de la Calle-Fabregat C , Godoy-Tena G , Andrés-León E , Hoo R , Porter T , Prigmore E , Hofmann M , Decker A , Martín J , Vento-Tormo R , Warnatz K , Ballestar E.
COVID-19 progression and convalescence in common variable immunodeficiency patients show dysregulated adaptive immune responses and persistent type I interferon and inflammasome activation.
Nature Communications. 2024 Nov;15(1):10344. DOI: 10.1038/s41467-024-54732-x
PMID: 39609471 - Citations: 0 [05/03/2025]
IF: 14,7 - QUARTIL 1

Epigenetic therapies

Maria Berdasco

Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R,

Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M.
Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study
Blood Adv. 2024 Jun 11;8(11):2691-2694. doi: 10.1182/bloodadvances.2023012479.
PMID: 38536941 - Citations: 4 [05/03/2025]
IF: 7,4 - QUARTIL 1

Regulatory RNA and chromatin

Sònia Guil

Srinivas T, Siqueira E, Guil S.
Techniques for investigating lncRNA transcript functions in neurodevelopment
Mol Psychiatry. 2024 Apr;29(4):874-890. doi: 10.1038/s41380-023-02377-5. Epub 2023 Dec 25. PMID: 38145986 - Citations: 16 [05/03/2025]
IF: 9,6 - QUARTIL 1

Ortega-Alarcon D, Claveria-Gimeno R, Vega S, Kalani L, Jorge-Torres OC, Esteller M, Ausio J, Abian O, Velazquez- Campoy A.
Extending MeCP2 interactome: canonical nucleosomal histones interact with MeCP2
Nucleic Acids Res. 2024 Apr 24;52(7):3636-3653. doi: 10.1093/nar/gkae051.
PMID: 38321951 - Citations: 4 [05/03/2025]
IF: 16,6 - QUARTIL 1

Alves LF, da Silva IN, de Mello DC, Fuziwara CS, Guil S, Esteller M, Geraldo MV. Epigenetic Regulation of DLK1-DIO3 Region in Thyroid Carcinoma
Cells. 2024 Jun 8;13(12):1001. doi: 10.3390/cells13121001.
PMID: 38920632 - Citations: 0 [05/03/2025]
IF: 5,1 - QUARTIL 2

Mathias C, Rodrigues AC, Baal SCS, de Azevedo ALK, Kozak VN, Alves LF, de Oliveira JC, Guil S, Gradia DF. The landscape of lncRNAs in cell granules: Insights into their significance in cancer
Wiley Interdiscip Rev RNA. 2024 Sep-Oct;15(5):e1870. doi: 10.1002/wrna.1870. PMID: 39268566 - Citations: 0 [05/03/2025]
IF: 6,4 - QUARTIL 1

3D chromatin organization

Biola M. Javierre

Serra F, Nieto-Aliseda A, Fanlo-Escudero L, Rovirosa L, Cabrera-Pasadas M, Lazarenkov A, Urmeneta B, Alcalde-Merino A, Nola EM, Okorokov AL, Fraser P, Graupera M, Castillo SD, Sardina JL, Valencia A, Javierre BM.
p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response Nat Commun. 2024 Apr 1;15(1):2821. doi: 10.1038/s41467-024-46666-1.
PMID: 38561401 - Citations: 8 [05/03/2025]
IF: 14,7 - QUARTIL 1

Lopez-Millan B, Rubio-Gayarre A, Vinyoles M, Trincado JL, Fraga MF, Fernandez-Fuentes N, Guerrero- Murillo M, Martinez-Moreno A, Velasco-Hernandez T, Falgàs A, Panisello C, Valcarcel G, Sardina JL, López-Martí P, Javierre BM, Del Valle-Pérez B, García de Herreros A, Locatelli F, Pieters R, Bardini M, Cazzaniga G, Rodríguez-Manzaneque JC, Hanewald T, Marschalek R, Milne TA, Stam RW, Tejedor JRR, Menendez P, Bueno C. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
Blood. 2024 Nov 7;144(19):2002-2017. doi: 10.1182/blood.2023022050.
PMID: 39093982 - Citations: 2 [05/03/2025]
IF: 21,1 - QUARTIL 1

Kodali S, Proietti L, Valcarcel G, López-Rubio AV, Pessina P, Eder T, Shi J, Jen A, Lupión-Garcia N, Starner AC, Bartels MD, Cui Y, Sands CM, Planas-Riverola A, Martínez A, Velasco-Hernandez T, Tomás-Daza L, Alber B, Manhart G, Mayer IM, Kollmann K, Fatica A, Menendez P, Shishkova E, Rau RE, Javierre BM, Coon J, Chen Q, Van Nostrand EL, Sardina JL, Grebien F, Di Stefano B.
RNA sequestration in P-bodies sustains myeloid leukaemia
Nat Cell Biol. 2024 Oct;26(10):1745-1758. doi: 10.1038/s41556-024-01489-6. Epub 2024 Aug 21. PMID: 39169219 - Citations: 2 [05/03/2025]
IF: 17,3 - QUARTIL 1

Alaswad Z, Attallah NE, Aboalazm B, Elmeslhy ES, Mekawy AS, Afify FA, Mahrous HK, Abdalla A, Rahmoon MA, Mohamed AA, Shata AH, Mansour RH, Aboul-Ela F, Elhadidy M, Javierre BM, El-Khamisy SF, Elserafy M. Insights into the human cDNA: A descriptive study using library screening in yeast
J Genet Eng Biotechnol. 2024 Dec;22(4):100427. doi: 10.1016/j.jgeb.2024.100427. Epub 2024 Oct 19. PMID:

39674632 - Citations: 0 [05/03/2025]
IF: 3,6 - QUARTIL 2

Acute lymphoblastic leukemia

Josep Maria Ribera

Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
Haematologica. 2024 Feb 1;109(2):543-552. doi: 10.3324/haematol.2023.283342
PMID: 37560813 - Citations: 3 [05/03/2025]
IF: 8,2 - QUARTIL 1

Enshaei A, Joy M, Butler ER, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, Moorman AV.
A robust and validated integrated prognostic index for de fi ning risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study
Blood Adv. 2024 Mar 12;8(5):1155-1166. doi: 10.1182/bloodadvances.2023011661. PMID: 38113467 - Citations: 1 [05/03/2025]
IF: 7,4 - QUARTIL 1

Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld AW, Rousselot P, Ribera JM, Bassan R.
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
Blood. 2024 May 9;143(19):1903-1930. doi: 10.1182/blood.2023023568.
PMID: 38306595 - Citations: 21 [05/03/2025]
IF: 21,1 - QUARTIL 1

Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann OG, Rijneveld AW, Rousselot P, Ribera JM, Bassan R.
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel
Blood. 2024 May 9;143(19):1891-1902. doi: 10.1182/blood.2023020794.
PMID: 38295337 - Citations: 14 [05/03/2025]
IF: 21,1n - QUARTIL 1

Hoelzer D, Bassan R, Boissel N, Roddie C, Ribera JM, Jerkeman M; ESMO Guidelines Committee.
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia Ann Oncol. 2024 Jan;35(1):15-28. doi: 10.1016/j.annonc.2023.09.3112. Epub 2023 Oct 11.
PMID: 37832649 - Citations: 6 [05/03/2025]
IF: 56,7 - QUARTIL 1

Salmanton-García J, Marchesi F, Farina F, Weinbergerová B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DS, Gomes da Silva M, Nunes Rodrigues R, López-García A, Córdoba R, Bilgin YM, Falces-Romero I, El-Ashwah S, Emarah Z, Besson C, Kohn M, Van Doesum J, Ammatuna E, Marchetti M, Labrador J, Zambrotta GPM, Verga L, Jaksic O, Nucci M, Piukovics K, Cabirta-Touzón A, Jiménez M, Arellano E, Espigado I, Blennow O, Nordlander A, Meers S, van Praet J, Aiello TF, Garcia-Vidal C, Fracchiolla N, Sciumè M, Seval GC, Žák P, Buquicchio C, Tascini C, Gräfe SK, Schönlein M, Adžić-Vukičević T, Bonuomo V, Cattaneo C, Nizamuddin S, Čerňan M, Plantefeve G, Prin R, Szotkovski T, Collins GP, Dargenio M, Petzer V, Wolf D, Čolović N, Prezioso L, Valković T, Passamonti F, Méndez GA, Sili U, Vena A, Bavastro M, Limongelli A, Duarte RF, Ledoux MP, Cvetanoski M, Stojanoski Z, Machado M, Batinić J, Magliano G, Biernat MM, Pantić N, Poulsen CB, Cuccaro A, Del Principe MI, Kulasekararaj A, Ormazabal-Vélez I, Busca A, Demirkan F, Ijaz M, Klimko N, Stoma I, Khostelidi S, Fernández N, Omrani AS, Bergantim R, De Jonge N, Fouquet G, Navrátil M, Abu-Zeinah G, Samarkos M, Maertens J, De Ramón C, Guidetti A, Magyari F, González-López TJ, et al. José-María Ribera-Santa Susana
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
EClinicalMedicine. 2024 Mar 18;71:102553. doi: 10.1016/j.eclinm.2024.102553. eCollection 2024 May.
PMID: 38533127 - Citations: 10 [05/03/2025]
IF: 9,6 - QUARTIL 1

Ribera JM, Morgades M, Ribera J, Montesinos P, Cano-Ferri I, Martínez P, Esteve J, Esteban D, García-Fortes M, Alonso N, González-Campos J, Bermúdez A, Torrent A, Genescà E, Maluquer C, Martínez-López J, García-Sanz R. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

Hemasphere. 2024 Apr 2;8(4):e67. doi: 10.1002/hem3.67. eCollection 2024 Apr.
PMID: 38566805 - Citations: 6 [05/03/2025]
IF: 12,1 - QUARTIL 1

De Greef J, Averbuch D, Tondeur L, Duréault A, Zuckerman T, Roussel X, Robin C, Xhaard A, Pagliuca S, Beguin Y, Botella-Garcia C, Khanna N, Bourgeois AL, Praet JV, Ho A, Kröger N, Leprêtre SD, Roos-Weil D, Aljurf M, Blijlevens N, Blau IW, Carlson K, Collin M, Ganser A, Villate A, Lakner J, Martin S, Nagler A, Ram R, Torrent A, Stamouli M, Mikulska M, Gil L, Wendel L, Tridello G, Knelange N, de la Camara R, Lortholary O, Fontanet A, Styczynski J, Maertens J, Coussement J, Lebeaux D.
Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
J Infect. 2024 Jun;88(6):106162. doi: 10.1016/j.jinf.2024.106162. Epub 2024 Apr 23. PMID: 38663756 - Citations: 0 [05/03/2025]
IF: 14,3 - QUARTIL 1

Hidalgo-Gómez G, Minguela A, Tazón-Vega B, Ribera J, Galián JA, Martínez-Banaclocha H, García-Garay M, Velasco P, Fuster-Soler JL, Armengol G, Ortega M.
Clonal heterogeneity and genomic evolution in intrachromosomal amplification of chromosome 21: A case report Br J Haematol. 2024 Jun;204(6):2512-2515. doi: 10.1111/bjh.19485. Epub 2024 Apr 26.
PMID: 38665061 - Citations: 0 [05/03/2025]
IF: 5,1 - QUARTIL 1

Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, Ribera JM.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia JAMA. 2024 Jun 4;331(21):1814-1823. doi: 10.1001/jama.2024.4783.
PMID: 38722621 - Citations: 22 [05/03/2025]
IF: 63,1 - QUARTIL 1

Mora E, Montoro J, Balaguer A, Rovira M, Cabrero M, Heras I, Ribera JM, Antelo G, Martin AA, Lopez Godino O, Torrent A, Villalba M, Chorao P, Sanz MA, Sanz J; Grupo Español de Trasplante Hematopoyético (GETH).
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia
Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298-z PMID: 38755458 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Xicoy B, Pomares H, Morgades M, Germing U, Arnan M, Tormo M, Palomo L, Orna E, Della Porta M, Schulz F, Díaz-Beya M, Esteban A, Molero A, Lanino L, Avendaño A, Hernández F, Roldan V, Ubezio M, Pineda A, Díez- Campelo M, Zamora L.
Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis Front Oncol. 2024 Jul 1;14:1385987. doi: 10.3389/fonc.2024.1385987. eCollection 2024.
PMID: 39011475 - Citations: 0 [05/03/2025]
IF: 3,5 - QUARTIL 2

Torrent A, Ribera JM.
Immunotherapy in first line treatment of adult acute lymphoblastic leukemia
Curr Opin Oncol. 2024 Nov 1;36(6):593-599. doi: 10.1097/CCO.0000000000001086. Epub 2024 Aug 12.
PMID: 39246156 - Citations: 0 [05/03/2025]
IF: 2,8 - QUARTIL 2

Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, Rijneveld AW, Gore L, Fleming S, Logan AC,
Ribera JM, Menne TF, Mezzi K, Zaman F, Velasco K, Boissel N
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Blood Cancer J. 2024 Nov 19;14(1):203. doi: 10.1038/s41408-024-01179-4. PMID: 39562780 - Citations: 0 [05/03/2025]
IF: 12,9 - QUARTIL 1

Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López- Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P; CETLAM and PETHEMA Groups.
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Cancers (Basel). 2024 Nov 30;16(23):4028. doi: 10.3390/cancers16234028. PMID: 39682214 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Navas-Acosta J, Hernández-Sánchez A, González T, Villaverde Ramiro Á, Santos S, Miguel C, Ribera J, Granada I, Morgades M, Sánchez R, Such E, Barrena S, Ciudad J, Dávila J, de Las Heras N, García-de Coca A, Labrador J, Queizán JA, Martín S, Orfao A, Ribera JM, Benito R, Hernández-Rivas JM.
Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia
Cancers (Basel). 2024 Dec 17;16(24):4200. doi: 10.3390/cancers16244200. PMID: 39766099 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, Cattaneo C, Collins S, Cwynarski K, Dalla Pria A, Hentrich M, Hoffmann C, Kersten MJ, Montoto S, Navarro JT, Oksenhendler E, Re A, Ribera JM, Schommers P, von Tresckow B, Buske C, Dreyling M, Davies A; EHA and ESMO Guidelines Committees. Electronic address: guidelines@ehaweb.org.
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis,
treatment and follow-up
Ann Oncol. 2024 Oct;35(10):840-859. doi: 10.1016/j.annonc.2024.06.003. Epub 2024 Sep 3. PMID: 39232987 - Citations: 0 [05/03/2025]
IF: 56,7 - QUARTIL 1

Cellular immunotherapy and gene therapy

Javier Briones

Esquirol A, Cadenas IG, Novelli S, Garrido A, Caballero AC, Oñate G, Lopez J, Redondo S, Argüello M, Saavedra S, Moreno C, Briones J, Sierra J, Martino R.
Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience
Ann Hematol. 2024 Jan;103(1):321-334. doi: 10.1007/s00277-023-05530-w. Epub 2023 Nov 16. PMID: 37971549 - Citations: 1 [05/03/2025]
IF: 3 - QUARTIL 2

Moreno-Martinez ME, Riba M, García-Cadenas I, Esquirol A, Yusta M, Redondo S, De Dios A, Portos JM, Aso O, Marcos-Fendian A, Font N, Briones J, Martino R, Feliu A.
Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement
Front Immunol. 2024 Jun 11;15:1397115. doi: 10.3389/fimmu.2024.1397115. eCollection 2024. PMID: 38919607 - Citations: 0 [05/03/2025]
IF: 5,7 - QUARTIL 1

Redondo S, García-Cadenas I, Esquirol A, Portos JM, Iranzo E, Arguello-Tomas M, Saavedra S, Oñate G, Caballero AC, Garrido A, López J, Muntañola A, Paviglianiti A, Miqueleiz S, Sierra J, Briones J, Martino R. Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation
Eur J Haematol. 2024 Dec;113(6):776-787. doi: 10.1111/ejh.14294. Epub 2024 Aug 18. PMID: 39155459 - Citations: 0 [05/03/2025]
IF: 2,3 - QUARTIL 2

Cellular systems genomics

Elisabetta Mereu

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, Roue G, Valcárcel D, Molero A, Zamora L, Xicoy B, Palomo L, Acha P, Manzanares A, Tobiasson M, Hellström-Lindberg E, Sole F, Esteller M. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy Cancer Res Commun. 2024 Feb 12;4(2):365-377. doi: 10.1158/2767-9764.CRC-23-0389. PMID: 38300528 - Citations: 4 [05/03/2025]
IF: 2 - QUARTIL 3

Thambyrajah R, Maqueda M, Fadlullah MZ, Proffitt M, Neo WH, Guillén Y, Casado-Pelaez M, Herrero-Molinero P, Brujas C, Castelluccio N, González J, Iglesias A, Marruecos L, Ruiz-Herguido C, Esteller M, Mereu E, Lacaud G, Espinosa L, Bigas A.
IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development Nat Commun. 2024 Jun 1;15(1):4673. doi: 10.1038/s41467-024-48854-5.

PMID: 38824124 - Citations: 3 [05/03/2025]
IF: 14,7 - QUARTIL 1

Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias.
Cell Rep Med. 2024 Nov 19;5(11):101803. doi: 10.1016/j.xcrm.2024.101803. Epub 2024 Oct 28.
PMID: 39471818 - Citations: 0 [05/03/2025]
IF: 11,7 - QUARTIL 1

Lymphoid neoplasms

Jose Tomàs Navarro

Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
Haematologica. 2024 Feb 1;109(2):543-552. doi: 10.3324/haematol.2023.283342
PMID: 37560813 - Citations: 3 [05/03/2025]
IF: 8,2 - QUARTIL 1

D'Alessandro A, Krisnevskaya E, Leguizamon V, Hernández I, de la Torre C, Bech JJ, Navarro JT, Vives- Corrons JL.
SARS-CoV-2 Infection and Anemia-A Focus on RBC Deformability and Membrane Proteomics-Integrated Observational Prospective Study
Microorganisms. 2024 Feb 23;12(3):453. doi: 10.3390/microorganisms12030453.
PMID: 38543504 - Citations: 2 [05/03/2025]
IF: 4,1 - QUARTIL 2

Iacoboni G, Iraola-Truchuelo J, O'Reilly M, Navarro V, Menne T, Kwon M, Martín-López AÁ, Chaganti S, Delgado J, Roddie C, Pérez A, Norman J, Guerreiro M, Gibb A, Caballero AC, Besley C, Martínez-Cibrián N, Mussetti A, Sanderson R, Luzardo H, Iyengar S, Sánchez JM, Jones C, Sancho JM, Barba P, Latif AL, López-Corral L, Hernani R, Reguera JL, Sureda A, Garcia-Sancho AM, Bastos M, Abrisqueta P, Kuhnl A
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
Hemasphere. 2024 May 21;8(5):e62. doi: 10.1002/hem3.62
PMID: 38774657 - Citations: 5 [05/03/2025]
IF: 12,1 - QUARTIL 1

Jurado Tapiador R, González P, Hernandez-Rodriguez I.
Late diagnosis of sitosterolemia in an adult case with unexplained hemolytic anemia
Int J Lab Hematol. 2024 Dec;46(6):985-987. doi: 10.1111/ijlh.14322. Epub 2024 May 29.
PMID: 38808537 - Citations: 0 [05/03/2025]
IF: 2,2 - QUARTIL 3

Sancho JM, Abrisqueta P, Kumar A, Cordoba R, Tani M, Langmuir P, Rappold E, Liu T, Lopez-Guillermo A.
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine plus rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL-112)
Leuk Lymphoma. 2024 Jul;65(7):911-921. doi: 10.1080/10428194.2024.2331626. Epub 2024 Apr 10.
PMID: 38598516 - Citations: 0 [05/03/2025]
IF: 2,2 - QUARTIL 3

Rajamaki A, Sorigue M, Prusila REI, Kuusisto MEL, Kuitunen H, Jantunen E, Mercadal S, Turpeenniemi-Hujanen T,
Sancho JM, Sunela K, Kuittinen O.
Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice
Acta Oncol. 2024 May 6;63:267-272. doi: 10.2340/1651-226X.2024.24377.
PMID: 38709114 - Citations: 0 [05/03/2025]
IF: 2,7 - QUARTIL 3

Harmanen M, Sorigue M, Khan M, Prusila R, Klaavuniemi T, Kari E, Jantunen E, Sunela K, Rajamäki A, Alanne E,
Kuitunen H, Jukkola A, Sancho JM, Kuittinen O, Rönkä A.
Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis
Eur J Haematol. 2024 Aug;113(2):218-226. doi: 10.1111/ejh.14219. Epub 2024 Apr 25.

PMID: 38661269 - Citations: 1 [05/03/2025]
IF: 2,3 - QUARTIL 2

Celades C, Tuset M, Ambrosioni J, Calvo J, Lizondo T, Sabato S, Guardia A, Chapchap EC, Navarro JT, Molto J. Leveraging interdisciplinary management in people with HIV and lymphoid neoplasms J Antimicrob Chemother. 2024 Oct 1;79(10):2493-2499. doi: 10.1093/jac/dkae244.
PMID: 39045785 - Citations: 0 [05/03/2025]
IF: 3,9 - QUARTIL 1

Spanjaart AM, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrián N, Barba P, Kwon M, Lopez-Corral L, Martinez- Lopez J, Ferra C, Di Blasi R, Ghesquieres H, Mutsaers P, Calkoen F, Jak M, van Doesum J, Vermaat JSP, van der Poel M, Maertens J, Gambella M, Metafuni E, Ciceri F, Saccardi R, Nicholson E, Tholouli E, Matthew C, Potter V, Bloor A, Besley C, Roddie C, Wilson K, Nagler A, Campos A, Petersen SL, Folber F, Bader P, Finke J, Kroger N, Knelange N, de La Camara R, Kersten MJ, Mielke S.
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
PMID: 39043963 - Citations: 0 [05/03/2025]
IF: 12,8 - QUARTIL 1

Xicoy B, Pomares H, Morgades M, Germing U, Arnan M, Tormo M, Palomo L, Orna E, Della Porta M, Schulz F, Díaz-Beya M, Esteban A, Molero A, Lanino L, Avendaño A, Hernández F, Roldan V, Ubezio M, Pineda A, Díez- Campelo M, Zamora L.
Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis Front Oncol. 2024 Jul 1;14:1385987. doi: 10.3389/fonc.2024.1385987. eCollection 2024.
PMID: 39011475 - Citations: 0 [05/03/2025]
IF: 3,5 - QUARTIL 2

Sancho JM, Sorigué M, Rubio-Azpeitia E.
Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review J Blood Med. 2024 May 25;15:239-254. doi: 10.2147/JBM.S463946. eCollection 2024.
PMID: 38812568 - Citations: 0 [05/03/2025]
IF: 2,1 - QUARTIL 3

Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, Cattaneo C, Collins S, Cwynarski K, Pria AD, Hentrich M, Hoffmann C, Kersten MJ, Montoto S, Navarro JT, Oksenhendler E, Re A, Ribera JM, Schommers P, von Tresckow B, Buske C, Dreyling M, Davies A; EHA and ESMO Guidelines Committees.
Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hemasphere. 2024 Sep 3;8(9):e150. doi: 10.1002/hem3.150. eCollection 2024 Sep.
PMID: 39233903 - Citations: 0 [05/03/2025]
IF: 12,1 - QUARTIL 1

Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, Cattaneo C, Collins S, Cwynarski K, Dalla Pria A, Hentrich M, Hoffmann C, Kersten MJ, Montoto S, Navarro JT, Oksenhendler E, Re A, Ribera JM, Schommers P, von Tresckow B, Buske C, Dreyling M, Davies A; EHA and ESMO Guidelines Committees. Electronic address: guidelines@ehaweb.org.
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol. 2024 Oct;35(10):840-859. doi: 10.1016/j.annonc.2024.06.003. Epub 2024 Sep 3.
PMID: 39232987 - Citations: 0 [05/03/2025]
IF: 56,7 - QUARTIL 1

Padró-Casas C, Basagaña M, Martínez-Colls MDM, García-Olivé I, Pollan Guisasola C, Teniente-Serra A, Martínez- Cáceres E, Navarro JT, Martínez-Rivera C.
Prognostic Factors in Severe Eosinophilic Asthma in a Pediatric Population: A Prospective Cohort Study in Spain J Clin Med. 2024 Nov 27;13(23):7202. doi: 10.3390/jcm13237202.
PMID: 39685659 - Citations: 0 [05/03/2025]
IF: 3 - QUARTIL 1

Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López- Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P; CETLAM and PETHEMA Groups.
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid

Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Cancers (Basel). 2024 Nov 30;16(23):4028. doi: 10.3390/cancers16234028.
PMID: 39682214 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Ródenas Quiñonero I, Marco-Ayala J, Chen-Liang TH, de la Cruz-Vicente F, Baumann T, Navarro JT, Martín García- Sancho A, Martin-Santos T, López-Jiménez J, Andreu R, Parra E, Usas A, Alonso D, Fernández-González M, Palomo Rumschisky P, Frutos L, Navarro JL, Alvarez-Perez RM, Sarandeses P, Cortes M, Tamayo P, Uña J, Martínez-Lorca A, Ruiz C, Lozano ML, Ortuño FJ.
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Cancers (Basel). 2024 Dec 16;16(24):4189. doi: 10.3390/cancers16244189.
PMID: 39766089 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Lymphoma translational group
Gaël Roué

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, Roue G, Valcárcel D, Molero A, Zamora L, Xicoy B, Palomo L, Acha P, Manzanares A, Tobiasson M, Hellström-Lindberg E, Sole F, Esteller M. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
Cancer Res Commun. 2024 Feb 12;4(2):365-377. doi: 10.1158/2767-9764.CRC-23-0389.
PMID: 38300528 - Citations: 4 [05/03/2025]
IF: 2 - QUARTIL 3

Martínez-Asensio M, Sàrrias L, Gorjón-de-Pablo G, Fernández-Serrano M, Camaló-Vila J, Gibert A, Puig de la Bellacasa R, Teixidó J, Roué G, Borrell JI, Estrada-Tejedor R.
Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity
Int J Mol Sci. 2024 Aug 30;25(17):9446. doi: 10.3390/ijms25179446.
PMID: 39273392 - Citations: 0 [05/03/2025]
IF: 4,9 - QUARTIL 1

Mechanisms of cancer and ageing Lab (South)
Salvador Macip

Ward JA, Romartinez-Alonso B, Kay DF, Bellamy-Carter J, Thurairajah B, Basran J, Kwon H, Leney AC, Macip S, Roversi P, Muskett FW, Doveston RG.
Characterising the Protein-Protein Interaction Between MDM2 and 14-3-3; Proof of Concept for Small Molecule Stabilisation
J Biol Chem. 2024 Feb;300(2):105651. doi: 10.1016/j.jbc.2024.105651. Epub 2024 Jan 16.
PMID: 38237679 - Citations: 4 [05/03/2025]
IF: 4 - QUARTIL 2

Dhokia V, Albati A, Smith H, Thomas G, Macip S.
A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing
Biochem Soc Trans. 2024 Aug 28;52(4):1661-1671. doi: 10.1042/BST20231066.
PMID: 38940746 - Citations: 2 [05/03/2025]
IF: 3,8 - QUARTIL 2

Rius-Bonet J, Macip S, Massip-Salcedo M, Closa D.
Effects of Fasting on THP1 Macrophage Metabolism and Inflammatory Profile Int J Mol Sci. 2024 Aug 20;25(16):9029. doi: 10.3390/ijms25169029.
PMID: 39201723 - Citations: 0 [05/03/2025]
IF: 4,9 - QUARTIL 1

Multiple myeloma group
Albert Oriol

Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490.
PMID: 37646657 - Citations: 4 [05/03/2025]
IF: 8,2 - QUARTIL 1

Lakhwani S; Rosiñol L; Puig N; Pico-Picos MA; Medina-González L; Martínez-López J; Paiva B; Cedena MT; Oriol A; Ríos-Tamayo R; Blanchard

MJ; Jarque I; Bargay J; Moraleda JM; Carrillo-Cruz E; Sureda A; Krsnik I; González E; Casado LF; Martí JM; Encinas C; De Arriba F; Palomera L; Sampol A; González-Montes Y; Motlló C; De La Cruz J; Alonso R; Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J; Hernández MT.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Haematologica. 2024 Jun 1;109(6):1909-1917. doi: 10.3324/haematol.2023.284154.
PMID: 38031761 - Citations: 3 [05/03/2025]
IF: 8,2 - QUARTIL 1

Oriol A; Dimopoulos M; Schjesvold F; Beksac M; Facon T; Dhanasiri S; Guo S; Mu Y; Hong K; Gentili C; Galli M; Yagci M; Larocca A; Richardson P; Weisel K.
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):165-176.e4. doi: 10.1016/j.clml.2023.10.009. Epub 2023 Nov 8.
PMID: 38072743 - Citations: 2 [05/03/2025]
IF: 2,7 - QUARTIL 2

Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ.
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):194-202. doi: 10.1016/j.clml.2023.11.001. Epub 2023 Nov 14.
PMID: 38052709 - Citations: 4 [05/03/2025]
IF: 2,7 - QUARTIL 2

Gonzalez-Montes Y, Osca-Gelis G, Rodriguez-Romanos R, Villavicencio A, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Gómez B, Granada I, Gallardo D. CD200 genotype is associated with clinical outcome of patients with multiple myeloma
Front Immunol. 2024 Feb 22;15:1252445. doi: 10.3389/fimmu.2024.1252445. eCollection 2024.
PMID: 38455039 - Citations: 1 [05/03/2025]
IF: 5,7 - QUARTIL 1

Perrot A, Delimpasi S, Spanoudakis E, Frølund U, Belotti A, Oriol A, Moreau P, McFadden I, Xia Q, Arora M, Dimopoulos MA.
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study
Leuk Lymphoma. 2024 Jun;65(6):833-842. doi: 10.1080/10428194.2024.2322030. Epub 2024 Mar 18.
PMID: 38497533 - Citations: 0 [05/03/2025]
IF: 2,2 - QUARTIL 3

Suvannasankha A, Bahlis N, Trudel S, Weisel K, Koenecke C, Oriol A, Voorhees PM, Alonso AA, Callander NS, Mateos MV, Reddy N, Hakim S, LaMacchia J, Patel N, Williams D, Jewell RC, Zhou X, Gupta I, Opalinska J, Nooka AK. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Cancer. 2024 Aug 1;130(15):2629-2641. doi: 10.1002/cncr.35319. Epub 2024 Apr 17.
PMID: 38630908 - Citations: 1 [05/03/2025]
IF: 6,1 - QUARTIL 1

Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3.
PMID: 38684670 - Citations: 0 [05/03/2025]
IF: 12,9 - QUARTIL 1

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/

NEJMoa2405090. Epub 2024 Jun 1.
PMID: 38828933 - Citations: 23 [05/03/2025]
IF: 96,2 - QUARTIL 1

Oriol A, Hájek R, Spicka I, Sandhu I, Cohen YC, Gatt ME, Mariz J, Cavo M, Berdeja J, Jin K, Bar M, Das P, Motte- Mohs R, Wang Y, Perumal D, Costa LJ.
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):703-714.
PMID: 38849283 - Citations: 0 [05/03/2025]
IF: 2,7 - QUARTIL 2

Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez- Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial
Haematologica. 2024 Dec 1;109(12):4056-4066.
PMID: 38988266 - Citations: 0 [05/03/2025]
IF: 8,2 - QUARTIL 1

Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos- Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM- Pethema).
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22.
PMID: 39038268 - Citations: 3 [05/03/2025]
IF: 42,1 - QUARTIL 1

Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P.
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
Lancet Haematol. 2024 Oct;11(10):e741-e750. doi: 10.1016/S2352-3026(24)00148-0. Epub 2024 Jul 24.
PMID: 39067465 - Citations: 7 [05/03/2025]
IF: 15,4 - QUARTIL 1

Quach H, Parmar G, Ocio EM, Prince HM, Oriol A, Crowther H, Tsukada N, Bories P, Madan S, Nathwani N, Sunami K, Semiond D, Yu D, Cordero P, Macé S, Suzan F, Moreau P.
A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Haematologica. 2024 Dec 1;109(12):4078-4082. doi: 10.3324/haematol.2023.284730.
PMID: 39157871 - Citations: 0 [05/03/2025]
IF: 8,2 - QUARTIL 1

Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, García-Mateo A, Hernández-Rivas JÁ, Ramila E, Krsnik I, Casado Montero LF, De Arriba F, Palomera L, Sampol A, Moraleda JM, Casanova M, Delgado P, Lafuente A, Amutio E, López-Martínez A, Altés A, Ruíz MÁ, Alegre A, Lopez-Anglada L, De La Cruz J, Alonso Fernández R, Bladé Creixenti J, Lahuerta JJ, San-Miguel J, Hernández MT
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Ann Hematol. 2024 Dec;103(12):5651-5661. doi: 10.1007/s00277-024-06031-0. Epub 2024 Oct 23.
PMID: 39438321 - Citations: 0 [05/03/2025]
IF: 3 - QUARTIL 2

Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Online ahead of

print. PMID: 39652675 - Citations: 2 [05/03/2025]
IF: 96,2 - QUARTIL 1

González-Calle V, Rodriguez-Otero P, Calasanz MJ, Guijarro M, Martínez-López J, Rosiñol L, Hernández MT, Teruel AI, Gironella M, Oriol A, de la Rubia J, González-Rodríguez AP, Bargay J, de Arriba F, Palomera L, González-Pérez MS, Sureda A, Ocio E, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Gutiérrez NC
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience Hemasphere. 2024 Dec 10;8(12):e70031. doi: 10.1002/hem3.70031. eCollection 2024 Dec. PMID: 39665068 - Citations: 0 [05/03/2025]
IF: 12,1 - QUARTIL 1

Puig N, Agulló C, Contreras T, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Íñigo MB, Sureda A, Lakhwani S, de la Rubia J, González-Calle V, Cabañas V, Palomera L, Moraleda JM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV
Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
Blood. 2024 Dec 5;144(23):2432-2438. doi: 10.1182/blood.2024024995
PMID: 39293025 - Citations: 2 [05/03/2025]
IF: 21,1 - QUARTIL 1

Lozano E, Mena MP, Garrabou G, Cardús O, Díaz T, Moreno DF, Mañé-Pujol J, Oliver-Caldés A, Battram A, Tovar N, Cibeira MT, Rodríguez-Lobato LG, Bladé J, Fernández de Larrea C, Rosiñol L.
Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma
Clin Cancer Res. 2024 Sep 3;30(17):3944-3955. doi: 10.1158/1078-0432.CCR-24-0117.
PMID: 38990101 - Citations: 0 [05/03/2025]
IF: 10 - QUARTIL 1

Nuclear architecture in leukemia

Gregoire Stik

Naderi J, Magalhaes AP, Kibar G, Stik G, Zhang Y, Mackowiak SD, Wieler HM, Rossi F, Buschow R, Christou-Kent M, Alcoverro-Bertran M, Graf T, Vingron M, Hnisz D.
An activity-specificity trade-off encoded in human transcription factors
Nat Cell Biol. 2024 Aug;26(8):1309-1321. doi: 10.1038/s41556-024-01411-0. Epub 2024 Jul 5.
PMID: 38969762 - Citations: 10 [05/03/2025]
IF: 17,3 - QUARTIL 1

Stem cell biology, developmental leukemia and immunotherapy

Pablo Menéndez

Molina O, Ortega-Sabater C, Thampi N, Fernández-Fuentes N, Guerrero-Murillo M, Martínez-Moreno A, Vinyoles M, Velasco-Hernández T, Bueno C, Trincado JL, Granada I, Campos D, Giménez C, Boer JM, den Boer ML, Calvo GF, Camós M, Fuster JL, Velasco P, Ballerini P, Locatelli F, Mullighan CG, Spierings DCJ, Foijer F, Pérez-García VM, Menéndez P.
Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression EMBO Mol Med. 2024 Jan 15. doi: 10.1038/s44321-023-00006-w.
PMID: 38177531 - Citations: 3 [05/03/2025]
IF: 9 - QUARTIL 1

Safi R, Menéndez P, Pol A.
Lipid droplets provide metabolic flexibility for cancer progression
FEBS Lett. 2024 May;598(10):1301-1327. doi: 10.1002/1873-3468.14820. Epub 2024 Feb 7. PMID: 38325881 - Citations: 9 [05/03/2025]
IF: 3 - QUARTIL 2

Díez-Alonso L, Falgas A, Arroyo-Ródenas J, Romencín PA, Martínez A, Gómez-Rosel M, Blanco B, Jiménez-Reinoso A, Mayado A, Pérez-Pons A, Aguilar-Sopeña Ó, Ramírez-Fernández Á, Segura-Tudela A, Perez-Amill L, Tapia-Galisteo A, Domínguez-Alonso C, Rubio-Pérez L, Jara M, Solé F, Hangiu O, Almagro L, Albitre Á, Penela P, Sanz L, Anguita E, Valeri A, García-Ortiz A, Río P, Juan M, Martínez-López J, Roda-Navarro P, Martín-Antonio B, Orfao A, Menéndez P, Bueno C, Álvarez-Vallina L.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo
Sci Transl Med. 2024 Feb 14;16(734):eadg7962. doi: 10.1126/scitranslmed.adg7962 PMID: 38354229 - Citations: 6 [05/03/2025]
IF: 15,8 - QUARTIL 1

Blanco-Heredia J, Souza CA, Trincado JL, Gonzalez-Cao M, Gonçalves-Ribeiro S, Gil SR, Pravdyvets D,

Cedeño S, Callari M, Marra A, Gazzo AM, Weigelt B, Pareja F, Vougiouklakis T, Jungbluth AA, Rosell R, Brander C, Tresserra F, Reis-Filho JS, Tiezzi DG, de la Iglesia N, Heyn H, De Mattos-Arruda L.
Converging and evolving immuno-genomic routes toward immune escape in breast cancer
Nat Commun. 2024 Feb 21;15(1):1302. doi: 10.1038/s41467-024-45292-1.
PMID: 38383522 - Citations: 4 [05/03/2025]
IF: 14,7 - QUARTIL 1

Velasco-Hernandez T, Trincado JL, Vinyoles M, Closa A, Martínez-Moreno A, Gutiérrez-Agüera F, Molina O, Rodríguez-Cortez VC, Ximeno-Parpal P, Fernández-Fuentes N, Petazzi P, Beneyto-Calabuig S, Velten L, Romecin P, Casquero R, Abollo-Jiménez F, de la Guardia RD, Lorden P, Bataller A, Lapillonne H, Stam RW, Vives S, Torrebadell M, Fuster JL, Bueno C, Sarry JE, Eyras E, Heyn H, Menéndez P.
Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells
Hemasphere. 2024 Feb 26;8(2):e45. doi: 10.1002/hem3.45. eCollection 2024 Feb. PMID: 38435427 - Citations: 3 [05/03/2025]
IF: 12,1 - QUARTIL 1

Mensurado S, Condeço C, Sánchez-Martínez D, Shirley S, Coelho RML, Tirado N, Vinyoles M, Blanco-Domínguez R, Barros L, Galvão B, Custódio N, Gomes da Silva M, Menéndez P, Silva-Santos B.
CD155/PVR determines acute myeloid leukemia Delta One T cells
Blood. 2024 Apr 11;143(15):1488-1495. doi: 10.1182/blood.2023022992.
PMID: 38437507 - Citations: 7 [05/03/2025]
IF: 21,1 - QUARTIL 1

Bousquets-Muñoz P, Molina O, Varela I, Álvarez-Eguiluz Á, Fernández-Mateos J, Gómez A, Sánchez EG, Balbín M, Ruano D, Ramírez-Orellana M, Puente XS, Menéndez P, Velasco-Hernandez T.
Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML
Leukemia. 2024 Aug;38(8):1808-1812. doi: 10.1038/s41375-024-02293-9. Epub 2024 May 28.
PMID: 38806630 - Citations: 1 [05/03/2025]
IF: 12,8 - QUARTIL 1

Benítez L, Castro-Barquero S, Crispi F, Youssef L, Crovetto F, Fischer U, Kameri E, Bueno C, Camos M, Menéndez P, Heinäniemi M, Borkhardt A, Gratacós E.
Maternal Lifestyle and Prenatal Risk Factors for Childhood Leukemia: A Review of the Existing Evidence Fetal Diagn Ther. 2024;51(4):395-410. doi: 10.1159/000539141. Epub 2024 May 7.
PMID: 38710162 - Citations: 0 [05/03/2025]
IF: 1,6 - QUARTIL 3

Lopez-Millan B, Rubio-Gayarre A, Vinyoles M, Trincado JL, Fraga MF, Fernandez-Fuentes N, Guerrero- Murillo M, Martinez-Moreno A, Velasco-Hernandez T, Falgàs A, Panisello C, Valcarcel G, Sardina JL, López-Martí P, Javierre BM, Del Valle-Pérez B, García de Herreros A, Locatelli F, Pieters R, Bardini M, Cazzaniga G, Rodríguez-Manzaneque JC, Hanewald T, Marschalek R, Milne TA, Stam RW, Tejedor JRR, Menendez P, Bueno C. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
Blood. 2024 Nov 7;144(19):2002-2017. doi: 10.1182/blood.2023022050.
PMID: 39093982 - Citations: 2 [05/03/2025]
IF: 21,1 - QUARTIL 1

Kodali S, Proietti L, Valcarcel G, López-Rubio AV, Pessina P, Eder T, Shi J, Jen A, Lupión-Garcia N, Starner AC, Bartels MD, Cui Y, Sands CM, Planas-Riverola A, Martínez A, Velasco-Hernandez T, Tomás-Daza L, Alber B, Manhart G, Mayer IM, Kollmann K, Fatica A, Menendez P, Shishkova E, Rau RE, Javierre BM, Coon J, Chen Q, Van Nostrand EL, Sardina JL, Grebien F, Di Stefano B.
RNA sequestration in P-bodies sustains myeloid leukaemia
Nat Cell Biol. 2024 Oct;26(10):1745-1758. doi: 10.1038/s41556-024-01489-6. Epub 2024 Aug 21. PMID: 39169219 - Citations: 2 [05/03/2025]
IF: 17,3 - QUARTIL 1

Panisello C, Aschero R, Martinez-Moreno A, Roca Ho H, Falgas A, González-Navarro EA, Carabelli J, Pradenas E, Lázaro-Díez M, Prado JG, Blanco J, Carrillo J, Juan M, Carcaboso ÁM, Bueno C, Menendez P.
NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease
J Immunother Cancer. 2024 Oct 7;12(10):e009198. doi: 10.1136/jitc-2024-009198. PMID: 39379097 - Citations: 1 [05/03/2025]
IF: 10,3 - QUARTIL 1

Sjövall D, Ghosh S, Fernandez-Fuentes N, Velasco-Hernandez T, Hogmalm A, Menendez P, Hansson J, Guibentif C, Jaako P.
Defective ribosome assembly impairs leukemia progression in a murine model of acute myeloid leukemia Cell Rep. 2024 Nov 26;43(11):114864. doi: 10.1016/j.celrep.2024.114864. Epub 2024 Oct 16.

PMID: 39412990 - Citations: 0 [05/03/2025]
IF: 7,5 - QUARTIL 1

Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias.
Cell Rep Med. 2024 Nov 19;5(11):101803. doi: 10.1016/j.xcrm.2024.101803. Epub 2024 Oct 28.
PMID: 39471818 - Citations: 0 [05/03/2025]
IF: 11,7 - QUARTIL 1

Justicia-Lirio P, Tristán-Manzano M, Maldonado-Pérez N, Barbero-Jiménez C, Cortijo-Gutiérrez M, Pavlovic K, Molina- Estevez FJ, Muñoz P, Hinckley-Boned A, Rodriguez-Madoz JR, Prosper F, Griñán-Lison C, Navarro-Marchal SA, Panisello C, Muñoz-Ballester J, González-Sierra PA, Herrera C, Marchal JA, Martín F
First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas
Mol Ther Nucleic Acids. 2024 Aug 15;35(4):102308. doi: 10.1016/j.omtn.2024.102308. eCollection 2024 Dec 10
PMID: 39640015 - Citations: 0 [05/03/2025]
IF: 6,5- QUARTIL 1

Petazzi P, Gutierrez-Agüera F, Roca-Ho H, Castaño J, Bueno C, Alvarez N, Forrester LM, Sevilla A, Fidanza A, Menendez P.
Generation of an inducible dCas9-SAM human PSC line for endogenous gene activation
Front Cell Dev Biol. 2024 Nov 29;12:1484955. doi: 10.3389/fcell.2024.1484955. eCollection 2024. PMID: 39676795 - Citations: 0 [05/03/2025]
IF: 4,6 - QUARTIL 1

Esquinas E, Moreno-Sanz A, Sandá V, Stodulski-Ciesla D, Borregón J, Peña-Blanque V, Fernández-Calles J, Fernandez-Fuentes N, Serrano-Lopez J, Juan M, Engel P, Llamas-Sillero P, Solán-Blanco L, Martin-Antonio B. Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen
J Immunother Cancer. 2024 Dec 18;12(12):e009485. doi: 10.1136/jitc-2024-009485. PMID: 39694704 - Citations: 0 [05/03/2025]
IF: 10,3 - QUARTIL 1

Safi R, Mohsen-Kanson T, Kouzi F, El-Saghir J, Dermesrobian V, Zugasti I, Zibara K, Menéndez P, El Hajj H, El- Sabban M.
Direct Interaction Between CD34(+) Hematopoietic Stem Cells and Mesenchymal Stem Cells Reciprocally Preserves Stemness
Cancers (Basel). 2024 Nov 27;16(23):3972. doi: 10.3390/cancers16233972. PMID: 39682159 - Citations: 0 [05/03/2025]
IF: 4,5- QUARTIL 1

Petazzi P, Ventura T, Luongo FP, McClafferty H, May A, Taylor HA, Shipston MJ, Romanò N, Forrester LM, Menendez P, Fidanza A
A novel human pluripotent stem cell gene activation system identifies IGFBP2 as a mediator in the production of haematopoietic progenitors in vitro
Elife. 2024 Dec 23:13:RP94884. doi: 10.7554/eLife.94884. PMID: 39714446 - Citations: 0 [05/03/2025]
IF: 6,4 - QUARTIL 1

Stem cells and cancer

Anna Bigas

Solé L, Lobo-Jarne T, Cabré-Romans JJ, González A, Fernández L, Marruecos L, Guix M, Cuatrecasas M, López S, Bellosillo B, Torres F, Iglesias M, Bigas A, Espinosa L.
Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients
Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871(3):119658. doi: 10.1016/j.bbamcr.2024.119658. Epub 2024 Jan 10.
PMID: 38216091 - Citations: 0 [05/03/2025]
IF: 4,6 - QUARTIL 1

Thambyrajah R, Maqueda M, Neo WH, Imbach K, Guillén Y, Grases D, Fadlullah Z, Gambera S, Matteini F, Wang X, Calero-Nieto FJ, Esteller M, Florian MC, Porta E, Benedito R, Göttgens B, Lacaud G, Espinosa L, Bigas A.
Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate Nat Commun. 2024 Feb 21;15(1):1604. doi: 10.1038/s41467-024-45716-y.
PMID: 38383534 - Citations: 5 [05/03/2025]
IF: 14,7 - QUARTIL 1

Palma LG, Bigas A.
Making Human Hematopoietic Stem Cells Without Transgenes

Cell Reprogram. 2024 Apr;26(2):43-45. doi: 10.1089/cell.2024.0020. Epub 2024 Mar 26. PMID: 38530081 - Citations: 0 [05/03/2025]
IF: 1,2 - QUARTIL 4

Thambyrajah R, Maqueda M, Fadlullah MZ, Proffitt M, Neo WH, Guillén Y, Casado-Pelaez M, Herrero-Molinero P, Brujas C, Castelluccio N, González J, Iglesias A, Marruecos L, Ruiz-Herguido C, Esteller M, Mereu E, Lacaud G, Espinosa L, Bigas A.
IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development Nat Commun. 2024 Jun 1;15(1):4673. doi: 10.1038/s41467-024-48854-5.
PMID: 38824124 - Citations: 3 [05/03/2025]
IF: 14,7 - QUARTIL 1

Moreno-Cabrera JM, Feliubadaló L, Pineda M, Prada-Dacasa P, Ramos-Muntada M, Del Valle J, Brunet J, Gel B, Currás-Freixes M, Calsina B, Salazar-Hidalgo ME, Rodríguez-Balada M, Roig B, Fernández-Castillejo S, Durán Domínguez M, Arranz Ledo M, Infante Sanz M, Castillejo A, Dámaso E, Soto JL, de Miguel M, Hidalgo Calero B, Sánchez-Zapardiel JM, Ramon Y Cajal T, Lasa A, Gisbert-Beamud A, López-Novo A, Ruiz-Ponte C, Potrony M, Álvarez-Mora MI, Osorio A, Lorda-Sánchez I, Robledo M, Cascón A, Ruiz A, Spataro N, Hernan I, Borràs E, Moles- Fernández A, Earl J, Cadiñanos J, Sánchez-Heras AB, Bigas A, Capellá G, Lázaro C.
SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population Database (Oxford). 2024 Jul 4;2024:baae055. doi: 10.1093/database/baae055.
PMID: 38965703 - Citations: 0 [05/03/2025]
IF: 3,4 - QUARTIL 1

Barrero M, Lazarenkov A, Blanco E, Palma LG, López-Rubio AV, Bauer M, Bigas A, Di Croce L, Sardina JL, Payer B.
The interferon γ pathway enhances pluripotency and X-chromosome reactivation in iPSC reprogramming Sci Adv. 2024 Aug 9;10(32):eadj8862. doi: 10.1126/sciadv.adj8862. Epub 2024 Aug 7.
PMID: 39110794 - Citations: 0 [05/03/2025]
IF: 11,7 - QUARTIL 1

Bigas A, Kartha GM.
Making blood from iPSCs: Reaching for the most sought-after prize
Cell Stem Cell. 2024 Dec 5;31(12):1730-1731. doi: 10.1016/j.stem.2024.11.008. PMID: 39642863 - Citations: 0 [05/03/2025]
IF: 19,8 - QUARTIL 1

T cell lymphomas

Laura Mondragón

Krug A, Mhaidly R, Tosolini M, Mondragon L, Tari G, Turtos AM, Paul-Bellon R, Asnafi V, Marchetti S, Di Mascio L, Travert M, Bost F, Bachy E, Argüello RJ, Fournié JJ, Gaulard P, Lemonnier F, Ricci JE, Verhoeyen E.
Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma Cell Death Discov. 2024 Jun 19;10(1):292. doi: 10.1038/s41420-024-02061-9. PMID: 38897995 - Citations: 0 [05/03/2025]
IF: 6,1 - QUARTIL 1

Chromatin, metabolism and cell fate

Marcus Buschbeck

Meers O, Buschbeck M.
A FACT about macroH2A removal in immune gene activation
Mol Cell. 2024 Aug 22;84(16):3001-3002. doi: 10.1016/j.molcel.2024.07.028.
PMID: 39178834 - Citations: 0 [05/03/2025]
IF: 14,5 - QUARTIL 1

Arroyo M, Casas-Delucchi CS, Pabba MK, Prorok P, Pradhan SK, Rausch C, Lehmkuhl A, Maiser A, Buschbeck M, Pasque V, Bernstein E, Luck K, Cardoso MC.
Histone variant macroH2A1 regulates synchronous firing of replication origins in the inactive X chromosome Nucleic Acids Res. 2024 Oct 28;52(19):11659-11688. doi: 10.1093/nar/gkae734.
PMID: 39189450 - Citations: 0 [05/03/2025]
IF: 16,6 - QUARTIL 1

Nagarajan D, Parracho RT, Corujo D, Xie M, Kutkaite G, Olsen TK, Rúbies Bedós M, Salehi M, Baryawno N, Menden MP, Chen X, Buschbeck M, Mao Y.
Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma J Clin Invest. 2024 Sep 10;134(21):e175310. doi: 10.1172/JCI175310.
PMID: 39255035 - Citations: 0 [05/03/2025]
IF: 13,3 - QUARTIL 1

Descriptive Epidemiology, Genetics and Cancer Prevention

Rafael Marcos-Gragera

Trama A, Botta L, Stiller C, Visser O, Cañete-Nieto A, Spycher B, Bielska-Lasota M, Katalinic A, Vener C, Innos K, Marcos-Gragera R, Paapsi K, Guevara M, Demuru E, Mousavi SM, Blum M, Eberle A, Ferrari A, Bernasconi A, Lasalvia P; EUROCARE-6 Working Group.
Survival of European adolescents and young adults diagnosed with cancer in 2010-2014
Eur J Cancer. 2024 May:202:113558. doi: 10.1016/j.ejca.2024.113558. Epub 2024 Jan 24. PMID: 38489859 - Citations: 4 [05/03/2025]
IF: 7,6 - QUARTIL 1

Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Maso LD, Lepage C, Molinié F, Bouvier AM, Marcos- Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V; EUROCARE-6 WG.
Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers
Eur J Cancer. 2024 Sep:208:114187. doi: 10.1016/j.ejca.2024.114187. Epub 2024 Jul 9.
PMID: 39013266 - Citations: 0 [05/03/2025]
IF: 7,6 - QUARTIL 1

Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R
Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain Lung Cancer. 2024 Nov:197:107995. doi: 10.1016/j.lungcan.2024.107995. Epub 2024 Oct 20.
PMID: 39447337 - Citations: 1 [05/03/2025]
IF: 4,5 - QUARTIL 1

Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F, Znaor A
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045
J Natl Cancer Inst. 2024 Dec 10:djae321. doi: 10.1093/jnci/djae321. Online ahead of print. PMID: 39658225 - Citations: 0 [05/03/2025]
IF: 9,9 - QUARTIL 1

Petrova D, Redondo-Sánchez D, Rodríguez-Barranco M, Marcos-Gragera R, Guevara M, Carulla M, López de Munain A, Vizcaíno A, Del Barco S, González-Flores E, Pollán M, Sánchez MJ.
Socioeconomic inequalities in adherence to clinical practice guidelines and breast cancer survival: a multicentre population-based study in Spain
BMJ Qual Saf. 2024 Dec 31:bmjqs-2024-017809. doi: 10.1136/bmjqs-2024-017809. Online ahead of print.
PMID: 39740986 - Citations: 0 [05/03/2025]
IF: 5,6 - QUARTIL 1

Epigenetic control of haematopoiesis

José Luis Sardina

Serra F, Nieto-Aliseda A, Fanlo-Escudero L, Rovirosa L, Cabrera-Pasadas M, Lazarenkov A, Urmeneta B, Alcalde-Merino A, Nola EM, Okorokov AL, Fraser P, Graupera M, Castillo SD, Sardina JL, Valencia A, Javierre BM.
p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response
Nat Commun. 2024 Apr 1;15(1):2821. doi: 10.1038/s41467-024-46666-1.
PMID: 38561401 - Citations: 8 [05/03/2025]
IF: 14,7 - QUARTIL 1

Lopez-Millan B, Rubio-Gayarre A, Vinyoles M, Trincado JL, Fraga MF, Fernandez-Fuentes N, Guerrero- Murillo M, Martinez-Moreno A, Velasco-Hernandez T, Falgàs A, Panisello C, Valcarcel G, Sardina JL, López-Martí P, Javierre BM, Del Valle-Pérez B, García de Herreros A, Locatelli F, Pieters R, Bardini M, Cazzaniga G, Rodríguez-Manzaneque JC, Hanewald T, Marschalek R, Milne TA, Stam RW, Tejedor JRR, Menendez P, Bueno C. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression
Blood. 2024 Nov 7;144(19):2002-2017. doi: 10.1182/blood.2023022050.
PMID: 39093982 - Citations: 2 [05/03/2025]
IF: 21,1 - QUARTIL 1

Kodali S, Proietti L, Valcarcel G, López-Rubio AV, Pessina P, Eder T, Shi J, Jen A, Lupión-Garcia N, Starner AC, Bartels MD, Cui Y, Sands CM, Planas-Riverola A, Martínez A, Velasco-Hernandez T, Tomás-Daza L, Alber B, Manhart G, Mayer IM, Kollmann K, Fatica A, Menendez P, Shishkova E, Rau RE, Javierre BM, Coon J, Chen Q, Van Nostrand EL, Sardina JL, Grebien F, Di Stefano B.
RNA sequestration in P-bodies sustains myeloid leukaemia
Nat Cell Biol. 2024 Oct;26(10):1745-1758. doi:

10.1038/s41556-024-01489-6. Epub 2024 Aug 21.
PMID: 39169219 - Citations: 2 [05/03/2025]
IF: 17,3 - QUARTIL 1

Andres Gamez-Garcia, Maria Espinosa-Alcantud, Alberto Bueno-Costa, Elisenda Alari-Pahissa, Anna Marazuela-Duque, Joshua K. Thackray, Chandni Ray, Clara Berenguer, Poonam Kumari, Joan Josep Bech, Thomas Braun, Alessandro Ianni, Jay A. Tischfield, Lourdes Serrano, Manel Esteller, Jose L. Sardina, Carolina De La Torre, Mikael Sigvardsson, Berta N. Vazquez; Alejandro Vaquero
A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5 Nat Immunol. 2024 Dec;25(12):2308-2319. doi: 10.1038/s41590-024-01995-7. Epub 2024 Oct 18.
PMID: 39424985 - Citations: 3 [05/03/2025]
IF: 27,7 - QUARTIL 1

Barrero M, Lazarenkov A, Blanco E, Palma LG, López-Rubio AV, Bauer M, Bigas A, Di Croce L, Sardina JL, Payer B.
The interferon γ pathway enhances pluripotency and X-chromosome reactivation in iPSC reprogramming Sci Adv. 2024 Aug 9;10(32):eadj8862. doi: 10.1126/sciadv.adj8862. Epub 2024 Aug 7.
PMID: 39110794 - Citations: 0 [05/03/2025]
IF: 11,7 - QUARTIL 1

Hematological diseases, transplant, and cell therapy
Jordi Sierra

Esquirol A, Cadenas IG, Novelli S, Garrido A, Caballero AC, Oñate G, Lopez J, Redondo S, Argüello M, Saavedra S, Moreno C, Briones J, Sierra J, Martino R.
Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience Ann Hematol. 2024 Jan;103(1):321-334. doi: 10.1007/s00277-023-05530-w. Epub 2023 Nov 16.
PMID: 37971549 - Citations: 1 [05/03/2025]
IF: 3 - QUARTIL 2

Redondo S, García-Cadenas I, Esquirol A, Portos JM, Iranzo E, Arguello-Tomas M, Saavedra S, Oñate G, Caballero AC, Garrido A, López J, Muntañola A, Paviglianiti A, Miqueleiz S, Sierra J, Briones J, Martino R.
Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation
Eur J Haematol. 2024 Dec;113(6):776-787. doi: 10.1111/ejh.14294. Epub 2024 Aug 18.
PMID: 39155459 - Citations: 0 [05/03/2025]
IF: 2,3 - QUARTIL 2

Esquirol A, Pascual MJ, Montoro J, Piñana JL, Ferrà C, Herruzo B, Garcia-Cadenas I, Balaguer A, Perez A, Huguet M, Redondo S, Villalba M, Hernandez-Boluda JC, Chorao P, Hernani R, Sanz J, Solano C, Sierra J, Martino R Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil
Transplant Cell Ther. 2024 Oct;30(10):1025.e1-1025.e14. doi: 10.1016/j.jtct.2024.07.027. Epub 2024 Aug 6. PMID: 39116938.
PMID: 39116938 - Citations: 0 [05/03/2025]
IF: 3,6 - QUARTIL 1

Leukemia and immuno-oncology
Laura Belver

Campagnari A, Belver L.
NOTCH1-Induced T-Cell Acute Lymphoblastic Leukemia In Vivo Models. Methods Mol Biol. 2024;2773:9-24. doi: 10.1007/978-1-0716-3714-2_2.
PMID: 38236532 - Citations: 0 [05/03/2025]

Myelodysplastic syndromes
Francesc Solé

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, Roue G, Valcárcel D, Molero A, Zamora L, Xicoy B, Palomo L, Acha P,

Manzanares A, Tobiasson M, Hellström-Lindberg E, Sole F, Esteller M. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy Cancer Res Commun. 2024 Feb 12;4(2):365-377. doi: 10.1158/2767-9764.CRC-23-0389.
PMID: 38300528 - Citations: 4 [05/03/2025]
IF: 2 - QUARTIL 3

Díez-Alonso L, Falgas A, Arroyo-Ródenas J, Romencín PA, Martínez A, Gómez-Rosel M, Blanco B, Jiménez-Reinoso A, Mayado A, Pérez-Pons A, Aguilar-Sopeña Ó, Ramírez-Fernández Á, Segura-Tudela A, Perez-Amill L, Tapia-Galisteo A, Domínguez-Alonso C, Rubio-Pérez L, Jara M, Solé F, Hangiu O, Almagro L, Albitre Á, Penela P, Sanz L, Anguita E, Valeri A, García-Ortiz A, Río P, Juan M, Martínez-López J, Roda-Navarro P, Martín-Antonio B, Orfao A, Menéndez P, Bueno C, Álvarez-Vallina L.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo
Sci Transl Med. 2024 Feb 14;16(734):eadg7962. doi: 10.1126/scitranslmed.adg7962
PMID: 38354229 - Citations: 6 [05/03/2025]
IF: 15,8 - QUARTIL 1

Bistué-Rovira À, Rico LG, Bardina J, Juncà J, Granada I, Bradford JA, Ward MD, Salvia R, Solé F, Petriz J. Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib: Implications for Therapy Resistance
Int J Mol Sci. 2024 Feb 7;25(4):1994. doi: 10.3390/ijms25041994.
PMID: 38396682 - Citations: 0 [05/03/2025]
IF: 4,9 - QUARTIL 1

Noguera-Castells A, Campillo-Marcos I, Davalos V, García-Prieto CA, Valcárcel D, Molero A, Palomo L, Gattermann N, Wulfert M, Chaparro-González L, Solé F, Cabezón M, Jiménez-Lorenzo MJ, Xicoy B, Zamora L, De Stefano A, Casalin I, Finelli C, Follo MY, Esteller M.
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study
Br J Haematol. 2024 May;204(5):1838-1843. doi: 10.1111/bjh.19392. Epub 2024 Mar 12.
PMID: 38471524 - Citations: 2 [05/03/2025]
IF: 5,1 - QUARTIL 1

Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa JE, Kosmider O, Hasserjian RP, Jädersten M, Germing U, Sanz GF, van de Loosdrecht AA, Gurnari C, Follo MY, Thol FR, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase DT, Sander B, Orna E, Zoldan K, Eder LN, Sperr WR, Thalhammer R, Ganster C, Adès L, Tobiasson M, Palomo L, Della Porta MG, Huberman KH, Fenaux P, Belickova M, Savona MR, Klimek V, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Finelli C, Voso MT, Shih LY, Ogawa S, Fontenay M, Jansen JH, Cervera J, Ebert BL, Bejar R, Greenberg PL, Gattermann N, Malcovati L, Cazzola M, Beck DB, Hellstrom-Lindberg ES, Papaemmanuil E.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Blood. 2024 Sep 12;144(11):1221-1229. doi: 10.1182/blood.2023023723.
PMID: 38687605 - Citations: 10 [05/03/2025]
IF: 21,1 - QUARTIL 1

Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET; Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. GenoMed4all and Synthema Consortiums (B.Xicoy en els Colaboradors)
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
J Clin Oncol. 2024 Aug 20;42(24):2873-2886. doi: 10.1200/JCO.23.02175. Epub 2024 May 9
PMID: 38723212 - Citations: 6 [05/03/2025]
IF: 42,1 - QUARTIL 1

Serrano G, Berastegui N, Díaz-Mazkiaran A, García-Olloqui P, Rodriguez-Res C, Huerga-Dominguez S, Ainciburu M, Vilas-Zornoza A, Martin-Uriz PS, Aguirre-Ruiz P, Ullate-Agote A, Ariceta B, Lamo-Espinosa JM, Acha P, Calvete O, Jimenez T, Molero A, Montoro MJ, Díez-Campelo M, Valcarcel D, Solé F, Alfonso-Pierola A, Ochoa I, Prósper F, Ezponda T, Hernaez M.
Single-cell transcriptional profile of CD34+hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

Nat Commun. 2024 Jun 20;15(1):5272. doi: 10.1038/s41467-024-49529-x.
PMID: 38902243 - Citations: 0 [05/03/2025]
IF: 14,7 - QUARTIL 1

Bernard E, Hasserjian RP, Greenberg PL, Arango Ossa JE, Creignou M, Tuechler H, Gutiérrez-Abril J, Domenico D, Medina-Martinez JS, Levine MF, Liosis K, Farnoud N, Sirenko M, Jädersten M, Germing U, Sanz GF, Van de Loosdrecht AA, Nannya Y, Kosmider O, Follo MY, Thol FR, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase DT, Ganster C, Ades L, Tobiasson M, Palomo L, Della Porta MG, Fenaux P, Belickova M, Savona MR, Klimek V, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Ogawa S, Cazzola M, Hellstrom-Lindberg ES, Papaemmanuil E.
Molecular taxonomy of myelodysplastic syndromes and its clinical implications
Blood. 2024 Oct 10;144(15):1617-1632. doi: 10.1182/blood.2023023727.
PMID: 38958467 - Citations: 9 [05/03/2025]
IF: 21,1 - QUARTIL 1

Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al- Ali N, Xicoy B, Lopez F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Díaz Varela N, Platzbecker U, Haase DT, Díez-Campelo M, Della Porta MG, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D.
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion Blood. 2024 Oct 17;144(16):1722-1731. doi: 10.1182/blood.2024023840.
PMID: 39074355 - Citations: 2 [05/03/2025]
IF: 21,1 - QUARTIL 1

Mestre J, Chaparro L, Manzanares A, Xicoy B, Zamora L, Sole F, Calvete O.
Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants
EJHaem. 2024 Oct 2;5(5):1021-1027. doi: 10.1002/jha2.1012. eCollection 2024 Oct.
PMID: 39415912 - Citations: 0 [05/03/2025]

Myeloid neoplasms

Blanca Xicoy & Lurdes Zamora

Griffin M, Eikema DJ, Verheggen I, Kulagin A, Tjon JM, Fattizzo B, Ingram W, Zaidi U, Desnica L, Giammarco S, Drozd-Sokolowska J, Xicoy B, Patriarca A, Loschi M, Szmigielska-Kaplon A, Beier F, Cignetti A, Drexler B, Gavriilaki E, Lanza F, Orvain C, Risitano AM, De la Camara R, De Latour RP.
SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria
Haematologica. 2024 Jan 1. doi: 10.3324/haematol.2023.283863.
PMID: 37584297 - Citations: 1 [05/03/2025]
IF: 8,2 - QUARTIL 1

Castaño-Díez S, Pomares H, Esteban D, Guijarro F, Jiménez-Vicente C, Zugasti I, Álamo JR, Mayayo VT, López- Guerra M, de la Fuente C, Charry P, Cortés-Bullich A, Bataller Á, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Díaz-Beyá M.
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic
Br J Haematol. 2024 Mar;204(3):892-897. doi: 10.1111/bjh.19217. Epub 2023 Nov 27.
PMID: 38013238 - Citations: 4 [05/03/2025]
IF: 5,1 - QUARTIL 1

Vallejo C, Rosell A, Xicoy B, García C, Albo C, Polo M, Jarque I, Esteban B, Codesido ML.
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Ann Hematol. 2024 Mar;103(3):705-713. doi: 10.1007/s00277-023-05602-x. Epub 2024 Jan 4.
PMID: 38175253 - Citations: 0 [05/03/2025]
IF: 3 - QUARTIL 2

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, Roue G, Valcárcel D, Molero A, Zamora L, Xicoy B, Palomo L, Acha P, Manzanares A, Tobiasson M, Hellström-Lindberg E, Sole F, Esteller M. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy Cancer Res Commun. 2024 Feb 12;4(2):365-377. doi: 10.1158/2767-9764.CRC-23-0389.
PMID: 38300528 - Citations: 4 [05/03/2025]
IF: 2 - QUARTIL 3

Hernández-Sánchez A, Villaverde-Ramiro Á, Arellano-Rodrigo E, Garrote M, Martín I, Mosquera-

Orgueira A, Gómez- Casares MT, Ferrer-Marín F, Such E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, de Villambrosía SG, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín A, Raya JM, González JA, Cuevas B, Xicoy B, Pérez-Encinas M, Bellosillo B, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC; Spanish MPN Group (GEMFIN).
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis Am J Hematol. 2024 Apr;99(4):755-758. doi: 10.1002/ajh.27203. Epub 2024 Jan 30.
PMID: 38291566 - Citations: 4 [05/03/2025]
IF: 10,1 - QUARTIL 1

Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L; Grupo Español de Leucemia Mieloide Crónica (GELMC).
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
J Clin Med. 2024 Jan 29;13(3):779. doi: 10.3390/jcm13030779.
PMID: 38337473 - Citations: 2 [05/03/2025]
IF: 3 - QUARTIL 1

Mosquera Orgueira A, Perez Encinas MM, Diaz Varela N, Wang YH, Mora E, Diaz-Beya M, Montoro MJ, Pomares Marin H, Ramos Ortega F, Tormo M, Jerez A, Nomdedeu J, de Miguel Sanchez C, Arenillas L, Carcel P, Cedena Romero MT, Xicoy Cirici B, Rivero Arango E, Del Orbe Barreto RA, Benlloch L, Lin CC, Tien HF, Pérez Míguez C, Crucitti D, Díez Campelo M, Valcárcel D.
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
Br J Haematol. 2024 Apr;204(4):1529-1535. doi: 10.1111/bjh.19341. Epub 2024 Feb 27.
PMID: 38411250 - Citations: 0 [05/03/2025]
IF: 5,1 - QUARTIL 1

Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4.
PMID: 38438627 - Citations: 4 [05/03/2025]
IF: 3 - QUARTIL 2

Noguera-Castells A, Campillo-Marcos I, Davalos V, García-Prieto CA, Valcárcel D, Molero A, Palomo L, Gattermann N, Wulfert M, Chaparro-González L, Solé F, Cabezón M, Jiménez-Lorenzo MJ, Xicoy B, Zamora L, De Stefano A, Casalin I, Finelli C, Follo MY, Esteller M.
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study
Br J Haematol. 2024 May;204(5):1838-1843. doi: 10.1111/bjh.19392. Epub 2024 Mar 12.
PMID: 38471524 - Citations: 2 [05/03/2025]
IF: 5,1 - QUARTIL 1

Mosquera-Orgueira A, Arellano-Rodrigo E, Garrote M, Martín I, Pérez-Encinas M, Gómez-Casares MT, Hernández- Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, Heras NL, Magro E, Pérez-Míguez C, Crucitti D, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Nangalia J, Hernández-Rivas JM, Bellosillo B, Álvarez- Larrán A, Hernández-Boluda JC; Spanish MPN Group (GEMFIN).
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis Hemasphere. 2024 Mar 20;8(3):e60. doi: 10.1002/hem3.60. eCollection 2024 Mar.
PMID: 38510992 - Citations: 1 [05/03/2025]
IF: 12,1 - QUARTIL 1

Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M.
Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study Blood Adv. 2024 Jun 11;8(11):2691-2694. doi: 10.1182/bloodadvances.2023012479.
PMID: 38536941 - Citations: 4 [05/03/2025]
IF: 7,4 - QUARTIL 1

Pérez-Lamas L, de Paz Arias R, Díaz RMA, Montero LFC, Payer ÁR, Sierra M, Marín FF, López RP, Cirici BX, Steegmann JL, Gómez Casares MT, Martínez-López J, García-Gutiérrez V.

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Ann Hematol. 2024 Oct;103(10):4045-4055. doi: 10.1007/s00277-024-05662-7. Epub 2024 Apr 3.
PMID: 38568260 - Citations: 1 [05/03/2025]
IF: 3 - QUARTIL 2

Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa JE, Kosmider O, Hasserjian RP, Jädersten M, Germing U, Sanz GF, van de Loosdrecht AA, Gurnari C, Follo MY, Thol FR, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase DT, Sander B, Orna E, Zoldan K, Eder LN, Sperr WR, Thalhammer R, Ganster C, Adès L, Tobiasson M, Palomo L, Della Porta MG, Huberman KH, Fenaux P, Belickova M, Savona MR, Klimek V, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Finelli C, Voso MT, Shih LY, Ogawa S, Fontenay M, Jansen JH, Cervera J, Ebert BL, Bejar R, Greenberg PL, Gattermann N, Malcovati L, Cazzola M, Beck DB, Hellstrom-Lindberg ES, Papaemmanuil E.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood. 2024 Sep 12;144(11):1221-1229. doi: 10.1182/blood.2023023723.
PMID: 38687605 - Citations: 10 [05/03/2025]
IF: 21,1 - QUARTIL 1

Bernard E, Hasserjian RP, Greenberg PL, Arango Ossa JE, Creignou M, Tuechler H, Gutiérrez-Abril J, Domenico D, Medina-Martinez JS, Levine MF, Liosis K, Farnoud N, Sirenko M, Jädersten M, Germing U, Sanz GF, Van de Loosdrecht AA, Nannya Y, Kosmider O, Follo MY, Thol FR, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase DT, Ganster C, Ades L, Tobiasson M, Palomo L, Della Porta MG, Fenaux P, Belickova M, Savona MR, Klimek V, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Ogawa S, Cazzola M, Hellstrom- Lindberg ES, Papaemmanuil E.
Molecular taxonomy of myelodysplastic syndromes and its clinical implications Blood. 2024 Oct 10;144(15):1617-1632. doi: 10.1182/blood.2023023727.
PMID: 38958467 - Citations: 9 [05/03/2025]
IF: 21,1 - QUARTIL 1

Díez-Campelo M, López-Cadenas F, Xicoy B, Lumbreras E, González T, Del Rey González M, Sánchez-García J, Coll Jordà R, Slama B, Hernández-Rivas JÁ, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Götze KS, Arar A, Toribio S, Del Cañizo C, Hernández-Rivas JM, Fenaux P.
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3trial
Lancet Haematol. 2024 Sep;11(9):e659-e670. doi: 10.1016/S2352-3026(24)00142-X. Epub 2024 Jul 18.
PMID: 39033767 - Citations: 2 [05/03/2025]
IF: 15,4 - QUARTIL 1

Xicoy B, Pomares H, Morgades M, Germing U, Arnan M, Tormo M, Palomo L, Orna E, Della Porta M, Schulz F, Díaz-Beya M, Esteban A, Molero A, Lanino L, Avendaño A, Hernández F, Roldan V, Ubezio M, Pineda A, Díez- Campelo M, Zamora L.
Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis Front Oncol. 2024 Jul 1;14:1385987. doi: 10.3389/fonc.2024.1385987. eCollection 2024.
PMID: 39011475 - Citations: 0 [05/03/2025]
IF: 3,5 - QUARTIL 2

Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al- Ali N, Xicoy B, Lopez F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Díaz Varela N, Platzbecker U, Haase DT, Díez-Campelo M, Della Porta MG, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D.
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion Blood. 2024 Oct 17;144(16):1722-1731. doi: 10.1182/blood.2024023840.
PMID: 39074355 - Citations: 2 [05/03/2025]
IF: 21,1 - QUARTIL 1

Pastor-Galán I, Pereira A, Arellano-Rodrigo E, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Hernández- Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Garrote M, Ferrer B, Pérez-Encinas M, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC.
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia. 2024 Nov;38(11):2483-2486. doi: 10.1038/s41375-024-02389-2. Epub 2024 Aug 30.
PMID: 39215061 - Citations: 0 [05/03/2025]
IF: 12,8 - QUARTIL 1

Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, Iurlo A, Kim I, Rose S, Brown P, Hernandez C, Wang J, Kiladjian JJ.
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3trial
Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9.
PMID: 39265613 - Citations: 4 [05/03/2025]
IF: 15,4 - QUARTIL 1

García-Gutiérrez V, Gómez-Casares MT, Xicoy B, Casado-Montero F, Orti G, Giraldo P, Hernández-Boluda JC.
Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia
Front Oncol. 2024 Aug 26;14:1405467. doi: 10.3389/fonc.2024.1405467. eCollection 2024.
PMID: 39252937 - Citations: 0 [05/03/2025]
IF: 3,5 - QUARTIL 2

López-Gómez, J.; Villarreal, L.; Andrés, M.; Ponte, I.; Xicoy, B.; Zamora, L.; Vilaseca, M.; Roque, A Quantification of Histone H1 Subtypes Using Targeted Proteomics Biomolecules 2024, 14(10), 1221; https://doi.org/10.3390/biom14101221
PMID: 39456154 - Citations: 0 [05/03/2025]
IF: 4,8 - QUARTIL 1

Mestre J, Chaparro L, Manzanares A, Xicoy B, Zamora L, Sole F, Calvete O.
Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants
EJHaem. 2024 Oct 2;5(5):1021-1027. doi: 10.1002/jha2.1012. eCollection 2024 Oct.
PMID: 39415912 - Citations: 0 [05/03/2025]

Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET; Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. GenoMed4all and Synthema Consortiums (B.Xicoy en els Colaboradors)
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
J Clin Oncol. 2024 Aug 20;42(24):2873-2886. doi: 10.1200/JCO.23.02175. Epub 2024 May 9
PMID: 38723212 - Citations: 6 [05/03/2025]
IF: 42,1 - QUARTIL 1

Myeloid neoplasms - Hospital Clínic

Jordi Esteve

Castaño-Díez S, Pomares H, Esteban D, Guijarro F, Jiménez-Vicente C, Zugasti I, Álamo JR, Mayayo VT, López- Guerra M, de la Fuente C, Charry P, Cortés-Bullich A, Bataller Á, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Díaz-Beyá M.
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic
Br J Haematol. 2024 Mar;204(3):892-897. doi: 10.1111/bjh.19217. Epub 2023 Nov 27.
PMID: 38013238 - Citations: 4 [05/03/2025]
IF: 5,1 - QUARTIL 1

Castaño-Díez S, Guijarro F, López-Guerra M, Pérez-Valencia AI, Gómez-Núñez M, Colomer D, Díaz-Beyá M, Esteve J, Rozman M.
Infrequent Presentations of Chronic NPM1-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the Literature
Cancers (Basel). 2024 Feb 7;16(4):705. doi: 10.3390/cancers16040705.
PMID: 38398096 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Oncogenesis and antitumor drug group

Ramon Mangues

Sánchez JM, López-Laguna H, Parladé E, Somma AD, Livieri AL, Álamo P, Mangues R, Unzueta U, Villaverde A, Vázquez E.
Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids
Adv Sci (Weinh). 2024 Jun;11(21):e2309427. doi: 10.1002/

advs.202309427. Epub 2024 Mar 19.
PMID: 38501900 - Citations: 4 [05/03/2025]
IF: 14,3 - QUARTIL 1

Virgili AC, Salazar J, Gallardo A, López-Pousa A, Terés R, Bagué S, Orellana R, Fumagalli C, Mangues R, Alba-Castellón L, Unzueta U, Casanova I, Sebio A.
CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas
Diagnostics (Basel). 2024 Jun 6;14(11):1195. doi: 10.3390/diagnostics14111195.
PMID: 38893721 - Citations: 0 [05/03/2025]
IF: 3 - QUARTIL 1

Favaro, MTP; Alamo, P; Roher, N; Chillon, M; Lascorz, J; Márquez, M; Corchero, JL; Mendoza, R; Martínez-Torró, C; Ferrer-Miralles, N; Ferreira, LCS; Mangues, R; Vázquez, E; Parladé, E; Villaverde, A
Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses
ACS MATERIALS LETTERS 2024; Vol 6; Issue 3
PMID: '0000 - Citations: 1 [05/03/2025]
IF: 9,6 - QUARTIL 1

Parladé E, García-Leon A, Voltà-Durán E, Unzueta U, Mangues R, Casanova I, Villaverde A, Vázquez E. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles
Eur J Pharm Biopharm. 2024 Sep:202:114410. doi: 10.1016/j.ejpb.2024.114410. Epub 2024 Jul 14. PMID: 39004320 - Citations: 0 [05/03/2025]
IF: 4,4- QUARTIL 1

Marianna TP Favaro, Hèctor López-Laguna, Eric Voltà-Durán, Lorena Alba-Castellon, Julieta M. Sánchez, Isolda Casanova, Ugutz Unzueta, Ramón Mangues, Antonio Villaverde, Esther Vázquez.
Lyophilization of biomimetic amyloids preserves their regulatable, endocrine-like functions for nanoparticle release
APPL MATER TODAY 2024 Aug; 39: 102348 doi: 10.1016/j.apmt.2024.102348
PMID: '00000 - Citations: 1 [05/03/2025]
IF: 7,2 - QUARTIL 1

Transcriptional dynamics in leukemia
Sergi Cuartero

Kalita B, Sahu S, Bharadwaj A, Panneerselvam L, Martinez-Cebrian G, Agarwal M, Mathew SJ.
The Wnt-pathway corepressor TLE3 interacts with the histone methyltransferase KMT1A to inhibit differentiation in Rhabdomyosarcoma
Oncogene. 2024 Feb;43(7):524-538. doi: 10.1038/s41388-023-02911-3. Epub 2024 Jan 4.
PMID: 38177411 - Citations: 1 [05/03/2025]
IF: 6,9 - QUARTIL 1

Wang W, Dernst A, Martin B, Lorenzi L, Cadefau-Fabregat M, Phulphagar K, Wagener A, Budden C, Stair N, Wagner T, Färber H, Jaensch A, Stahl R, Duthie F, Schmidt SV, Coll RC, Meissner F, Cuartero S, Latz E, Mangan MSJ.
Butyrate and propionate are microbial danger signals that activate the NLRP3 inflammasome in human macrophages upon TLR stimulation
Cell Rep. 2024 Sep 24;43(9):114736. doi: 10.1016/j.celrep.2024.114736. Epub 2024 Sep 13.
PMID: 39277863 - Citations: 4 [05/03/2025]
IF: 7,5 - QUARTIL 1

Barcelona endothelium team
Enric Carreras

Escribano-Serrat S, Rodríguez-Lobato LG, Charry P, Martínez-Cibrian N, Suárez-Lledó M, Rivero A, Moreno-Castaño AB, Solano MT, Arcarons J, Nomdedeu M, Cid J, Lozano M, Pedraza A, Rosiñol L, Esteve J, Urbano-Ispizua Á, Palomo M, Fernández-Avilés F, Martínez C, Díaz-Ricart M, Carreras E, Rovira M, Salas MQ.
Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post- transplant cyclophosphamide-based prophylaxis
Cytotherapy. 2024 Jan 15:S1465-3249(23)01097-6. doi: 10.1016/j.jcyt.2023.10.008. PMID: 37952139 - Citations: 3 [05/03/2025]
IF: 3,7 - QUARTIL 1

Brusosa M, Ruiz S, Monge I, Solano MT, Rosiñol L, Esteve J, Carreras E, Marcos MÁ, Riu G, Carcelero E, Martinez C,
Fernández-Avilés F, Rovira M, Suárez-Lledó M, Salas MQ.
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study
Ann Hematol. 2024 Feb;103(2):609-621. doi: 10.1007/s00277-023-05542-6. Epub 2023 Nov 14. PMID:

37957371 - Citations: 5 [05/03/2025]
IF: 3 - QUARTIL 2

Youssef L, Testa L, Crovetto F, Crispi F.
10. Role of high dimensional technology in preeclampsia (omics in preeclampsia)
Best Pract Res Clin Obstet Gynaecol. 2024 Feb:92:102427. doi: 10.1016/j.bpobgyn.2023.102427. Epub 2023 Nov 18.
PMID: 37995432 - Citations: 1 [05/03/2025]
IF: 3,9 - QUARTIL 1

Pedraza A, Salas MQ, Rodríguez-Lobato LG, Escribano-Serrat S, Suárez-Lledo M, Martínez-Cebrian N, Solano MT, Arcarons J, Rosiñol L, Gutiérrez-García G, Fernández-Avilés F, Moreno-Castaño AB, Molina P, Pino M, Carreras E, Díaz-Ricart M, Rovira M, Palomo M, Martínez C.
Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation
Transplant Cell Ther. 2024 Feb;30(2):187.e1-187.e12. doi: 10.1016/j.jtct.2023.11.016. Epub 2023 Nov 23. PMID: 38000709 - Citations: 8 [05/03/2025]
IF: 3,2 - QUARTIL 2

Salas MQ, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LG, Brusosa M, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Arcarons J, de Llobet N, Rosiñol L, Esteve J, Urbano-Ispizua Á, Carreras E, Fernández-Avilés F, Rovira M, Martinez C.
Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations
Transplant Cell Ther. 2024 Feb;30(2):213.e1-213.e12. doi: 10.1016/j.jtct.2023.11.020. Epub 2023 Nov 30. PMID: 38042256 - Citations: 6 [05/03/2025]
IF: 3,6 - QUARTIL 1

Samanbar S, Piñeyroa JA, Moreno-Castaño AB, Pino M, Torramadé-Moix S, Martinez-Sanchez J, Lozano M, Sanz C, Escolar G, Diaz-Ricart M.
T-TAS® 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion
Blood Transfus. 2024 Mar;22(2):166-175. doi: 10.2450/BloodTransfus.550. Epub 2023 Nov 29. PMID: 38063791 - Citations: 3 [05/03/2025]
IF: 2,4 - QUARTIL 2

Escribano-Serrat S, Rodríguez-Lobato LG, Suárez-Lledó M, Pedraza A, Charry P, Cid J, Lozano M, Esteve J, Rosiñol L, Fernández-Avilés F, Carreras E, Díaz-Ricart M, Martínez C, Rovira M, Salas MQ.
Improving the EASIX' predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation Bone Marrow Transplant. 2024 Jul;59(7):1022-1024. doi: 10.1038/s41409-024-02267-6. Epub 2024 Mar 23. PMID: 38521886 - Citations: 1 [05/03/2025]
IF: 4,5 - QUARTIL 1

Tolosa-Ridao C, Cascos E, Rodríguez-Lobato LG, Pedraza A, Suárez-Lledó M, Charry P, Solano MT, Martinez-Sanchez J, Cid J, Lozano M, Rosiñol L, Esteve J, Urbano-Ispizua Á, Fernández-Avilés F, Martínez C, Carreras E, Díaz-Ricart M, Rovira M, Salas MQ.
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation
Bone Marrow Transplant. 2024 Jul;59(7):974-982. doi: 10.1038/s41409-024-02270-x. Epub 2024 Mar 23. PMID: 38521885 - Citations: 1 [05/03/2025]
IF: 4,5 - QUARTIL 1

Jiménez-Vicente C, Charry P, Castaño-Diez S, Guijarro F, López-Guerra M, Pérez-Valencia AI, Martinez-Roca A, Cortés-Bullich A, Munárriz D, Solano MT, Rosiñol L, Carreras E, Urbano-Ispizua Á, Fernández-Avilés F, Martinez C, Suárez-Lledó M, Díaz-Beyá M, Rovira M, Salas MQ, Esteve J.
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
Br J Haematol. 2024 Jul;205(1):256-267. doi: 10.1111/bjh.19518. Epub 2024 May 29. PMID: 38811025 - Citations: 2 [05/03/2025]
IF: 5,1 - QUARTIL 1

Castro-Barquero S, Crovetto F, Estruch R, María Ruiz-León A, Larroya M, Sacanella E, Casanovas-Garriga F, Casas I, Nakaki A, Youssef L, Trejo-Domínguez A, Benitez L, Genero M, Vieta E, Gratacós E, Crispi F, Casas R.
Validation of a pregnancy-adapted Mediterranean Diet Adherence Screener (preg-MEDAS): a validation study nested in the Improving Mothers for a better PrenAtal Care Trial BarCeloNa (IMPACT BCN) trial
Am J Clin Nutr. 2024 Aug;120(2):449-458. doi: 10.1016/j.ajcnut.2024.05.025. Epub 2024 Jun 1 PMID: 38830408 - Citations: 0 [05/03/2025]
IF: 6,5 - QUARTIL 1

Nakaki A, Gomez Y, Castro-Barquero S, Conti A, Vellvé K, Casas I, Genero M, Youssef L, Segalés L, Benitez L, Casas R, Vieta E, Bargallo N, Toschi N, Estruch R, Crispi F, Gratacos E, Crovetto F.
The Mediterranean Diet in Pregnancy: Implications

for Maternal Brain Morphometry in a Secondary Analysis of the IMPACT BCN Randomized Clinical Trial Nutrients. 2024 May 24;16(11):1604. doi: 10.3390/nu16111604.
PMID: 38892540 - Citations: 0 [05/03/2025]
IF: 4,8 - QUARTIL 1

Benítez L, Castro-Barquero S, Crispi F, Youssef L, Crovetto F, Fischer U, Kameri E, Bueno C, Camos M, Menéndez P, Heinäniemi M, Borkhardt A, Gratacós E.
Maternal Lifestyle and Prenatal Risk Factors for Childhood Leukemia: A Review of the Existing Evidence Fetal Diagn Ther. 2024;51(4):395-410. doi: 10.1159/000539141. Epub 2024 May 7.
PMID: 38710162 - Citations: 0 [05/03/2025]
IF: 1,6 - QUARTIL 3

Nakaki A, Denaro E, Crimella M, Castellani R, Vellvé K, Izquierdo N, Basso A, Paules C, Casas R, Benitez L, Casas I, Larroya M, Genero M, Castro-Barquero S, Gomez-Gomez A, Pozo ÓJ, Vieta E, Estruch R, Nadal A, Gratacós E, Crovetto F, Crispi F, Youssef L.
Effect of Mediterranean diet or mindfulness-based stress reduction during pregnancy on placental volume and perfusion: A subanalysis of the IMPACT BCN randomized clinical trial
Acta Obstet Gynecol Scand. 2024 Oct;103(10):2042-2052. doi: 10.1111/aogs.14874. Epub 2024 Jul 22. PMID: 39037192 - Citations: 1 [05/03/2025]
IF: 3,5 - QUARTIL 1

Escribano-Serrat S, Pedraza A, Suárez-Lledó M, Charry P, De Moner B, Martinez-Sanchez J, Ramos A, Ventosa- Capell H, Moreno C, Guardia L, Monge-Escartín I, Riu G, Carcelero E, Cid J, Lozano M, Gómez P, García E, Martín L, Carreras E, Fernández-Avilés F, Martínez C, Rovira M, Salas MQ, Díaz-Ricart M.
Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation
Bone Marrow Transplant. 2024 Oct;59(10):1466-1476. doi: 10.1038/s41409-024-02388-y. Epub 2024 Aug 8.
PMID: 39117736 - Citations: 1 [05/03/2025]
IF: 4,5 - QUARTIL 1

Murillo V, Charry P, Suárez-Lledó M, Guardia L, Moreno C, Cid J, Lozano M, Pedraza A, Salinas R, Vilas V, Duch M, Díaz-Beya M, Rosiñol L, Esteve J, Carreras E, Fernández-Avilés F, Martínez C, Rovira M, Salas MQ.
Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide based prophylaxis
Eur J Haematol. 2024 Dec;113(6):765-775. doi: 10.1111/ejh.14291. Epub 2024 Aug 14. PMID: 39143681 - Citations: 0 [05/03/2025]
IF: 2,3 - QUARTIL 2

Abadía-Cuchí N, Clavero-Adell M, González J, Medel-Martinez A, Fabre M, Ayerza-Casas A, Youssef L, Lerma-Irureta J, Maestro-Quibus P, Rodriguez-Calvo J, Ruiz-Martinez S, Lerma D, Schoolermer J, Oros D, Paules C
Impact of suspected preterm labour in foetal cardiovascular and metabolic programming: a prospective cohort study protocol
BMJ Open. 2024 Nov 24;14(11):e087430. doi: 10.1136/bmjopen-2024-087430. PMID: 39581725 - Citations: 0 [05/03/2025]
IF: 2,4 - QUARTIL 1

Ramos A, Youssef L, Molina P, Torramadé-Moix S, Martinez-Sanchez J, Moreno-Castaño AB, Blasco M, Guillén- Olmos E, De Moner B, Pino M, Tortajada M, Camacho M, Borrell M, Crovetto F, Ramirez-Bajo MJ, Ventura-Aguiar P, Banon-Maneus E, Rovira J, Escolar G, Carreras E, Gratacos E, Diaz-Ricart M, Crispi F, Palomo M
Circulating extracellular vesicles and neutrophil extracellular traps contribute to endothelial dysfunction in preeclampsia
Front Immunol. 2024 Dec 13:15:1488127. doi: 10.3389/fimmu.2024.1488127. eCollection 2024
PMID: 39735539 - Citations: 0 [05/03/2025]
IF: 5,7 - QUARTIL 1

Salas MQ, Rodríguez-Lobato LG, Charry P, Suárez-Lledó M, Pedraza A, Solano MT, Arcarons J, Cid J, Lozano M, Rosiñol L, Esteve J, Carreras E, Fernández-Avilés F, Martínez C, Rovira M.
Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era.
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S3-S12. doi: 10.1016/j.htct.2023.07.008 PMID: 37891074 - Citations: 0 [05/03/2025]
IF: 1,8 - QUARTIL 3

Blood Stem Cell Identity

Vincenzo Calvanese

Aguadé-Gorgorió J, Jami-Alahmadi Y, Calvanese V, Kardouh M, Fares I, Johnson H, Rezek V, Ma F, Magnusson M, Wang Y, Shin JE, Nance KJ, Goodridge HS, Liebscher S, Schenke-Layland K, Crooks GM, Wohlschlegel JA, Mikkola HKA.

MYCT1 controls environmental sensing in human haematopoietic stem cells
Nature. 2024 Jun;630(8016):412-420. doi: 10.1038/s41586-024-07478-x. Epub 2024 Jun 5.
PMID: 38839950 - Citations: 5 [05/03/2025]
IF: 50,5- QUARTIL 1

Hematology Research

David Gallardo

Gonzalez-Montes Y, Osca-Gelis G, Rodriguez-Romanos R, Villavicencio A, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Gómez B, Granada I, Gallardo D. CD200 genotype is associated with clinical outcome of patients with multiple myeloma
Front Immunol. 2024 Feb 22;15:1252445. doi: 10.3389/fimmu.2024.1252445. eCollection 2024.
PMID: 38455039 - Citations: 1 [05/03/2025]
IF: 5,7 - QUARTIL 1

Stem cell transplantation and cellular Immunotherapy

Alvaro Urbano - Ispizua

Pedraza A, Salas MQ, Rodríguez-Lobato LG, Escribano-Serrat S, Suárez-Lledo M, Martínez-Cebrian N, Solano MT, Arcarons J, Rosiñol L, Gutiérrez-García G, Fernández-Avilés F, Moreno-Castaño AB, Molina P, Pino M, Carreras E, Díaz-Ricart M, Rovira M, Palomo M, Martínez C.
Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation
Transplant Cell Ther. 2024 Feb;30(2):187.e1-187.e12. doi: 10.1016/j.jtct.2023.11.016. Epub 2023 Nov 23. PMID: 38000709 - Citations: 8 [05/03/2025]
IF: 3,2 - QUARTIL 2

Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, Onida F, Sánchez-Ortega I, Burman J, Castilla Llorente C, Cervera R, Ciceri F, Doria A, Henes J, Lindsay J, Mackensen A, Muraro PA, Ricart E, Rovira M, Zuckerman T, Yakoub-Agha I, Farge D.
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
EClinicalMedicine. 2024 Feb 10;69:102476. doi: 10.1016/j.eclinm.2024.102476. eCollection 2024 Mar.
PMID: 38361991 - Citations: 17 [05/03/2025]
IF: 9,6 - QUARTIL 1

Giordano A, Rovira M, Veny M, Barastegui R, Marín P, Martínez C, Fernández-Avilés F, Suárez-Lledó M, Domènech A, Serrahima A, Lozano M, Cid J, Ordás I, Fernández-Clotet A, Caballol B, Gallego M, Vara A, Masamunt MC, Giner À, Teubel I, Esteller M, Corraliza AM, Panés J, Salas A, Ricart E.
Cyclophosphamide-free Mobilisation Increases Safety While Preserving the Efficacy of Autologous Haematopoietic Stem Cell Transplantation in Refractory Crohn's Disease Patients
J Crohns Colitis. 2024 Oct 15;18(10):1701-1712. doi: 10.1093/ecco-jcc/jjae076. PMID: 38757210 - Citations: 1 [05/03/2025]
IF: 8,3 - QUARTIL 1

Mora E, Montoro J, Balaguer A, Rovira M, Cabrero M, Heras I, Ribera JM, Antelo G, Martin AA, Lopez Godino O, Torrent A, Villalba M, Chorao P, Sanz MA, Sanz J; Grupo Español de Trasplante Hematopoyético (GETH).
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia
Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298-z PMID: 38755458 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Reményi P, Versluis J, Rovira M, Blaise D, Labussière- Wallet H, Montoro J, Sica S, Meijer E, Itälä-Remes M, Schaap N, Bulabois CE, Piemontese S, Mohty M, Ciceri F. Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT Blood. 2024 Jun 13;143(24):2534-2543. doi: 10.1182/blood.2023023697.
PMID: 38657278 - Citations: 13 [05/03/2025]
IF: 21,1 - QUARTIL 1

Piemontese S, Labopin M, Choi G, Broers AEC, Peccatori J, Meijer E, Van Gorkom G, Rovira M, Pascual Cascon MJ, Sica S, Vydra J, Kulagin A,

Spyridonidis A, Nagler A, Bazarbachi A, Savani B, Brissot E, Sanz J, Mohty M, Ciceri F. Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide
Leukemia. 2024 Sep;38(9):2016-2022. doi: 10.1038/s41375-024-02359-8. Epub 2024 Jul 24.
PMID: 39048722 - Citations: 2 [05/03/2025]
IF: 12,8 - QUARTIL 1

Juárez A, Salas MQ, Pedraza A, Suárez-Lledó M, Rodríguez-Lobato LG, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Charry P, Arcarons J, Llobet N, Rosiñol L, Fernández-Avilés F, Rovira M, Martínez C.
Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study
Cancers (Basel). 2024 Jul 17;16(14):2567. doi: 10.3390/cancers16142567. PMID: 39061206 - Citations: 2 [05/03/2025]
IF: 4,5 - QUARTIL 1

Piñana JL, Giménez E, Vázquez L, Marcos MÁ, Guerreiro M, Duarte R, Pérez A, de Miguel C, Espigado I, González- Vicent M, Suarez-Lledó M, García-Cadenas I, Martino R, Cedillo A, Rovira M, de la Cámara R, Navarro D, Solano C. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024065. doi: 10.4084/MJHID.2024.065. eCollection 2024. PMID: 39258183 - Citations: 0 [05/03/2025]
IF: 6,1 - QUARTIL 1

Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias.
Cell Rep Med. 2024 Nov 19;5(11):101803. doi: 10.1016/j.xcrm.2024.101803. Epub 2024 Oct 28.
PMID: 39471818 - Citations: 0 [05/03/2025]
IF: 11,7 - QUARTIL 1

Bioinformatics

Angelika Merkel

Arribas V, Onetti Y, Ramiro-Pareta M, Villacampa P, Beck H, Alberola M, Esteve-Codina A, Merkel A, Sperandio M, Martínez-Estrada OM, Schmid B, Montanez E.
Endothelial TDP-43 controls sprouting angiogenesis and vascular barrier integrity, and its deletion triggers neuroinflammation
JCI Insight. 2024 Feb 1;9(5):e177819. doi: 10.1172/jci.insight.177819. PMID: 38300714 - Citations: 4 [05/03/2025]
IF: 6,3 - QUARTIL 1

Wiltshire E, de Moura MC, Piñeyro D, Joshi RS.
Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues
Hum Genomics. 2024 Mar 12;18(1):24. doi: 10.1186/s40246-024-00592-x. PMID: 38475971 - Citations: 0 [05/03/2025]
IF: 3,8 - QUARTIL 2

Cytogenetics

Isabel Granada

Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin- Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E.
BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases
Haematologica. 2024 Feb 1;109(2):493-508. doi: 10.3324/haematol.2023.283209.
PMID: 37560801 - Citations: 3 [05/03/2025]
IF: 8,2 - QUARTIL 1

Molina O, Ortega-Sabater C, Thampi N, Fernández-Fuentes N, Guerrero-Murillo M, Martínez-Moreno A, Vinyoles M, Velasco-Hernández T, Bueno C, Trincado

JL, Granada I, Campos D, Giménez C, Boer JM, den Boer ML, Calvo GF, Camós M, Fuster JL, Velasco P, Ballerini P, Locatelli F, Mullighan CG, Spierings DCJ, Foijer F, Pérez-García VM, Menéndez P.
Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression EMBO Mol Med. 2024 Jan 15. doi: 10.1038/s44321-023-00006-w.
PMID: 38177531 - Citations: 3 [05/03/2025]
IF: 9 - QUARTIL 1

Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L; Grupo Español de Leucemia Mieloide Crónica (GELMC).
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
J Clin Med. 2024 Jan 29;13(3):779. doi: 10.3390/jcm13030779.
PMID: 38337473 - Citations: 2 [05/03/2025]
IF: 3 - QUARTIL 1

Bistué-Rovira À, Rico LG, Bardina J, Juncà J, Granada I, Bradford JA, Ward MD, Salvia R, Solé F, Petriz J. Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib: Implications for Therapy Resistance
Int J Mol Sci. 2024 Feb 7;25(4):1994. doi: 10.3390/ijms25041994.
PMID: 38396682 - Citations: 0 [05/03/2025]
IF: 4,9 - QUARTIL 1

Gonzalez-Montes Y, Osca-Gelis G, Rodriguez-Romanos R, Villavicencio A, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Gómez B, Granada I, Gallardo D. CD200 genotype is associated with clinical outcome of patients with multiple myeloma
Front Immunol. 2024 Feb 22;15:1252445. doi: 10.3389/fimmu.2024.1252445. eCollection 2024.
PMID: 38455039 - Citations: 1 [05/03/2025]
IF: 5,7 - QUARTIL 1

Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M.
Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study Blood Adv. 2024 Jun 11;8(11):2691-2694. doi: 10.1182/bloodadvances.2023012479.
PMID: 38536941 - Citations: 4 [05/03/2025]
IF: 7,4 - QUARTIL 1

Navas-Acosta J, Hernández-Sánchez A, González T, Villaverde Ramiro Á, Santos S, Miguel C, Ribera J, Granada I, Morgades M, Sánchez R, Such E, Barrena S, Ciudad J, Dávila J, de Las Heras N, García-de Coca A, Labrador J, Queizán JA, Martín S, Orfao A, Ribera JM, Benito R, Hernández-Rivas JM.
Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia
Cancers (Basel). 2024 Dec 17;16(24):4200. doi: 10.3390/cancers16244200.
PMID: 39766099 - Citations: 0 [05/03/2025]
IF: 4,5 - QUARTIL 1

Genomics

Raquel Pluvinet

Monfort-Ferré D, Boronat-Toscano A, Sánchez-Herrero JF, Caro A, Menacho M, Vañó-Segarra I, Martí M, Espina B, Pluvinet R, Cabrinety L, Abadia C, Ejarque M, Nuñez-Roa C, Maymo-Masip E, Sumoy L, Vendrell J, Fernández- Veledo S, Serena C.
Genome-wide DNA Methylome and Transcriptome Profiling Reveals Key Genes Involved in the Dysregulation of Adipose Stem Cells in Crohn's Disease
J Crohns Colitis. 2024 Oct 15;18(10):1644-1659. doi: 10.1093/ecco-jcc/jjae072.
PMID: 38747506 - Citations: 2 [05/03/2025]
IF: 8,3 - QUARTIL 1

Microarrays

Maria Del Mar Mallo

Levy B, Kanagal-Shamanna R, Sahajpal NS, Neveling K, Rack K, Dewaele B, Olde Weghuis D, Stevens-Kroef M, Puiggros A, Mallo M, Clifford B, Mantere T, Hoischen A, Espinet B, Kolhe R, Solé F, Raca G, Smith AC.
A framework for the clinical implementation of optical genome mapping in hematologic malignancies Am J Hematol. 2024 Apr;99(4):642-

661. doi: 10.1002/ajh.27175. Epub 2024 Jan 2.
PMID: 38164980 - Citations: 8 [05/03/2025]
IF: 10,1 - QUARTIL 1

Gorria T, Crous C, Pineda E, Hernandez A, Domenech M, Sanz C, Jares P, Muñoz-Mármol AM, Arpí-Llucía O, Melendez B, Gut M, Esteve A, Esteve-Codina A, Parra G, Alameda F, Carrato C, Aldecoa I, Mallo M, de la Iglesia N, Balana C.
The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation
Cancers (Basel). 2024 Feb 9;16(4):735. doi: 10.3390/cancers16040735.
PMID: 38398126 - Citations: 1 [05/03/2025]
IF: 4,5 - QUARTIL 1

Proteomics

Carolina de la Torre

D'Alessandro A, Krisnevskaya E, Leguizamon V, Hernández I, de la Torre C, Bech JJ, Navarro JT, Vives- Corrons JL.
SARS-CoV-2 Infection and Anemia-A Focus on RBC Deformability and Membrane Proteomics-Integrated Observational Prospective Study
Microorganisms. 2024 Feb 23;12(3):453. doi: 10.3390/microorganisms12030453.
PMID: 38543504 - Citations: 2 [05/03/2025]
IF: 4,1 - QUARTIL 2

Ramos R, Vinyals A, Campos-Martin R, Cabré E, Bech JJ, Vaquero J, Gonzalez-Sanchez E, Bertran E, Ferreres JR, Lorenzo D, De La Torre CG, Fabregat I, Caminal JM, Fabra À.
New Insights into the Exosome-Induced Migration of Uveal Melanoma Cells and the Pre-Metastatic Niche Formation in the Liver
Cancers (Basel). 2024 Aug 27;16(17):2977. doi: 10.3390/cancers16172977. PMID: 39272836 - Citations: 2 [05/03/2025]
IF: 4,5 - QUARTIL 1

Andres Gamez-Garcia, Maria Espinosa-Alcantud, Alberto Bueno-Costa, Elisenda Alari-Pahissa, Anna Marazuela-Duque, Joshua K. Thackray, Chandni Ray, Clara Berenguer, Poonam Kumari, Joan Josep Bech, Thomas Braun, Alessandro Ianni, Jay A. Tischfield, Lourdes Serrano, Manel Esteller, Jose L. Sardina, Carolina De La Torre, Mikael Sigvardsson, Berta N. Vazquez; Alejandro Vaquero
A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5 Nat Immunol. 2024 Dec;25(12):2308-2319. doi: 10.1038/s41590-024-01995-7. Epub 2024 Oct 18.
PMID: 39424985 - Citations: 3 [05/03/2025]
IF: 27,7 - QUARTIL 1

Gualdrón-López M, Ayllon-Hermida A, Cortes-Serra N, Resa-Infante P, Bech-Serra JJ, Aparici-Herraiz I, Nicolau- Fernandez M, Erkizia I, Gutierrez-Chamorro L, Marfil S, Pradenas E, Ávila Nieto C, Cucurull B, Montaner-Tarbés S, Muelas M, Sotil R, Ballana E, Urrea V, Fraile L, Montoya M, Vergara J, Segales J, Carrillo J, Izquierdo-Useros N, Blanco J, Fernandez-Becerra C, de La Torre C, Pinazo MJ, Martinez-Picado J, Del Portillo HA
Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides
Front Cell Infect Microbiol. 2024 Nov 6:14:1442743. doi: 10.3389/fcimb.2024.1442743. eCollection 2024 PMID: 39569406 - Citations: 0 [05/03/2025]
IF: 4,6 - QUARTIL 1

Single cell

Caterina Mata

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E, Roue G, Valcárcel D, Molero A, Zamora L, Xicoy B, Palomo L, Acha P, Manzanares A, Tobiasson M, Hellström-Lindberg E, Sole F, Esteller M. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy Cancer Res Commun. 2024 Feb 12;4(2):365-377. doi: 10.1158/2767-9764.CRC-23-0389.
PMID: 38300528 - Citations: 4 [05/03/2025]
IF: 2 - QUARTIL 3

Institutions involved

The Josep Carreras Institute strives to establish continuing cooperation agreements and aims to broaden its strategic alliances and agreements with the pharmaceutical industry and other private organizations. The following organizations are currently associated with our Institute:

Founding members

JOSEP CARRERAS Leukaemia Foundation

Generalitat de Catalunya Government of Catalonia

With the institutional collaboration of

Ajuntament de Badalona

UAB Universitat Autònoma de Barcelona

Universitat de Barcelona

Public Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR

asociación española contra el cáncer

CERCA Centres de Recerca de Catalunya

European Commission

erc European Research Council

L'Acadèmia Fundació Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears

FECYT Fundación Española para la Ciencia y la Tecnología

Health Canada Santé Canada

European Commission Horizon 2020 European Union funding for Research & Innovation

ICREA

SEHH Sociedad Española de Hematología y Hemoterapia

Unión Europea Fondo Europeo de Desarrollo Regional "Una manera de hacer Europa"

Special thanks to all the staff for your outstanding work.

Individually we are strong.
Together we are unstoppable!

Coordination
Helena Díaz and Ainoa Olmo

Text, data, and figures
Josep Carreras Leukaemia Research Institute

Photography
Josep Carreras Leukaemia Research Institute's archives

Design and Printing
Iglésies Associats

For any matter concerning this report please contact:
communication@carrerasresearch.org

This report can also be downloaded from:
http://www.carrerasresearch.org

Josep Carreras Leukaemia Research Institute

Josep Carreras Building
Ctra de Can Ruti, Camí de les Escoles, s/n
08916 Badalona, Barcelona
Tel. (+34) 93 557 28 00

Annual report 2024

www.carrerasresearch.org

MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES

AGENCIA ESTATAL DE INVESTIGACIÓN

EXCELENCIA SEVERO OCHOA
04/2024 - 03/2030

Josep Carreras LEUKAEMIA Research Institute

Annual report 2024

www.carrerasresearch.org